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Thesis Abstract 
Introduction 
Oral dosage forms (ODFs), particularly solid ODFs, are the most popular and most 
commonly prescribed of all medication formulations. Older adults are the highest 
consumers of prescription medication. However, age-related pharmacokinetic, 
pharmacodynamic and physiological changes can complicate the administration of 
oral medicines to older adults and may result in these ODFs being modified (e.g. 
tablets crushed or split, or capsules opened) in order to facilitate administration of 
the appropriate dose or to overcome swallowing difficulties. These modifications 
may impact on the safety and/or efficacy of the medication, which could have 
clinical consequences for patients. In addition, many of these modifications 
represent an off-licence use of the medication, which has subsequent legal 
implications for healthcare professionals. Despite guidelines advocating that the 
modification of ODFs should be avoided, it appears to be common practice. 
Therefore, there is a need to gain a greater understanding of ODF modifications for 
older adults. 
Aim 
The overall aim of this research was to investigate ODF modifications for older 
adults in an Irish setting and to gain an understanding of the factors influencing this 
practice. 
Methods 
A mixed methods approach, using both quantitative and qualitative research 
methods, was used. Initially, a quantitative systematic review was conducted to 
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identify the available evidence on the prevalence of difficulty swallowing ODFs and 
the modification of ODFs to overcome swallowing difficulties amongst the older 
cohort. Secondly, a qualitative systematic review was undertaken to determine the 
knowledge, attitudes and beliefs of patients, healthcare professionals and carers 
about ODF modifications. The findings of these reviews served to guide the 
generation of research questions for the empirical, primary research studies. A 
retrospective audit of drug charts in one aged care facility (ACF) in Ireland was 
completed to provide preliminary data on ODF modifications in an Irish setting. 
Following this, a qualitative, semi-structured interview study was conducted with 
nurses working in acute and long-term care settings, to elucidate their knowledge, 
attitudes and beliefs about ODF modification and administration for older adults. 
Based on the findings of these studies, a direct observation of medication 
administration to older adults in five ACFs was conducted to provide more in-depth 
information on ODF modifications. Finally, the views and experiences of 
community-dwelling older adults and their carers around ODF modifications were 
explored using qualitative, semi-structured interviews.  
Results 
The quantitative systematic review highlighted the paucity of studies investigating 
ODF modifications, with only three studies describing modifications in care settings, 
which when combined with the limitations of the data collection methods used, 
demonstrated the requirement for further research investigating this issue. The 
qualitative systematic review provided useful insights into the factors that influence 
the knowledge, attitudes and beliefs of healthcare professionals and patients about 
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ODF modifications; highlighting that (i) the variability of individual patient’s 
requirements, (ii) poor communication practices and (iii) lack of knowledge about 
modifications, when combined with (iv) the complex healthcare environment, 
complicate decision-making regarding ODF modification. Results from the 
retrospective audit emphasised that modifications were commonly required to 
ensure patients’ needs could be met, particularly for fractional dosing. Whilst there 
was a lack of evidence-based information to support decision making around 
modifications, in many cases no suitable alternatives were available. This was 
echoed in the nurse interview study, with modifications seen to be a routine and 
necessary occurrence in older patient care. The nurses’ role as patient advocate 
however, helps to optimise formulation suitability within current limitations. The 
direct observation study once again demonstrated the ubiquity of ODF 
modifications, providing detailed insights into ODF modification practices in an Irish 
setting but also highlighting the challenges encountered when administering oral 
medicines to older adults. Finally, the challenges encountered in the community-
setting were elucidated, and there is a clear need for greater engagement with the 
issue of ODF suitability for community-dwelling older adults. 
Conclusions 
This thesis has made a significant contribution to understanding ODF modifications 
for older adults. It is clear that ODFs are not meeting the needs of the older cohort. 
Modifications are common and necessary, due to age-related changes combined 
with limitations of currently available formulations. This thesis has provided 
important information about current practices, but has also highlighted the 
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complex factors that give rise to the need to modify ODFs for older adults. There is 
a need to prioritise engaging with this issue in order to optimise ODF suitability for 
older adults. This will necessitate input from a wide variety of key stakeholders, 
including healthcare professionals, industry and regulatory bodies, as well as 
patients and carers. The findings of this thesis provide direction and important 
insights that will guide this process.  
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Chapter 1: Introduction 
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1.1 Introduction 
Globally, the fact that we are living longer is a tribute to the strides that have been 
made in public health. However, this ageing demographic profile presents 
challenges from a healthcare perspective, and this served as the impetus for this 
thesis. Medicines optimisation for older adults has been a key focus of research and 
policy with significant advances reported in the appropriateness of prescribing for 
the older person. Whilst these improvements must be acknowledged, there is still a 
dearth of research examining the suitability of medications for older adults. 
Ultimately for a medication to be effective, it must be capable of being safely 
administered to the patient using an appropriate formulation. Oral dosage forms 
(ODFs), particularly solid ODFs, are the most commonly prescribed of all 
formulations. However, age-related changes complicate administration and may 
result in ODFs being modified, e.g. tablets being crushed or split or capsules being 
opened, to “tailor” them to the needs of individual older patients. These 
modifications can alter the pharmacological profile of the drug in vivo and 
consequently, the safety and efficacy of the medication. In addition, the potential 
legal implications of using a medication outside the terms of the product licence are 
an important consideration.  
 
The research undertaken focused on the practical suitability of ODFs for older 
adults by investigating ODF modifications in an Irish setting. In order to 
comprehensively address this topic, a mixed methods approach was used for this 
thesis, which comprises: two systematic reviews (one quantitative and one 
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qualitative); two primary quantitative research studies and; two primary qualitative 
research studies. This introductory chapter will begin by providing a background to 
the research area which will highlight the rationale for, and the importance of, this 
research. Salient features of the Irish healthcare landscape will be detailed. 
Following this, the hypothesis underpinning the research will be described along 
with the overall aim of the thesis. The specific objectives defined to achieve this aim 
will be outlined. Based on the aim and objectives, the methodological approach 
utilised will be justified. Finally, a brief overview of the thesis will be provided. 
 
1.2 Background 
1.2.1 The ageing population 
Providing medication for the growing older population is one of the most significant 
challenges facing the healthcare sector and optimising its use is complicated by 
many factors including, age-related physiological changes, non-adherence and cost. 
The ageing population profile is a global reality that has arisen due to a decline in 
birth rates coupled with an increase in life expectancy (1). In 2017, the global 
population aged 60 years and older, was estimated to be 962 million, a substantial 
increase from 382 million in 1980 (2). This trend in population ageing is set to 
continue worldwide with current estimates suggesting that the population aged 60 
years and older will double to 2.1 billion by 2050, while the population aged 80 
years and older is expected to triple from 137 million in 2017 to 425 million by 2050 
(1, 2). 
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While the United Nations (UN) use 60 years to define the beginning of old age, in 
Ireland and other developed nations, the older population is generally considered 
to include those aged 65 years and older (3, 4). In Ireland, the 2016 Census found 
that there were 637,567 people aged 65 years and older, representing 13.4% of the 
total population (5). However, substantial growth is anticipated in the coming 
decades with projections suggesting that by 2046 there will be 1.4 million people 
aged 65 years and older (6). The expansion in the “very old” cohort (aged ≥80 years) 
will be even more dramatic, with estimates suggesting an increase from 128,000 in 
2011 to 484,000 by 2046 (6). 
 
Population ageing and the increase in life expectancy worldwide has been 
described as “one of humanity’s greatest triumphs” (7). However, this success is 
accompanied by substantial challenges from socioeconomic and healthcare 
perspectives. A coherent, proactive, timely and co-ordinated approach to policy 
development and planning will be required to address the social, economic and 
healthcare implications brought about by this expansion in the older cohort. As 
highlighted by the World Health Organisation (WHO), consideration of the “rights, 
needs, preferences and capacities of older people” (7) is of particular importance to 
ensure that the challenges inherent in this triumph do not overwhelm the success 
story of population ageing. This approach will be critical in the healthcare sector, 
where, in the past, the requirements of older adults have often been neglected (8). 
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1.2.2 Healthcare utilisation amongst the older cohort 
Understanding the needs, preferences and capacities of older adults from a 
healthcare perspective is vital given the significant pressures already placed on 
healthcare systems coupled with the increased demands that will be encountered 
by these already stretched systems due to the expansion of the older population.  
 
1.2.2.1 Health service utilisation 
The older cohort represents a heterogeneous population with significant inter-
individual variability in health status and functional capacity. While chronological 
age alone is not a good predictor of health status or level of dependence of an older 
individual (7, 9), it is clear from the literature that the older population are the most 
frequent users of healthcare services at all levels of care provision (10-12). 
 
In the acute care sector, managing acute exacerbations of chronic conditions, as 
well as treating acute, episodic illnesses experienced by older adults, contributes 
substantially to resource utilisation. Internationally, it is consistently demonstrated 
that the older cohort have the highest rates of hospitalisation (13, 14). Within the 
Irish context, in 2015, 52% of in-patient bed days and 39% of day cases in acute 
hospitals were used by patients aged ≥65 years (15). Given that of the €19.9 billion 
total healthcare expenditure, 35% is accounted for in the hospital sector, the 
financial implications of high rates of acute hospital utilisation become clear (16). 
Further insights into the costs specifically pertaining to the older cohort can be 
gained by examining the Case Mix Index (CMI) (17). Higher CMI scores indicate 
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increased complexity which in turn results in greater expenditure (17). Data from 
the Department of Health have shown that CMI inpatient activity scores ranged 
from 1.59 to 1.61 for patients aged 65 years and older in 2015 (17), compared to 
between 0.68 and 1.47 for individuals aged 15 to 64 years (17). Therefore, older 
patients are generally more complex and hence, more costly to treat than younger 
patients (17).  
 
Higher rates of service utilisation are also evident in primary care, with national and 
international literature consistently demonstrating higher General Practitioner (GP) 
consultation rates amongst older adults (18-21). Research in Ireland has found that 
the average number of GP consultations for all individuals aged 15 years and older 
is 4.3 per year, however for older adults this rises to 7.1 consultations per annum 
(22). 
 
As the population continues to age, the demand for long-term care (LTC) is likely to 
grow. In 2015, across “Organisation for Economic Co-operation and Development” 
(OECD) countries, government spending on LTC provision accounted for 1.7% of the 
gross domestic product (GDP) (23). However, by 2060, this figure is expected to 
double (23). In 2016, 22,762 people aged ≥65 years in Ireland (3.7% of the older 
population) were resident in nursing homes, an increase of 9.4% since 2011 (24). 
The nursing home sector in Ireland includes public, private and voluntary nursing 
homes which differ based on their funding and governance structures (25). 
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However, regardless of the type of nursing home, all those requiring long-term 
nursing home care are entitled to apply for financial support from the 
Government’s Nursing Homes Support Scheme (NHSS), more commonly known as 
the “Fair Deal” scheme. This scheme was introduced in 2009 with the aim of 
facilitating access to long-term residential care for those in need. Under this means 
tested scheme, individual residents make a contribution to their care (80% of 
disposable income and 7.5% of the value of any assets per annum), with the 
outstanding balance paid by the State (26). In 2016, 23,002 people received support 
under the NHSS, with the majority (70.5%) aged 80 years and older (27). During this 
time, the total expenditure on care provision for NHSS clients was €1.26 billion 
(€921 million from exchequer funding and €337 million from client contributions), 
an increase from €1.17 billion in 2014 (27). The demand for LTC beds is projected to 
increase by 40% by 2030 (28), again highlighting the challenges faced by the 
healthcare system in meeting the needs of the older population. 
 
It is clear that the high rates of health service utilisation by the older cohort present 
significant challenges for the healthcare sector from both capacity and expenditure 
perspectives. Age-related changes in the prevalence of disease are a key factor 
driving this utilisation. The prevalence of chronic disease increases with age (10, 
29). A study involving a group of community-dwelling older adults conducted as 
part of “The Irish Longitudinal Study on Ageing” (TILDA) found that participants had 
a median of three doctor diagnosed chronic conditions (30). Similarly, the Health 
Service Executive (HSE) estimated that in 2016, 542,400 people aged ≥65 years in 
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Ireland had at least one chronic disease, while 404,470 (65%) had two or more 
chronic illnesses (31). Multimorbidity, defined as the co-existence of two or more 
chronic diseases, has been shown to increase substantially with age (32-36), and is 
associated with increased healthcare utilisation rates and expenditure (37-39). 
Healthcare systems have traditionally focused on specialisation and disease-specific 
treatment approaches (40-42). This has been reflected in the organisation and 
delivery of healthcare, and the education of healthcare professionals. Clinical 
practice guidelines are generally developed based on the management and 
treatment of single diseases in isolation and therefore, are of limited use for 
healthcare professionals managing multi-morbid patients (40, 42-46). Therefore, 
providing holistic, person-centred and evidence-based care to the growing cohort 
of multi-morbid older adults is a challenge that healthcare systems must address, 
particularly in light of findings that healthcare professionals have reported feeling 
ill-equipped and unsure of how to manage these multi-morbid patients (47, 48). 
 
1.2.2.2 Medication utilisation 
As a consequence of the high prevalence of chronic illness and multimorbidity, 
older adults are the highest consumers of prescription medications. It has been 
estimated that, despite accounting for only 12-18% of the population of developed 
countries, people aged 60 years and over consume approximately 50% of all 
prescribed medicines and are responsible for 60% of medication related costs (49). 
Studies investigating medication usage amongst older Irish patients have shown 
that community-dwelling older adults are prescribed a median of 5 to 6 regular 
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medications (30, 50), whilst those in nursing homes are prescribed a median of 8 
(51, 52). 
 
In Ireland, payment for medications is provided through a number of drug schemes, 
the most significant of which, from a cost perspective, is the General Medical 
Services (GMS) Scheme. Within the GMS or “medical card” scheme, eligible 
individuals are entitled to free GP care and pay a co-payment for prescription 
medicines (currently €2 per item up to a maximum of €20 per family, per calendar 
month) (53). Eligibility for this scheme is based on means testing (54). Previously, 
individuals aged 70 years and older were automatically entitled to a medical card 
regardless of income (55). This automatic entitlement was removed on the 1st of 
January 2009 (55), however the income thresholds differ for those aged <70 years 
compared to those aged ≥70 years (56). In 2016, 35.4% of the Irish population were 
covered on the GMS scheme, with individuals aged ≥65 years accounting for 25.7% 
of the total GMS population (57). 
 
In 2016, of the €1,343.3 million paid to pharmacists under the community drugs 
schemes, €1,026.7 million related to the GMS scheme (57). In total, the average 
pharmacy cost paid by the Government for a GMS patient per year was €613.67 
(57). However, the average pharmacy cost was substantially higher for older 
patients than younger patients as outlined in Table 1.1. Therefore, it is clear that 
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the high rates of medication use amongst the older cohort have significant 
economic implications. 
 
Table 1.1 Average pharmacy cost per GMS eligible person 
Age Group Average Cost per Eligible Person (€) 
<5 years 118.08 
5-11 years 77.95 
12-15 years 81.38 
16-24 years 167.27 
25-34 years 287.04 
35-44 years 371.62 
45-54 years 566.20 
55-64 years 892.25 
65-69 years 1,074.60 
70-74 years 1,169.52 
≥75 years 1,594.47 
All Eligible Persons 613.67 
Adapted from: Primary Care Reimbursement Service Statistical Analysis of Claims 
and Payments 2016 (57) 
 
1.2.3 Age-related changes complicate medication use 
Given the high rates of medication utilisation, combined with the projected 
expansion of the older cohort, it is unsurprising that much research in the medical 
and pharmacy fields has focused on optimising medication use for older adults. The 
impetus for this research has also been driven by the fact that due to age-related 
physiological, pharmacokinetic and pharmacodynamic changes, older adults are 
particularly susceptible to medication related problems including drug-drug 
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interactions, drug-disease interactions and adverse drug reactions (58, 59). The 
National Institute for Health and Care Excellence (NICE) in the United Kingdom (UK) 
has defined “Medicines Optimisation” as: “A person-centred approach to safe and 
effective medicines use, to ensure people obtain the best possible outcomes from 
their medicines” (60). Medicines optimisation has also been defined as: “The 
process by which healthcare professionals engage with individual patients to 
understand their views, opinions and beliefs, to share their clinical and medicines 
knowledge so that the most appropriate evidence based care for each individual can 
be agreed,” (61) or simply, “engaging with individual patients to get their medicines 
right for them” (61). Ensuring that medication meets the unique needs of the 
individual patient is a key component of medicines optimisation (61). 
 
To date, medicines optimisation research has focused on inappropriate prescribing 
and selecting the most clinically appropriate drugs to reduce adverse outcomes. 
Significant improvements have been seen, with Moriarty et al. (62) reporting that 
despite an increase in polypharmacy, the quality of prescribing for older adults in 
Ireland has improved, with a 60% decrease in the risk of potentially inappropriate 
prescribing. While selecting the most clinically appropriate drug is a vital first step 
in the medicines optimisation process, other important considerations, including 
the practical suitability of the medication, have been neglected in research and 
practice. There is growing awareness that commercial dosage forms can prove 
problematic and unacceptable for older adults (8, 63, 64). This thesis investigates if 
oral medicines are meeting the needs of older adults at a practical level as a 
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number of age-related changes can complicate ODF administration and may result 
in ODFs being modified to tailor them to individual patient’s needs. 
 
1.2.3.1 Oral dosage forms 
The oral route of drug administration is preferred as it is the simplest, most 
convenient and safest route of drug administration (65). There are a wide variety of 
ODFs available but the most popular, from a patient and healthcare professional 
perspective, are solid ODFs i.e. tablets and capsules. Solid ODFs are preferred as 
they are convenient and safe dosage forms that facilitate accurate drug dosing, in 
an easy to administer formulation that ensures the chemical and physical stability 
of the drug (65). Tablets and capsules also offer advantages for the pharmaceutical 
industry as they can be mass produced using well-defined and controlled 
procedures to produce dosage forms of consistent quality at comparatively low 
price (65). However, for some patients, ODFs and the one-size-fits-all approach may 
prove problematic. This may result in ODFs being modified, which has previously 
been defined by Richey et al. (66) as, “any alteration of an oral dosage form that 
can be performed at the point of administration”(66). This definition will also be 
used to describe modifications throughout this thesis. 
 
1.2.3.2 ODF modifications for swallowing difficulties 
The first step in the administration of ODFs involves the patient swallowing the 
dosage form so that it passes safely from the oral cavity into the stomach via the 
oesophagus. Swallowing is a complex mechanism that involves the coordinated 
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action of more than 30 nerves and muscles (67). Swallowing centres in the 
brainstem coordinate the action of muscles in the mouth, pharynx, larynx and 
oesophagus during the swallowing process. These swallowing centres in the 
brainstem receive sensory input from afferent cranial nerves, while modulatory 
input is received from higher centres in the brain (68). The physiology of a normal 
swallow is divided into three distinct phases: (i) the oral phase; (ii) the pharyngeal 
phase and; (iii) the oesophageal phase (67, 68). The oral phase is the volitional 
component of the swallow and involves the formation of a suitable bolus and the 
transfer of this bolus into the pharynx (67). During the pharyngeal phase, the bolus 
is propelled through the pharynx into the oesophagus via the upper oesophageal 
sphincter. This is a reflex (involuntary) action that occurs rapidly, in less than one 
second (67, 69). During the pharyngeal phase, the epiglottis covers the larynx to 
protect the airway (67). The oral and nasal cavities are also sealed off to prevent 
regurgitation of the bolus (67, 70). The oesophageal phase begins when the bolus 
passes through the upper oesophageal sphincter and the peristaltic wave carries 
the bolus through the oesophagus and the lower oesophageal sphincter into the 
stomach (71). 
 
Ageing is associated with natural alterations in the anatomic, physiological, neural, 
motoric and sensory mechanisms that underpin swallowing (63, 67, 72). These age-
related changes are evident in all three phases of deglutition and include: 
decreased isometric tongue pressure, reduction in muscle mass and strength, 
reduced receptor density and responsiveness, decreased pharyngeal sensation, 
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prolongation of the oropharyngeal swallowing phase, slow bolus velocity and 
prolongation of the time for upper oesophageal sphincter relaxation (63, 68, 70, 
73). Presbyphagia is the term used to describe these characteristic changes in the 
swallowing mechanism of otherwise healthy older adults (63, 72, 73). These 
changes are not inherently pathological and, in isolation do not result in any 
clinically relevant swallowing impairment (63). However, presbyphagia reduces the 
functional swallowing reserve which partly explains why older adults are at 
increased risk of developing dysphagia (difficulty swallowing) (72, 73). In addition, 
dysphagia is a common co-morbidity associated with many age-related diseases 
and many of the medications prescribed to older adults can disrupt the swallowing 
function by: (i) causing xerostomia, (ii) directly damaging the oesophagus or; (iii) 
dysphagia may arise as an adverse effect associated with the pharmacological 
action of the drug (63, 72). Therefore, the presence of these additional risk factors 
for dysphagia can ultimately affect the swallow beyond the normal effects of 
ageing, which accounts for the observation that older adults are more likely to 
experience dysphagia than the general population. Table 1.2 summarises some of 
the common age-related diseases and medication classes that are frequently 
implicated in the development of dysphagia and swallowing disorders amongst 
older adults (63, 68, 71). Whilst the prevalence of dysphagia is known to increase 
with age (67), it has also been shown that amongst the older population, the 
prevalence of dysphagia increases with increased levels of care (63). It is estimated 
that between 11% and 33% of community-dwelling, independently-living older 
adults experience dysphagia (74-78) compared to between 31% and 68% of nursing 
home residents (67, 79-81). 
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Table 1.2 Age-related medical conditions and drug classes that contribute to dysphagia 
(63, 68, 71) 
Medical Conditions with Dysphagia as a Co-morbidity (list not exhaustive) 
Neurological Disorders Musculoskeletal Neoplastic 
Stroke Myasthenia gravis Brain tumours 
Alzheimer’s Disease Connective tissue disease Neck tumours 
Parkinson’s Disease Osteoarthritis Oropharyngeal tumours 
Motor Neurone Disease Sarcoidosis  
Drug Classes that can Impair Swallowing Function (list not exhaustive) 
Drug classes associated 
with xerostomia 
Drug classes associated 
with oesophagitis 
Drug classes with 
dysphagia as a 
complication 
Anticholinergics Bisphosphonates Analgesics 
Antidepressants Iron salts Anticholinergics 
Antipsychotics Non-steroidal anti-
inflammatory drugs 
Antipsychotics 
Diuretics Tetracycline antibiotics Cytotoxics 
 
Dysphagia complicates the administration of medicines to older adults (63) and the 
use of solid ODFs in patients with dysphagia has been shown to increase the risk of 
penetration and aspiration (82). Therefore, in order to overcome the challenges 
associated with administering medication to patients with dysphagia, ODFs may be 
modified.  
 
Swallowing medication is a learned response, accounting for the difficulties often 
experienced by children and adolescents (83). Adults may also report difficulty 
swallowing medication in the absence of objective evidence of swallowing 
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dysfunction. ODFs may be modified to overcome the difficulty experienced by these 
individuals. Reports on the prevalence of difficulty swallowing ODFs vary. It has 
been reported that between 9 and 60% of community-dwelling adult patients 
experience difficulty swallowing ODFs (84-87). There is a paucity of data from an 
Irish setting and data specifically pertaining to the older cohort. However, it is 
highlighted by these studies that, of those who experience difficulty swallowing 
medication, between 27% and 68% modify medicines to facilitate intake (84-87). 
Therefore, it is clear that individuals who find it difficult to take oral medicines 
frequently resort to modifying ODFs. Given the increased prevalence of both 
dysphagia and polypharmacy with increased age (67, 88), it is anticipated that 
difficulty swallowing ODFs is likely to be a substantial issue amongst older adults, 
which is a significant cause for concern.  
 
1.2.3.3 ODF modifications for fractional dosing  
Selecting and administering the correct dose of a medication is vital to optimise 
therapeutic outcomes and minimise adverse events. Dosing requirements for older 
adults, however, are complicated by age-related physiological changes that alter 
the pharmacokinetic and pharmacodynamic properties of medicines. The 
magnitude of the effect that a drug elicits in the body is dependent on: (i) the 
concentration of the drug at the site of action; (ii) the number of receptors and 
their affinity for the drug at the site of action; (iii) signal transduction mechanisms 
and; (iv) homeostatic regulation (89, 90). Pharmacokinetics relates to the rate and 
extent of drug absorption, distribution, metabolism and excretion. Age-related 
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pharmacokinetic changes result in altered drug concentrations at the site of action, 
which has implications for both therapeutic and adverse effects (90). Table 1.3 
summarises some common age-related pharmacokinetic changes and the potential 
effect of these changes on various drugs (89-94). 
Table 1.3 Age-related pharmacokinetic changes (89-94) 
Stage Age-Related Change Potential Effect Drug Examples 
Absorption 
↓ Gastric motility  ↓ Rate of absorption Digoxin, Allopurinol 
 
↓ Carrier-mediated 
transport 
↓ Extent of absorption  Calcium, Iron, 
Vitamins 
Distribution 
↓ Total body water  ↑ Plasma concentration 
of hydrophilic drugs 
Digoxin, Theophylline 
↑ Body fat  ↑ Half-life of lipophilic 
drugs 
Diazepam, 
Amiodarone 
↓ Plasma albumin 
levels 
↑ Concentration of 
unbound acidic drugs 
Coumarins, 
Phenytoin 
Metabolism 
↓ First Pass 
Metabolism (FPM) 
↑ Plasma concentration 
of drugs that undergo 
extensive FPM 
Propranolol, 
Verapamil, Nifedipine 
 
↓ Bioavailability of pro-
drugs that require FPM for 
activation 
Enalapril, Perindopril 
↓ Phase I 
metabolism 
↓ Metabolic clearance Amitriptyline, 
Lidocaine 
Excretion 
↓ Renal blood flow ↓ Clearance and ↑ 
plasma concentration of 
renally eliminated drugs 
Diuretics, Digoxin, 
Lithium, 
Aminoglycosides 
↓ Glomerular 
Filtration Rate  
↓ Tubular secretion 
Legend: FPM = First Pass Metabolism 
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Pharmacodynamics relates to the action or effect that a drug elicits in the body. 
Age-related pharmacodynamic changes are associated with altered sensitivity to 
drugs and arise due to alterations in receptors, signal transduction or homeostatic 
mechanisms (92). Whilst the clinical implications of age-related pharmacodynamic 
changes are often more difficult to predict than the pharmacokinetic changes, 
numerous examples have been documented in the literature (Table 1.4) (89, 90, 92, 
94).  
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Table 1.4 Clinical implications of age-related pharmacodynamic changes (89, 90, 92, 94) 
Drug/ Drug Class Effect of Pharmacodynamic 
Change 
Mechanism of 
Pharmacodynamic 
Change 
Benzodiazepines ↑ Central Nervous System 
(CNS) sensitivity including 
sedation, confusion, falls etc. 
Receptor changes: 
changes in GABAA-
benzodiazepine receptor 
complex number and 
composition 
Sulfonylureas ↑ Risk of hypoglycaemia Homeostatic mechanisms: 
age-dependent 
impairment of glucose 
counter-regulation 
Antihypertensives/ 
Diuretics 
↑ Risk of postural hypotension Homeostatic mechanisms: 
↓ Baroreceptor reflex 
sensitivity and 
responsiveness 
Antipsychotics ↑ Risk of extrapyramidal 
symptoms 
 
 
↑ Risk of anticholinergic effects 
Homeostatic mechanisms: 
Age-related ↓ in 
dopamine content in CNS 
 
Age-related ↓ in 
acetylcholine content in 
CNS 
Legend: CNS = Central Nervous System; GABA = gamma-Aminobutyric acid. 
 
Therefore, when prescribing medication for older adults, clinicians need to be 
cognisant of the potential for altered responses to medications due to changes in 
the pharmacokinetic profile of the drug or due to alterations in pharmacodynamic 
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properties. As a result, a policy of “start low and go slow” is commonly advocated 
when using medication in the older patient. However, as highlighted by Rochon et 
al. (95), this can prove challenging when using commercially available solid ODFs. 
These ODFs are routinely marketed based on the results of clinical trials that 
exclude older patients and therefore, the appropriate dose may not be available, or 
indeed, the evidence-base for the optimal dose in the older cohort may be absent. 
Therefore, in practice, when pursuing a policy of “start low and go slow” in an 
attempt to meet the unique dosing requirements of older adults, fractional dosing 
may be required (e.g. administration of half or quarter of a tablet).  
 
While for the reasons outlined above, fractional dosing may be routinely required, 
there are limited data on the prevalence of this practice, particularly in the older 
cohort. Studies conducted in community settings in Germany, the Netherlands and 
Sweden have suggested that between 10% and 31% of prescribed tablets are 
required to be split (96-98). These studies investigated tablet splitting in the general 
adult population and did not provide data on tablet splitting specifically for older 
adults (96-98). A Taiwanese study reported that 36% of prescriptions for narrow 
therapeutic index (NTI) drugs involved tablets being split, and stated that the 
prevalence of fractional dosing was high for older patients, particularly for digoxin 
and warfarin (99). One of the few studies specifically investigating fractional dosing 
in an older cohort, undertaken by Fischbach et al. (100) in a Canadian nursing home 
setting, found that 35% of all residents received at least one split tablet. Of the 157 
medications split, psychotropic medications (36.3%) were modified most 
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commonly, followed by cardiovascular medications (19.1%). A study conducted in a 
geriatric outpatients department in Brazil found that 35% of patients with dementia 
required fractionally dosed medicines compared to 24% of patients without 
dementia (101). There are no data on ODF modifications for fractional dosing in an 
Irish setting, for either the general adult population or the older cohort specifically. 
 
1.2.3.4 Implications of modifications  
For the reasons outlined previously, ODFs may need to be modified to meet the 
needs of older adults. These modifications may include: cutting or splitting tablets, 
crushing or grinding tablets, opening capsules or mixing the medication with food 
or liquid. While the intention underlying these modifications, to tailor the dosage 
form to meet the needs of the patient, is admirable, there are numerous potential 
consequences of modifications that are a cause for concern. ODFs are becoming 
increasingly complex with the dosage form controlling factors including the rate, 
extent and site of drug release and absorption as well as drug stability, both in the 
dosage form and the gastrointestinal tract (65). Therefore, there are potential 
clinical implications associated with modifications for either fractional dosing or 
swallowing difficulties. In addition, there are a number of legal and ethical 
considerations which healthcare professionals should be cognisant of, prior to 
authorising or undertaking any modifications.  
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1.2.3.4.1 Modifications for difficulty swallowing 
ODF modifications that are undertaken to facilitate administration to individuals 
with difficulty swallowing the intact dosage form include tablet crushing, splitting, 
or chewing, capsule opening, mixing medication with food or dispersing in liquid. 
Modifications such as these have been reported in community, long-term and 
acute-care settings (84-87, 102, 103). However, various commentators have 
highlighted potential concerns around ODF modifications including: the risk posed 
to healthcare professionals and carers due to exposure to powdered drug 
substances; drug instability; the potential for altered pharmacokinetic profiles and 
hence changes in drug bioavailability; oesophageal or gastric irritation; inaccurate 
drug dosing due to drug loss and; impact on palatability (104). The likelihood that 
modifying a dosage form can potentially lead to harmful outcomes depends on 
numerous factors including: the method of modification used; the characteristics of 
the dosage form and; the therapeutic index of the drug. As a result, it can be 
difficult to make general recommendations around ODF modifications. However, it 
is widely acknowledged that certain classes of medications and dosage forms 
should never be altered. For example, it is generally advised that carcinogenic, 
teratogenic, hormonal and steroidal products should not be modified due to the 
potential risk posed to carers by exposure to aerosolized drug particles. Table 1.5 
describes some commonly used dosage form types and the reasons that they 
should not be modified (104, 105). 
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Table 1.5 Examples of drug classes that should not be modified 
Dosage Form 
Type 
Potential Consequence of 
Modification 
Examples 
Enteric coated 
formulations 
Drug degradation or inactivation in 
the gastric acid and therefore 
diminished therapeutic efficacy  
Acid-labile drugs e.g. 
omeprazole, pancreatic 
enzymes 
Stomach or oesophageal irritation Corticosteroids, non-
steroidal anti-inflammatory 
drugs e.g. diclofenac, aspirin  
Premature drug release resulting in 
lower drug concentrations at site of 
action and reduced efficacy 
Drugs intended to be 
released at specific location 
in the gastrointestinal tract 
e.g. sulfasalazine 
Extended 
release 
formulations 
Altered drug release and hence 
absorption in vivo resulting in 
possible over dosing and toxicity 
initially followed by under dosing 
and loss of therapeutic efficacy 
Extended release 
carbamazepine, verapamil, 
opioid analgesics  
Some film or 
sugar coated 
drugs 
Drug instability Photosensitive drugs e.g. 
nifedipine 
Palatability issues Bitter tasting drugs e.g. 
ciprofloxacin 
 
For the categories of dosage forms mentioned above, healthcare professionals are 
generally cognisant of the need to administer these formulations whole. However, 
for other dosage forms, there can be ambiguity around whether modifications will 
have any unintended, negative clinical consequences. The need for healthcare 
professionals to be alert to the potential risks associated with ODF modification is 
highlighted in the case reported by Schier et al. (106) in which a fatality arose due 
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to the inappropriate crushing of an extended release formulation of nifedipine, 
prior to administration to a patient in hospital. There are numerous studies in the 
scientific literature reporting on the impact of crushing tablets or opening capsules 
on in vitro dissolution profiles (107-110) or in vivo pharmacokinetic behaviour (109-
113). The results of these studies highlight the variable effect of ODF modifications, 
for example, Song et al. (111) showed that apixaban tablets can be administered 
whole or crushed in either water or apple sauce with no difference in 
bioequivalence observed. In contrast, Cattaneo et al. (110) found significant 
differences in both in vitro dissolution behaviour and in vivo pharmacokinetic 
profiles between whole raltegravir tablets and modified (crushed or chewed) 
tablets.  
 
When ODFs are modified to overcome swallowing difficulties they are frequently 
mixed with food or liquid to facilitate administration. The potential for the 
administration vehicle to affect the pharmacokinetic properties of the drug in vivo 
must also be considered. Drug-food interactions can potentially affect drug 
absorption e.g. calcium interferes with the absorption of quinolone antibiotics, 
therefore it is recommended not to take milk or dairy products for two hours 
before or after ingestion of ciprofloxacin (114). A number of studies have 
investigated the in vitro effects of administering modified medicines in food on drug 
stability, disintegration and dissolution characteristics (107, 108). Both Carrier et al. 
(107) and Wells and Losin (108) found that certain vehicles negatively impacted on 
the stability and dissolution profile of medication, which could potentially alter drug 
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action in vivo. In general, most medicines are designed to be administered with 
water. Older adults with swallowing difficulties are often prescribed thickened 
fluids in order to minimise the risk of aspiration. This has led to interest in the use 
of thickened fluids for administering medication to patients with dysphagia. 
However, recent literature reports have demonstrated that the administration of 
modified medicines in thickened liquids can alter the dissolution characteristics of 
some medications (115, 116).  
 
Depending on the ODF and the administration vehicle used, modifying an ODF can 
potentially impact on drug release and absorption in vivo, which could potentially 
impact on therapeutic outcomes. In addition, Thong et al. (117) recently highlighted 
that the type of crushing device used could affect the amount of the active 
ingredient that can be delivered to the patient, which has obvious implications for 
dosing accuracy and therapeutic effect.  
 
In addition to the pharmacological concerns, the palatability and acceptability of 
modified ODFs from patient and carer perspectives must also be considered. The 
taste of modified medicines can be an issue that affects patient acceptance and 
adherence. Recent literature reports have highlighted that modifications often 
result in bitter or poor tasting formulations (118, 119). Greater consideration is 
being given to the palatability of medicines, particularly for paediatric patients 
(120), however for the older population the issue of palatability tends be neglected. 
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ODF modifications may, in addition, be difficult for older adults or carers to perform 
given the requirement for manual dexterity, visual acuity and knowledge around 
performing the modification. These factors are of importance when considering the 
appropriateness of ODFs and ODF modifications for older adults. 
 
1.2.3.4.2 Modifications for fractional dosing 
Modifications of ODFs for fractional dosing generally involve the administration of 
half or quarter of a tablet. Numerous methods of modification are used including 
commercial pill splitting devices, manual splitting by hand, using a knife or, getting a 
pharmacy to split a medication in advance, with both scored and unscored tablets 
reportedly being split (96, 121). The most significant concern is that the dose the 
patient receives may not be accurate. Studies investigating the accuracy of tablet 
splitting are numerous (122-127), however the results vary considerably, 
complicating the interpretation of the clinical implications of these findings (Table 
1.6). Initially, studies used the weight of split tablets as a surrogate indicator of 
dosing accuracy (122-126), however later studies used adapted United States 
Pharmacopoeia (USP) or European Pharmacopoeia (Ph.Eur) tests for uniformity of 
dosage units to evaluate the accuracy of tablet splitting (123, 124). Extrapolating 
uniformity of weight data to infer uniformity of drug content and hence dosing 
accuracy assumes that the active ingredient is homogenously distributed 
throughout the dosage form. However, this is often not the case, as demonstrated 
by Zhao et al. (128). To address this, a number of studies have sought to determine 
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whether tablet fractions contain the desired amount of active ingredient (127, 129, 
130).  
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Table 1.6 Summary of studies investigating the accuracy of fractional dosing 
Study Medication Method of Modification Method of 
Evaluation 
Criteria Findings 
McDevitt 
et al. (122) 
Hydrochlorothiazide Manually split by hand 
(n=876 tablets) 
Tablet splitter (n=51 
tablets) 
 
94 healthy volunteers 
Variation from 
ideal weight 
N/A Manually split tablets: 41.3% of tablet 
halves deviated from ideal weight by more 
than 10% and 12.4% deviated by more 
than 20% 
Tablet splitter: 37.3% deviated from ideal 
weight by more than 10% 
Peek et al. 
(125) 
Warfarin, Lisinopril, 
Metoprolol, Simvastatin 
2 tablet splitters 
30 men aged ≥50 years 
Deviation from 
expected weight 
N/A Doses deviated by between 9 and 37% 
from the intended dose 
Verrue et 
al. (126) 
Warfarin, Digoxin, 
Metformin, Levodopa 
and Carbidopa, 
Fenprocoumon, 
Spironolactone, 
Methylprednisolone, 
Lisinopril 
3 methods of 
modification used: tablet 
splitter; hand-splitting 
for scored and scissors 
for unscored tablets and; 
a kitchen knife 
5 volunteers 
Deviation from 
theoretical 
weight 
N/A Deviations from expected weights ranged 
from 5.5% to 18.9% 
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Study Medication Method of Modification Method of 
Evaluation 
Criteria Findings 
Polli et al. 
(123) 
Atorvastatin, 
Citalopram, 
Furosemide, Glipizide, 
Metoprolol,  Paroxetine, 
Sertraline, Warfarin, 
Lisinopril, Lovastatin, 
Rofecoxib, Simvastatin 
Tablet splitter 
 
Trained pharmacy 
student 
Weight 
Uniformity 
Adapted USP 
Test for 
Uniformity of 
Dosage Units 
Eight products passed: atorvastatin, 
citalopram, furosemide, glipizide, 
metoprolol, paroxetine, sertraline and 
warfarin 
Four products failed: lisinopril, lovastatin, 
rofecoxib and simvastatin 
Rosenberg 
et al. (124) 
22 prescriptions 
returned unused from 
long term care facilities 
Method unknown 
 
Pharmacists 
Weight 
Uniformity 
Adapted USP 
criteria  
Seven dispensed prescriptions (31.8%) met 
adapted weight uniformity standards 
Hill et al. 
(127) 
Warfarin, Simvastatin, 
Metoprolol succinate, 
Metoprolol tartrate, 
Citalopram and 
Lisinopril 
 
Tablet splitter 
 
Pharmacy students 
Weight 
uniformity and 
drug content 
Adapted USP 
specifications 
23.9% of tablet halves differed from 
sample mean values for drug content by 
more than specification limits 
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Study Medication Method of Modification Method of 
Evaluation 
Criteria Findings 
Helmy 
(129) 
16 medications A knife 
5 volunteers (2 men and 
3 women; aged 25-44 
years) 
Weight and 
content 
uniformity 
Adapted USP 
specifications 
16.2% fell outside weight limits, 15.0% fell 
outside content uniformity specifications 
and overall 6 medicines failed the test. 
Zaid (130) Lorazepam Method unknown Weight variation 
and drug content 
Adapted 
Ph.Eur Tests 
for Uniformity 
of Mass and 
Uniformity of 
Content 
Split lorazepam tablets met the adapted 
Ph.Eur criteria 
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Whilst numerous studies have investigated the potential impact of fractional dosing 
on uniformity of weight or content, there is limited evidence on the effect of 
fractional dosing on clinical outcomes. Three studies investigated the effect of a 
tablet splitting programme for statins on clinical laboratory measurements and in 
all three studies no clinically relevant differences in lipid parameters were observed 
between split tablet dosing and whole tablet dosing (131-133). Similarly, Rindone et 
al. (134) conducted a randomized crossover trial which found no significant 
differences in blood pressure when taking a full tablet of lisinopril compared to 
fractional dosing to provide an equivalent dose of anti-hypertensive.  
 
The studies on uniformity of weight and content for split tablets have 
demonstrated equivocal results (Table 1.6). Although the number of studies is 
limited, fractional dosing was not shown to adversely affect clinical outcomes in the 
four studies that investigated the short-term impact of fractional dosing (131-134). 
Given the ambiguity of the literature findings, it is unsurprising that debate exists 
around the appropriateness of modifying medicines for fractional dosing, with 
some authors advising that it is of limited clinical consequence or only of concern 
for NTI drugs while others advise caution (135-137). Various factors have been 
shown to impact the accuracy of fractional dosing. The method of modification 
used affects the dosing accuracy with splitting devices performing better than 
manual splitting by hand (138), while some tablet splitters performed better than 
others (125). Dosage form related factors play a role including: the shape of the 
tablet (123, 125); presence or absence of a score line (127); depth of the score line 
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(139) and; tablet hardness (123). Patient-related factors that have been shown to 
influence the accuracy of fractional dosing include: whether training or instructions 
were provided (125) and; the age of the patient, with older patients in particular 
experiencing difficulty (140). In addition, the clinical relevance of any potential 
alteration in the accuracy of dosing may be influenced by the therapeutic range of 
the medication, the half-life of the drug and whether the medication is for acute or 
chronic use (135-137). The sheer number of variables that can play a role makes the 
provision of guidelines and general recommendations in this area difficult. 
 
Another issue that must be considered is the acceptability of fractional dosing from 
a patient perspective as well as the ability of patients to perform modifications. 
Again, results vary with some studies reporting that patients experienced difficulty 
when breaking tablets (134, 141, 142) and found that tablets did not break evenly 
(121, 134, 141, 142), whilst other patients found tablet splitting to be acceptable 
and satisfactory (131). 
 
1.2.3.4.3 General considerations around modifications 
For healthcare professionals who prescribe, dispense or administer modified ODFs, 
the legal implications of the modification must also be considered. In order to have 
a medication placed on the market, pharmaceutical companies must apply for a 
marketing authorisation from a relevant competent authority: the Health Products 
Regulatory Authority (HPRA) for Ireland or; the European Medicines Agency (EMA) 
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for the European Union (EU) (143). During this process, the regulatory authorities 
evaluate whether the product meets the necessary standards of quality, safety and 
efficacy. The Summary of Product Characteristics (SPC) is an integral part of the 
application and contains essential information about the licensed use of the 
medicine: including details on the therapeutic indication, dose, contra-indications 
and method of administration. Any use of a product outside of the terms of the 
marketing authorisation is considered an “off-label” use of the medication (144). 
Therefore, unless a modification or a dose is expressly authorised in the SPC, it is 
considered an “off-label” use (145). The significance of this is that the 
pharmaceutical company do not bear any responsibility for harm that arises due to 
the off-label use of a medication, and the healthcare professionals bear 
responsibility for any adverse events that may occur (146). Off-label use of 
medication is a reality in paediatric (147), adult (148) and geriatric (149) medicine, 
however healthcare professionals must be aware of their legal responsibilities 
when prescribing, dispensing and administering modified medicines (104, 146). In 
particular, for pharmacists and nurses it is important to note that in the Republic of 
Ireland, only a registered medical practitioner, a registered dentist or a registered 
nurse prescriber can authorise an off-label use of a medication (104, 146).  
 
1.2.4 Guidelines on medicine administration and medicine modification 
Guidelines on medicine administration are issued by healthcare agencies and 
professional regulatory bodies. In addition, most healthcare settings, whether they 
provide acute or long-term care, have institution specific policies and protocols on 
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medicine administration, many of which provide direction on medicine 
modification.  
 
An Bord Altranais agus Cnáimhseachais na hÉireann, also known as the Nursing and 
Midwifery Board of Ireland (NMBI), regulate the nursing and midwifery professions 
in Ireland. In 2007, the NMBI published guidance for their members on medication 
management which is applicable in all healthcare settings where nurses administer 
medication (150). In addition, the Health Information and Quality Authority (HIQA), 
an independent authority which develops standards for health and social care 
services in Ireland, published Medicines Management Guidance in 2015 which 
applies to providers of residential care services for older people and for children 
and adults with disabilities (151). The administration of modified medications is 
addressed in both publications with comparable recommendations provided in 
each (150, 151). These guidance documents highlight that if a medicine is modified 
and this modification is not authorised in the SPC, the medication has been used 
outside the terms of the product licence. It is advised that if a modification is 
required to facilitate administration to a patient, the medical practitioner and 
pharmacist should be contacted to discuss whether alternative preparations or 
forms of administration would be suitable for the patient. If following consultation 
it is deemed necessary to modify the medication, it must be authorised by the 
medical practitioner on the patient’s medication chart or prescription sheet and 
appropriate advice should be sought from the pharmacist prior to modifying any 
medication (150, 151). Comparable guidance has been issued by regulatory bodies 
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in other jurisdictions (152, 153). These guidance documents recognise the key role 
of the pharmacist, recommending that a pharmacist’s advice should be sought 
regarding the appropriateness of ODF modification. These guidance documents 
serve as the basis for the development of institution-specific policies and protocols 
on medicine administration and modification.  
 
Whilst these guidance documents address ODF modifications in a generic manner, 
specific guidance on medicine modification is limited. Wright et al. (104) have 
published a consensus guideline on medicine administration to adult patients with 
swallowing difficulties which provides an algorithm to support decision making 
around medication use for such patients. It also details important points to consider 
in relation to ODF modifications including the potential for altered pharmacological 
effects, drug stability concerns, the potential risk associated with unintended 
exposure to healthcare staff and other patients etc. (104). In addition, various 
bodies including the UK Medicines Information Service of the National Health 
Service (NHS) have also issued general guidance on ODF modifications with a 
particular emphasis on types of ODFs that should not be modified e.g. modified 
release preparations or enteric coated formulations (154, 155). However, these 
documents do not provide specific recommendations for individual drug products 
or formulations. A variety of information sources are used by healthcare 
professionals when seeking information about the appropriateness of modifying 
specific drug formulations including consultation with peers or other healthcare 
professionals or the use of reference sources (156-158). Reference sources that 
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provide drug-specific recommendations include the SPC for the product, the NEWT 
Guidelines for Administration of Medication to Patients with Enteral Feeding Tubes 
or Swallowing Difficulties (159), the Handbook of Drug Administration via Enteral 
Feeding Tubes (160), The Australian Don’t Rush to Crush Handbook (161) and 
organisation-specific “do not crush” lists. The reference source used depends on 
custom, practice and jurisdiction. While numerous references are available, many 
studies have shown that healthcare professionals are unsure what drug-specific 
information sources are available and where they can be found leading to 
substantial concerns about undertaking modifications (156, 157). In addition, it is 
important to note that any recommendation in a resource other than the SPC still 
represents an off-label use of the medication.  
 
1.2.5 Regulatory perspective 
Ensuring the dose and formulation suitability of medications is an issue of 
importance for all consumers of medication and as a consequence, a number of 
International Conference on Harmonisation (ICH) Guidelines address these topics 
(162, 163). The critical importance of considering formulation suitability in the drug 
development process is acknowledged in the ICH Q8 guideline which states, “in all 
cases the product should be designed to meet patients’ needs”, and that the choice 
of dosage form must be justified, “The Pharmaceutical Development section should 
describe the knowledge that establishes that the type of dosage form selected and 
the formulation proposed are suitable for the intended use” (162). The issue of dose 
suitability is addressed in the ICH E4 guideline which specifies that the impact of 
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age on the dose and dose-response should be assessed during the drug 
development process (163). 
 
Whilst these guidelines highlight the importance of considering dose and 
formulation suitability in drug development (162, 163), no specific reference is 
made to the older adult. However, in recent years the need for patient-centric, age-
appropriate dosage form development to meet the needs of older adults is 
increasingly being acknowledged (164-168). This has led regulatory agencies to 
reflect on whether the regulatory environment supports the development, approval 
and use of medications for this cohort. This growing awareness amongst the 
regulatory community of the unique needs of the older cohort can be traced back 
to 1993, when the ICH published a guideline, “Studies in support of special 
populations: geriatrics E7”, which were adopted by regulatory agencies in Europe, 
the United States of America (USA) and Japan (169). This guideline highlighted that 
participants enrolled in clinical trials should be representative of the patient 
population that will be treated with the drug in clinical practice and as such, sought 
to encourage the inclusion of older patients in clinical trials (169). However, this 
guideline did not discuss the practical suitability of dosage forms for older adults 
nor did it require dose-response studies to be conducted for the older cohort unless 
the drug had effects on the CNS or if analyses indicated a potential for clinically 
significant, age-related differences in the effectiveness or adverse effect profile that 
could not be explained by age-related pharmacokinetic differences alone. Despite 
the adoption of this guideline, repeated commentators have voiced concern about 
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the sub-optimal inclusion of older adults in clinical trials (170, 171). The ICH E7 
Guidelines were subject to a review and a supplementary Questions and Answers 
document was published in 2010, which reiterated the importance of ensuring 
appropriate representation of older patients in clinical trials and encouraged the 
inclusion of older patients from the entire age-range, including those with co-
morbidities and concomitant therapies (172). Whilst the concept paper for this 
addendum raised the issue of difficulties with pill ingestion and dose adjustment 
and suggested that, “the development of galenical formulations that facilitate the 
dose adjustment and enable both the patients and the carers to reduce the risk of 
medication errors and to improve compliance could also be considered” (173), the 
subsequent Questions and Answers document made no reference to these issues 
(172). 
 
The EMA in particular, has taken several steps to ensure that the needs of the older 
cohort are considered in the development and evaluation of new medicines with 
the publication in 2011 of the Geriatric Medicines Strategy (64). In this Strategy, the 
EMA stated their overall vision for geriatric medicines and their two key aims of: (i) 
ensuring that the medicines used by older patients are of high quality, and 
appropriately researched and evaluated, throughout the lifecycle of the product, 
for use in this population and; (ii) improving the availability of information on the 
use of medicines for older people, thereby helping informed prescription (64). In 
August 2017, the EMA further strengthened their commitment to encouraging the 
development of age-appropriate medicines with the publication, for public 
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consultation, of a reflection paper on the pharmaceutical development of 
medicines for use in the older population (174). This reflection paper discusses 
many factors that can affect the acceptability and suitability of medicines for older 
adults including the route of administration and dosage form choice, dosing 
frequency, container closure systems etc. (174). The key issues under consideration 
in this thesis, the modification of ODFs to facilitate administration due to difficulty 
swallowing or for fractional dosing, are described as being important factors that 
should be considered in the development of medications for older adults (174). At 
present, this document is a reflection paper however, at the end of the consultation 
process; guidelines may be developed, informed by the issues raised.  
 
As outlined previously, if a modification or method of administration is not 
expressly authorised in the SPC, then it is considered an off-licence use of the 
medication. In the area of fractional dosing of medicines, concern has been 
expressed by regulatory agencies and academics alike about the presence of non-
functional score lines on tablets (175, 176). It is often assumed by healthcare 
professionals and patients that the presence of such score-lines indicates that the 
tablet can be divided into equal halves for fractional dosing (141). However, this is 
not always the case and the score-line may only be present to allow breaking the 
tablet to facilitate swallowing (177). In 2013, the Food and Drug Administration 
(FDA) issued guidance for industry detailing specific criteria that should be reported 
to support an authorisation application for scored tablets (178). These 
recommendations cover issues including: the appropriateness of the presence of a 
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score line based on the dose achieved following splitting compared to the minimum 
licensed dose; the safety of the split tablet and the risks associated with unintended 
exposure; finished product testing requirements; stability of split tablet portions on 
storage and; the ease of tablet splitting. However, it is important to note that these 
recommendations are non-binding. As regards the EMA’s position on tablet 
splitting, it is stated in the, “Guideline on pharmaceutical development of medicines 
for paediatric use”, that tablet splitting for fractional dosing may not always be 
acceptable particularly for NTI drugs, and the suitability of subdivision should be 
assessed if tablet splitting is considered appropriate for a formulation (179). 
However, these guidelines only relate to paediatric medication development and 
do not apply to medicines for either adults or older adults.  
 
Various pharmacopoeia requirements address the issue of splitting scored tablets 
for fractional dosing. The most recent version of the Ph.Eur. requires that tablets 
with a break mark, that is intended to divide the tablet into equal halves, must 
meet the requirements of the “Test for Uniformity of Mass of Subdivided Parts” 
however, this test is only required during product development and not for finished 
product release testing (180). In 2009, a stimulus article was published by the USP 
which proposed that loss of mass and accuracy of subdivision should be used as 
standards to evaluate the subdivision of scored tablets, but again it was 
recommended that this should only be required during the drug development 
process and not for product release testing (181). To date these standards have yet 
to be adopted in the USP. 
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 These guidelines, concept papers and reflection papers highlight that regulatory 
agencies are engaging with the complex area of medication suitability for older 
patients. Many parallels have been made between the challenges encountered in 
the use, development and approval of medicines for paediatric and older patients 
(182-184). Issues such as the lack of evidence from clinical trials, the absence of 
age-appropriate dosage forms, difficulties with the administration of solid ODFs, 
the absence of dosage forms that facilitate administration of the correct dose, and 
the routine modification of commercially available ODFs to overcome these 
challenges, are common to both groups (182-184). In order to encourage the 
development of age-appropriate formulations for paediatric patients, numerous 
legislative and regulatory changes were implemented (185). Central to these 
changes was the requirement for a Paediatric Investigation Plan (PIP) to be 
submitted to regulatory agencies documenting the studies that would be 
undertaken to assess the suitability of the medication for the paediatric cohort 
(185). There has been debate as to whether a similar “Geriatric Investigation Plan” 
should be implemented for older patients (186). However, a predominant 
argument against the need for a similar approach is the recognition that older 
adults, unlike paediatric patients, do not represent a minority as regards medication 
use but rather are the main users of medicines (187). Therefore, special incentives 
should not be required to ensure that drug development meets the needs of this 
cohort (187). The increased acknowledgement of the needs of older patients, 
combined with recent regulatory and pharmacopoeia changes, should help to 
encourage the routine consideration of the needs of this cohort during drug 
development and approval. Recent research has shown, that despite 
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improvements, there is a need for greater input from geriatric experts in regulatory 
agencies (188). This must also be supplemented by increased research investigating 
the actual challenges faced by older patients and their carers when using 
medication on a daily basis.  
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1.3 Hypothesis, aim and objectives 
1.3.1 Hypothesis 
The hypothesis that underpins this research is that ODFs are not meeting the needs 
of older patients. This necessitates the routine modification of ODFs to tailor them 
to older patients’ requirements. These ODF modifications are frequently outside 
the terms of the product licence and there may not be an evidence-base to support 
decision making around ODF modifications. 
 
1.3.2 Aim 
The overall aim was to investigate ODF modifications for older adults in an Irish 
setting and the factors influencing this practice. 
 
1.3.3 Objectives 
Three specific objectives were defined in order to achieve this aim. The objectives 
of this research were: 
1. To generate an evidence-base describing current literature investigating 
ODF modification practices and the factors that influence this practice. 
 Systematically review the quantitative literature on the prevalence 
of ODF modifications for older adults due to swallowing difficulties 
(Chapter 2). 
 Systematically review the qualitative literature on ODF modifications 
(Chapter 3). 
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2. To examine and describe current ODF modification practices for older adults 
in an Irish setting. 
 To investigate the prevalence of ODF modifications for older adults 
in care settings in Ireland (Chapters 4 and 6). 
 To identify the most commonly modified medications and the 
rationale for modification (Chapters 4 and 6). 
 To ascertain if there is an evidence-base to support these 
modifications (Chapters 4 and 6). 
3. To ascertain the knowledge, attitudes and beliefs of key stakeholders to 
elucidate the factors that influence ODF modifications in an Irish setting. 
 To investigate the knowledge, attitudes and beliefs of nurses about 
the modification of ODFs for older adults (Chapter 5). 
 To ascertain the knowledge, attitudes and beliefs of community-
dwelling older adults and carers about ODF modifications (Chapter 
7). 
 
1.4 Methodological justification 
A mixed methods approach, involving the use of both quantitative and qualitative 
methods, was chosen for this research based on the overall aim of the thesis and 
the complex nature of the topic of interest (189). This methodological approach is 
in keeping with the research paradigm of pragmatism that served as the 
philosophical approach to this thesis (190). It is increasingly recognised in 
healthcare research that neither positivist quantitative approaches nor 
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constructivist qualitative approaches alone can fully elucidate the complex 
phenomena observed and examined in healthcare (191, 192) As a result, 
pragmatism, which advocates the use of the most appropriate research method to 
interrogate a research question, be that quantitative, qualitative or mixed methods, 
has gained popularity in the field of healthcare research (190). 
 
The primary purpose of using mixed methods in this thesis was for 
complementarity i.e. different methods were used to address different aspects of 
the same phenomenon with the goal being the generation of a detailed and 
comprehensive understanding of this complex phenomenon (189). The overall aim 
of this thesis was to investigate ODF modifications in an Irish setting and the factors 
that influence this practice. As with any area of healthcare research, undertaking 
research in this area is inherently complex and to generate sufficient 
understanding, not only of the extent of the problem but also the factors 
influencing this problem, mixed methods are required (189). The first step of this 
research involved systematically reviewing the quantitative (Chapter 2) and 
qualitative (Chapter 3) literature to identify the current evidence base in this area 
and to identify knowledge gaps that should be addressed in this thesis. The findings 
of these reviews went on to inform the development of the individual studies that 
formed this thesis. The quantitative studies investigated the extent of ODF 
modifications for older adults in nursing home settings and were conducted from a 
positivist epistemological approach. While these studies provided necessary 
information on the extent of the problem and elucidated concerns about the 
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practice in an Irish setting, there were limitations to the depth of understanding 
that could be obtained (193). Key criticisms of quantitative based studies include 
the limited input that key stakeholders, particularly patients, have in the research 
with the result that the knowledge base generated does not reflect the priorities 
and needs of end users (194). The result of this can be that the body of research-
based knowledge can be at odds with the knowledge being used by patients, carers 
and other important stakeholders who manage these conditions in reality (194). To 
address this gap, qualitative research methods were used to investigate the 
knowledge, attitudes and beliefs of key stakeholders: nurses and; community-
dwelling patients and carers. The ultimate effect of the utilisation of these 
complementary research methods was that it facilitated the generation of a deep 
understanding of ODF modifications and the factors influencing this practice in an 
Irish setting, as well as ensuring that the limitations of one method were overcome 
by the strengths of the other method (189, 195). In this thesis, a “composite 
analysis” approach to the conduct and presentation of the quantitative and 
qualitative studies was used, as described by Yardley and Bishop (196). In this 
approach, the quantitative and qualitative studies, which investigated different 
aspects of the phenomenon of medicine modification, were conducted and 
presented as individual studies, which can be judged on their individual merits. 
However, the findings are interpreted and inter-related in the discussion, to provide 
more insight than could be achieved by either method alone.  
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1.5 Thesis outline 
This thesis consists of eight chapters which, when combined, provide a thorough 
and detailed investigation of ODF modifications for older adults and the factors 
influencing this practice in an Irish setting. Figure 1.1 provides an overview of the 
thesis and demonstrates how the aim and objectives are addressed by the 
individual studies undertaken as part of this doctoral research and how these 
studies combine to form the thesis. 
 
Chapter One: This chapter introduces this research topic, as well as defining the 
overall aim and objectives of the thesis.  
Chapter Two: This chapter consists of a systematic review of the quantitative 
literature to investigate the prevalence of difficulty swallowing ODFs amongst older 
adults and the prevalence of ODF modifications for older adults (Paper 1). 
Chapter Three: Chapter Three presents the findings of a qualitative systematic 
review on the knowledge, attitudes and beliefs of healthcare professionals, patients 
and carers about the modification of ODFs (Paper 2).  
Chapter Four: This chapter describes a retrospective review of drug charts in an 
aged care facility (ACF) in Ireland which sought to determine the extent of ODF 
modifications in an Irish setting, as well as elucidating the rationale and the 
evidence-base for these modifications (Paper 3). 
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Chapter Five: Chapter Five is a qualitative, semi-structured interview study 
undertaken with nurses working in acute and long-term care settings to explore 
their knowledge, attitudes and beliefs about ODF modifications (Paper 4). 
Chapter Six: Chapter Six describes an undisguised, direct observation of medication 
administration in 5 ACFs throughout Cork in Ireland. This chapter provides more in-
depth information on the extent of ODF modifications, as well as the methods of 
modification and administration of modified medicines (Paper 5). 
Chapter 7: Chapter Seven describes a qualitative, semi-structured interview study 
conducted with community-dwelling older adults and carers of community-dwelling 
older adults. This chapter explores the knowledge, attitudes and beliefs, as well as 
the experiences, of these key stakeholders around ODF modifications (Paper 6). 
Chapter 8: The final chapter of this thesis presents the overall discussion, taking 
into consideration the findings of each study that comprises this thesis (Chapters 2 
to 7). 
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Figure 1.1 Thesis outline
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Chapter 2: Older adults with difficulty swallowing oral dosage 
forms: a systematic review of the quantitative literature                            
 
 
 
Publication one: 
Mc Gillicuddy A, Crean AM, Sahm LJ. Older adults with difficulty swallowing oral 
medicines: a systematic review of the literature. Eur J Clin Pharmacol. 
2016;72(2):141-51. doi:https://doi.org/10.1007/s00228-015-1979-8  
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2.1 Abstract 
2.1.1 Background 
Swallowing ODFs may be challenging due to diagnosed swallowing disorders or 
patient self-reported difficulties. The prevalence of dysphagia increases with age 
due to an age-related decline in swallowing function combined with an increased 
prevalence of medical conditions that predispose to dysphagia. Medication use also 
increases with age; therefore, difficulty swallowing medication may complicate 
medicine administration to older patients. This may result in patients, carers or 
healthcare professionals modifying ODFs to facilitate administration. Modifying 
ODFs can impact on the safety, quality and efficacy of the medication.  
2.1.2 Aim 
The aim of this systematic review was to critically appraise the evidence regarding 
the prevalence of difficulty swallowing ODFs and the modification of ODFs to 
overcome swallowing difficulties in the older cohort.  
2.1.3 Methods 
A systematic search of PubMed, EMBASE, Medline, CINAHL, Scopus, Web of 
Science, The Cochrane Library, PsycINFO and ProQuest Databases was conducted 
from database inception to November 2014. Studies investigating the prevalence of 
difficulty swallowing ODFs or the modification of ODFs were eligible for inclusion. A 
narrative analysis of the results was conducted. 
2.1.4 Results 
Five studies met the inclusion criteria. The results suggested that approximately 
14% of community dwelling older patients experienced difficulty swallowing 
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medicines. Between one quarter and one third of occasions of medicine 
administration to older patients in care facilities involved the modification of ODFs.  
2.1.5 Conclusions  
Difficulty swallowing ODFs and the modification of medicines were reported as 
being common issues in the older cohort. However, evidence to support such 
contentions was limited. Future research should investigate the prevalence of 
medicine modification for older patients in all settings and identify what medicines 
are modified. This would facilitate the targeting of interventions to optimise 
medicine administration to older patients. 
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2.2 Introduction 
Current estimates suggest that the proportion of the global population aged 65 
years and older will increase from 8.0% in 2013 to 15.6% by 2050 (197). This trend 
towards an ageing population is evident in both developing and developed 
countries (198, 199). The ageing population profile presents significant challenges 
for healthcare providers. Older people are the most frequent users of healthcare 
services; they suffer from more chronic diseases (10) and experience increased 
levels of multi-morbidity (34, 35). Consequently, older patients tend to require 
more prescribed medications (34, 200), with studies showing that the number of 
prescribed medications increases with age (201, 202). The appropriate use of 
medicines is crucial to increasing life expectancy, maintaining health and improving 
the quality of life in older patients. However, various age-related changes in 
pharmacokinetics, pharmacodynamics and physiological function need to be 
considered when treating this heterogeneous cohort (92-94). While issues such as 
inappropriate prescribing, increased susceptibility for adverse events and altered 
pharmacokinetics are widely acknowledged (8), practical issues, such as the 
“swallowability” of the pharmaceutical form for individual patients, are often 
overlooked (8). 
 
The preferred route for drug administration is the oral route as it is a simple, 
convenient and non-invasive route that the majority of patients can safely manage 
with minimal input from healthcare professionals (65). However, the advantages of 
this route are lost if a patient cannot swallow the pharmaceutical form prescribed. 
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While the prevalence of dysphagia increases with age due to age-related decline in 
the swallowing mechanism (203) combined with increased prevalence of conditions 
that predispose to dysphagia (72), nonetheless the rates of dysphagia are setting-
dependent. The prevalence in the older cohort increases from approximately 15%, 
in those who live independently in the community (74-76) to between 40 and 60% 
in nursing home residents (80). In addition, many patients without a clinical 
diagnosis of dysphagia will report difficulty swallowing oral medications due to an 
aversion to swallowing medication (83) which in severe cases may be considered a 
form of psychogenic dysphagia or “phagophobia” (204).  
 
If a person experiences difficulty swallowing ODFs, they may resort to altering the 
dosage form or become non-compliant (87, 205). Modifying the dosage form is of 
particular concern as these physical changes e.g. crushing tablets, opening capsules 
etc., may affect the stability, efficacy and safety of the drug (106, 206). 
Administering medicines with food may also cause drug-food interactions which 
can affect drug stability or absorption of the drug in vivo (108, 207). In addition to 
the effect that modifications may have on the stability and therapeutic 
effectiveness of the drug, healthcare professionals need to be cognisant of their 
legal responsibilities in relation to these modifications (208). 
 
Despite the issues associated with the modification of ODFs and the numerous 
guidelines and opinion pieces published regarding the administration of medicines 
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to patients with difficulty swallowing (104, 209), no systematic review was 
identified that investigated the prevalence of difficulty swallowing ODFs or the 
prevalence of medicine modification amongst the older cohort. 
 
2.3 Aim of the systematic review 
The aim of this systematic review was to identify and critically appraise the 
available evidence regarding oral medicine use amongst older patients with 
difficulty swallowing oral medicines. To achieve this aim, two specific objectives 
were investigated: (i) to determine the prevalence of difficulty swallowing ODFs 
amongst older patients and; (ii) to quantify the prevalence of ODF modifications to 
facilitate drug administration to older patients with difficulty swallowing intact 
dosage forms.  
 
2.4 Methods 
2.4.1 Search strategy 
A search strategy was developed based on the use of index and free text terms 
related to (i) oral dosage forms, (ii) methods of modification and (iii) difficulty 
swallowing. The lack of index terms to describe methods of modification 
complicated the development of the search strategy. A comprehensive list of free 
text terms was devised to account for the numerous potential methods of 
modification. A qualified medical librarian reviewed and approved the search 
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strategy prior to undertaking the literature searches. The complete search strategy 
is provided in Appendix 1. 
 
A comprehensive, systematic literature search was undertaken in November 2014. 
The following databases were searched: PubMed, EMBASE, Medline, CINAHL, 
Scopus, Web of Science, The Cochrane Library, PsycINFO and ProQuest Databases. 
Databases were searched from inception to 11th November 2014. No time 
restrictions were placed on the search and articles were not excluded based on the 
date of publication. No language restrictions were applied during the initial 
literature search. The reference lists of included full text articles were hand-
searched to identify any further potentially relevant studies. Citation searching was 
undertaken to identify any potentially relevant articles that cited the papers 
included in the systematic review. 
 
2.4.2 Study selection 
Following removal of duplicates, two reviewers independently screened titles for 
relevance for inclusion (AMG and AMC). The abstracts of studies identified from the 
initial title screen were obtained and independently assessed by two reviewers 
(AMG and LJS) for potential inclusion in the review. Finally, the full text of studies 
identified from the abstract screen were obtained and reviewed independently by 
two reviewers (AMG and; LJS or AMC) to identify studies that met the inclusion 
criteria. In the case of disagreement between the two reviewers at any stage of the 
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selection process, the third researcher independently examined the study and 
following discussion, consensus was reached.  
 
2.4.3 Eligibility criteria 
For this review, similarly to Richey et al. (66), a modification was defined as; “ any 
alteration of an oral dosage form that can be performed at the point of 
administration”. The modification may be undertaken by patients, carers or 
healthcare staff. ODFs were defined as any dosage form that is to be administered 
orally by swallowing i.e. tablets, capsules and oral liquids. The purpose of the 
modification must have been to facilitate administration to a patient with difficulty 
swallowing the intact or unaltered dosage form. In contrast to the review 
undertaken by Richey et al. (66, 210), studies that investigated the modification of 
dosage forms to allow for fractional dosing were not considered.  
 
People aged 60 years and older were, for the purposes of this review, defined as 
older persons. There is a debate surrounding the definition of old age, which is both 
region and demographic specific (211). Most developed countries accept 65 years 
as the standard definition of an older person, however, the UN use 60 years to 
define an older population (199). It was determined a priori that studies involving 
patients aged <60 years would only be included if the results for patients aged ≥60 
years could be extracted and analysed separately. 
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The primary outcomes of interest were (i) the prevalence of difficulty swallowing 
ODFs amongst older patients in all settings and (ii) the prevalence of ODF 
modifications to facilitate administration to older patients with difficulty swallowing 
intact dosage forms. For this review, difficulty swallowing refers to difficulty 
swallowing oral medicines not to aberrations of swallowing function due to disease 
states or medical conditions. A detailed breakdown of the inclusion and exclusion 
criteria for the systematic review is provided in Table 2.1. 
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Table 2.1 Inclusion and exclusion criteria for the systematic review 
Inclusion Criteria Exclusion Criteria 
Studies presenting the results of original 
research in English. 
Systematic reviews, meta-analyses, 
conference abstracts, editorials and 
commentaries. 
Studies investigating oral medicine 
administration to patients aged 60 years 
and older. 
Studies investigating extemporaneous 
compounding of medicines by 
pharmacists. 
 
Studies undertaken in primary, 
secondary and tertiary care. 
Studies in which the purpose of the 
modification is to facilitate fractional 
dosing.  
Studies in which modifications are 
undertaken to facilitate medication 
administration to patients with difficulty 
swallowing the unmodified dosage 
form.  
Studies that solely investigate 
modifications to facilitate administration 
via enteral tubes.  
 
Difficulty swallowing in this review 
refers to difficulty swallowing oral 
medicines, not dysphagia. Studies in 
which patients or carers identify 
patients as having difficulty taking oral 
medicines will be included, even if the 
patient has no clinical evidence of 
swallowing dysfunction. 
Studies investigating the practice of 
covert administration of medications. 
 
Examples of modifications include, but 
are not limited to, crushing, grinding, 
cutting or splitting tablets, breaking 
open capsules, dissolving or dispersing 
intact or modified dosage forms in food 
or liquid, diluting oral liquids or adding 
thickening agents to oral liquids. 
Qualitative studies. 
 
 Studies that describe the results of 
interventions or quality improvement 
programmes. 
 Studies that report on medication 
administration errors. 
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2.4.4 Data extraction 
Data from each study included in the review were extracted into a modified version 
of the data extraction form developed by NICE (212). The data extraction form was 
initially piloted and subsequently modified by one reviewer (AMG). Data extraction 
was performed by one reviewer (AMG), and then independently verified by a 
second reviewer (AMC) for accuracy and completeness as per the Centre for 
Reviews and Dissemination’s Guidance for Undertaking Reviews in Health Care 
(213). In the case of any disagreements regarding the extracted data, following 
discussion, a consensus was reached between both reviewers.  
 
2.4.5 Quality appraisal 
The quality of the included studies was independently assessed by two reviewers 
(AMG and LJS) using a modified version of the critical appraisal criteria developed 
by Loney et al. (214). This scale was developed to critically appraise studies that 
investigate the prevalence or incidence of a health problem and it is particularly 
appropriate for evaluating cross-sectional studies (215). Any disagreement between 
reviewers regarding quality was resolved by discussion and consensus was reached. 
The results of the quality appraisal were used to moderate the findings of the 
review but were not used for inclusion or exclusion of studies. 
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2.4.6 Data synthesis 
Due to the heterogeneity of study settings, methodologies and outcomes reported, 
it was not possible to undertake a meta-analysis of the results. A narrative analysis 
was conducted. 
 
2.4.7 Reporting 
This systematic review was conducted according to the Preferred Reporting Items 
for Systematic Reviews and Meta-Analyses (PRISMA) guidelines (216). These 
guidelines were primarily developed for use for reviews of healthcare interventions. 
Due to the nature of this review, not all of the PRISMA guidelines were relevant, 
however, in so far as practical; the PRISMA guidelines were followed (Appendix 2). 
 
2.5 Results 
2.5.1 Study selection 
A total of 5,490 records were identified from the initial database search. The 
process of study selection is outlined in Figure 2.1. 
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Figure 2.1 Flow diagram of study selection process 
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2.5.2 Study characteristics 
The characteristics of the studies included in the review are summarised in Table 
2.2. All five studies used cross-sectional observational designs (102, 217-220). Two 
studies investigated the medicine taking practices of community-dwelling older 
patients (217, 218) and three studies investigated medication administration to 
older patients in care facilities (102, 219, 220). 
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Table 2.2 Characteristics of included studies 
Author 
(year); 
Country 
Description of 
study settings 
Inclusion Criteria Outcomes of Interest Method of Data 
Collection  
n Age 
categories 
(%) 
Gender 
(%) 
Mehuys et 
al. (2012) 
(217); 
 
Belgium 
86 Randomly 
selected 
community 
pharmacies  
(i) Aged ≥70 yrs, 
(ii) Using at least one 
chronic medicine, 
(iii) Home-dwelling, 
(iv) Ambulatory, 
(v) Regular client of 
the pharmacy 
Drug use: Types of drugs used 
and drug-drug interactions. 
Drug Adherence. 
Drug Knowledge. 
Practical Drug Management 
Capacity. 
Mixed methods: 
Data from electronic 
pharmacy database,  
Interview, 
Questionnaire. 
338 70-80 yrs: 
69.2% 
81-90 yrs: 
29.6% 
>90 yrs: 
1.2% 
M: 
46.4% 
F: 
53.6% 
Mercovich 
et al. 
(2014) 
(102); 
 
Australia 
Convenience 
sample of 2 
ACFs with a 
dementia unit 
and HDU at 
each ACF 
 
3 Medication 
administration 
rounds at each ACF 
over a two week 
period 
Extent of solid dosage form 
modifications. 
Commonly modified 
medications and methods of 
modification and 
administration. 
Direct observation of 
medication rounds. 
160 nr a nrb 
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Author 
(year); 
Country 
Description of 
study settings 
Inclusion Criteria Outcomes of Interest Method of Data 
Collection  
n Age 
categories 
(%) 
Gender 
(%) 
Paradiso et 
al. (2002) 
(219); 
 
Australia 
Stratified 
sample of 10 
ACFs: 4 high-
care; 3 low-
care; 3 co-
located care 
4 Medication rounds 
observed at four 
times during the day 
for four days over a 
one-week period at 
each ACF 
Extent of solid ODF 
modification, and extent of 
modification of medications 
which should not be altered. 
Methods used to alter and 
administer solid ODFs. 
Direct observation of 
medication rounds. 
586 nr a nrb 
Stubbs et 
al. (2008) 
(220); 
 
United 
Kingdom 
Two long-stay 
wards for older 
mentally ill 
inpatients in a 
large psychiatric 
hospital 
Inpatients admitted 
to Ward A or Ward B 
(two long-stay wards 
for older mentally ill 
inpatients) 
Extent of solid dose form 
modification.  
Drugs modified and the 
reasons for modifying. 
Frequency of inappropriate 
modifications. 
 
Direct observation of 
medication rounds. 
32 Median 
age 74yrs 
(range 60-
100 yrs) 
nrb 
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Author 
(year); 
Country 
Description of 
study settings 
Inclusion Criteria Outcomes of Interest Method of Data 
Collection  
n Age 
categories 
(%) 
Gender 
(%) 
Tordoff et 
al. (2010) 
(218); 
 
New 
Zealand 
Community 
setting; random 
sample from 
electoral roll 
(i) Community 
dwelling people,  
(ii) aged ≥75 yrs, 
(iii) taking one or 
more prescription 
medicine 
Participant’s medications,  
knowledge of medications 
purpose,  
problems taking medications, 
adherence. 
Interview using a 
structured questionnaire. 
316 75-79 yrs: 
34.8% 
 
80-84 yrs: 
39.6% 
 
≥85 yrs: 
25.6% 
M: 
54% 
 
F: 46% 
Legend: ACF = Aged Care Facility; yrs = Years; M = Male; F = Female; HDU = High Dependency Unit; nra = Not reported but authors were 
contacted regarding age of patients. Demographic details not recorded but stated that residents of ACFs would generally be >65 years; nrb = 
Not reported. 
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2.5.3 Quality appraisal 
A summary of the results of the quality appraisal for the included studies is 
provided in Table 2.3. The overall scores ranged from 3 to 6. The scores were not 
used to rank studies as low, medium and high quality as it is not recommended to 
rely on a numerical score for judging quality as this can be misleading (213).  
 
Issues identified included the lack of an objective assessment tool to identify the 
prevalence of difficulty swallowing medicines or the frequency of medication 
modification (217, 218). There is currently no validated screening tool available to 
investigate these outcomes. Of the three studies that investigated patients who 
were resident in care facilities (102, 219, 220), none provided adequate 
demographic details about the study settings or subjects. Two of the studies used 
convenience sampling and the sample sizes were small (102, 220). 
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Table 2.3 Quality appraisal of included studies using criteria developed by Loney et al.(214)  
Quality Appraisal Criteria Mehuys et al. 
(2012) (217) 
Mercovich et 
al. (2014) 
(102) 
Paradiso et 
al. (2002) 
(219) 
Stubbs et al. 
(2008) (220) 
Tordoff et al. 
(2010) (218) 
Is the study design appropriate for the research question? Y Y Y Y Y 
Is the sampling frame appropriate? Y N Y U Y 
Is the sample size adequate? Y N Y N Y 
Are objective, suitable and standard criteria used for 
measurement of the health problem? 
N Y Y Y N 
Is the health outcome measured in an unbiased fashion? U Y Y Y Y 
Is the response rate adequate? Y N N U U 
Are the estimates of prevalence given with confidence 
intervals and in detail by subgroup, if appropriate? 
U Y N N Y 
Are the study subjects and the setting described in detail 
and similar to those of interest? 
Y U U U Y 
Overall Score 5 4 5 3 6 
Legend: Y = Yes; N = No; U = Unclear. 
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2.5.4 Difficulty swallowing oral dosage forms 
Two studies reported on the prevalence of difficulty swallowing ODFs (217, 218). 
Both of these studies were undertaken in community settings. The observed 
prevalence in both studies was similar at 14% (218) and 14.8% (217). These studies 
relied on patient self-reported difficulty swallowing solid medications with the 
study by Tordoff et al. (218) enquiring about difficulty swallowing tablets or 
capsules and the study by Mehuys et al. (217) investigating difficulty swallowing 
tablets. The generalizability of these studies is limited by the age of the cohorts 
studied with no patients under 70 years of age being included. The voluntary nature 
of participation and inclusion of ambulatory patients only may also affect the 
generalizability of the results, as a more unwell cohort of patients may have been 
excluded, which may result in an underestimation of the prevalence. Both studies 
investigated a range of medication issues and neither was specifically designed to 
assess difficulty swallowing medication. Recall and reporting bias are also significant 
issues for both studies due to the use of patient self-report.  
 
2.5.5 Frequency of modifying oral dosage forms 
Three of the studies reported on the frequency of modifying ODFs (102, 219, 220). 
All three studies involved the direct observation of medication administration. The 
studies differ in how the frequency of modification was reported which does not 
allow for direct comparison of the results. 
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Mercovich et al. (102) found that 18% of residents (n=29) required at least one 
medication to be altered prior to administration and that in 59% of these cases, two 
or more medications were modified for the resident. The other studies did not 
report the number of patients requiring modified medications but rather reported 
the results as the prevalence of medicine modification as a proportion of the total 
number of solid ODFs administered (220) or occasions of medication administration 
observed (219). Paradiso et al. (219) found that 34% of the 1,207 occasions of 
medication administration observed involved the modification of one or more 
medicines. The prevalence was substantially higher in high-care facilities (46%) 
compared to low-care facilities (2%). Stubbs et al. (220) found that 25.5% of solid 
oral doses administered to older patients in long stay psychiatric wards were 
altered prior to administration. In both studies, residents may have been observed 
more than once. Therefore, it was not possible to determine the proportion of 
patients requiring medication modification. The generalizability of the findings of 
the studies was limited by the small sample size of the studies (102, 220) and the 
use of convenience rather than random sampling by two studies (102, 220). The 
method of data collection was appropriate in all studies as direct observation 
provides more reliable and complete data than chart review. The study conducted 
by Stubbs et al. (220) was undertaken in a psychiatric hospital and therefore the 
results may not be generalizable to the general older population.  
 
All of the studies investigated the modification of solid ODFs. Modifications of liquid 
dosage forms were not considered. Modified medications may be mixed with 
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various food vehicles to facilitate administration following alteration. The frequency 
of addition of modified medicines to food vehicles ranged from 54.9% to 100% of 
administered modified medications (219, 220). Vehicles described included 
sprinkling on meals or toast, mixing with jam, blended fruit, custard, yoghurt, 
honey, chocolate milk and thickened pear juice. 
 
2.5.6 Methods of modifying oral dosage forms 
Three studies reported on the methods used to modify ODFs (102, 219, 220). Two 
of the studies reported that the modifications observed were tablet crushing or 
capsule opening (102, 220), while the study by Paradiso et al. (219) only reported 
on tablet crushing. All of the studies reported the use of a mortar and pestle (102, 
219, 220), the use of pill crushing devices was observed in two studies (219, 220) 
while Mercovich et al. (102) reported the use of individual items e.g. glass cups or 
crushing medication between two spoons. None of the studies reported the 
frequency with which each method of modification was used.  
 
When multiple medications were to be modified prior to administration to patients 
it was found that all the medicines were crushed together in the same vessel (102, 
219). Sharing of crushing equipment between different residents was common, 
with Mercovich et al. (102) reporting that in all instances equipment was shared 
while  Paradiso et al. (219) reported that for 77% of cases of medicine modification 
observed, the equipment was shared. Inadequate cleaning of shared equipment, 
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leading to potential cross-contamination, was witnessed, as was spillage or loss of 
medication from the crushing vessel (102, 219, 220). Mercovich et al. (102) 
reported that in all instances observed, equipment was not cleaned and spillage or 
loss occurred. This was higher than that seen by Paradiso et al. (219) at 59% for 
inadequate cleaning and  70%  for spillage or loss. Stubbs et al. (220) did not report 
the frequency of such issues but did report concerns about inadequate cleanliness 
and spillage and loss from the crushing vessel. 
 
2.5.7 Other issues identified 
The proportion of altered medications that were classified as being unsuitable for 
modification ranged from 4.5% (220) to 17% (219) to 32% (102). The criteria used 
for determining whether the modification was appropriate varied between the 
studies: Stubbs et al. (220) used the manufacturer’s information on contra-
indications; Mercovich et al. (102) used the Australian Don’t Rush to Crush 
Handbook (161); while Paradiso et al. (219) used a list of medications that an expert 
panel determined were unsuitable for alteration.  
 
Stubbs et al. (220) also found that in 44% of cases the modification was not 
authorised by the prescriber. Neither of the other studies reported on the 
frequency with which the modification was authorised by the prescriber. 
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2.6 Discussion 
2.6.1 Summary of evidence 
This systematic review investigated difficulty swallowing ODFs amongst older 
patients and the modifications undertaken to overcome such difficulties. Reports 
and guidance documents for healthcare professionals advise that difficulty 
swallowing medications is a common issue amongst the older cohort and detail the 
clinical, professional and legal implications of modifying medicines (104, 146, 205, 
209). Ultimately, this review aimed to provide an evidence base for these 
guidelines. There was a dearth of evidence regarding this practice in older patients 
and the heterogeneity of the methodologies used and outcomes reported limited 
the comparability of the results.  
 
The results of the studies suggested that the prevalence of difficulty swallowing 
ODFs was approximately 14% amongst community-dwelling older patients. Studies 
investigating this outcome in other settings or in patients aged between 60 and 70 
years were not identified. Difficulty swallowing oral medicines was not the primary 
focus of either study and both studies relied on patient self-reported difficulties. 
These results may underestimate prevalence due to: the voluntary nature of 
participation (217, 218); the use of patient self-reported data (217, 218) and; only 
including ambulatory patients (217). This may mean that a potentially more unwell 
cohort, who may be more likely to suffer with swallowing difficulties, was excluded. 
The use of carers as a data source may help to overcome this limitation. A number 
of studies have previously investigated difficulty swallowing oral medicines in a 
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primary care setting as their primary outcome of interest (86, 87, 221). These 
studies were not eligible for inclusion in this review due to the age range of patients 
studied. The prevalence of difficulty swallowing oral medicines ranged from 11% of 
a general practice population with at least one risk factor for dysphagia (221) to 
37.4% of a general practice population taking at least one solid ODF for 4 weeks or 
more (86), to a high of 60% in a study by Strachan et al. (87). Reasons for the 
substantially higher prevalence in these studies may be due to the inclusion criteria 
used, as subjects were enrolled if they were suspected of having dysphagia (87) or if 
they experienced one or more risk factors for dysphagia e.g. stroke (221).  
 
The method used to assess the prevalence of difficulty swallowing was a major 
issue. The high prevalence in these studies (86, 87, 221) may stem from the 
phrasing of the questionnaire which effectively assessed lifetime prevalence of 
difficulty swallowing any tablet or capsule, whereas Mehuys et al. (217) and Tordoff 
et al. (218) focused on the difficulties patients experienced with their current 
medication regimen. All methods used in primary care settings relied on patient 
self-reported difficulties, which introduced the risk of recall and reporting bias. The 
ideal method of assessment would be direct observation of medication 
administration. However, this is impractical and unfeasible in a primary care setting. 
There is a need for the development of a validated, sensitive and specific tool for 
screening for difficulty swallowing oral medicines both for research purposes and 
for use in clinical practice. Subjective measures of swallowing difficulties have 
shown similar effectiveness to objective methods when screening for dysphagia in a 
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nursing home population (79) which suggests that a subjective tool could be used 
to identify patients with difficulty swallowing medicines. Lack of communication 
between patients and their healthcare provider is a serious concern in this area as 
patients consistently report that they do not inform their healthcare provider about 
difficulties swallowing medication (86, 87, 222) and healthcare professionals do not 
enquire about difficulty swallowing oral medicines prior to prescribing or dispensing 
(86, 87, 222). In fact, lack of communication between healthcare professionals has 
also been reported to be a major issue that hinders the provision of optimum care 
to patients with difficulty swallowing oral medicines (156, 157, 223). Routine use of 
a validated screening tool in daily practice would help to overcome the 
communication deficit evident at present, thereby identifying patients experiencing 
difficulty with their oral medication regimen. 
 
Three studies reported on the alteration of ODFs to facilitate the administration of 
medication to patients with difficulty swallowing. The alteration was the outcome 
of interest in these studies. Between one quarter and one third of medication 
administrations observed involved the modification of ODFs. Only one of the 
studies reported the proportion of patients who were administered modified 
medicines (220), which is a valuable term to quantify. Further research is required 
to establish the prevalence of ODF modifications for older adults in care settings. 
This research is vital to determine the extent of this practice, but in addition, to 
elucidate patient characteristics, medications and formulations that are associated 
with medicine modification. Addressing this knowledge gap is a crucial first step 
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that will facilitate the development of formulations and targeting of interventions 
that will be of most benefit to older patients who require modified medicines. All 
three studies were conducted in settings where a healthcare professional was 
responsible for the decision regarding medicine alteration. No eligible study 
evaluated the prevalence of medication modification in a community setting. 
Research in general populations suggests that 60% of people with difficulty 
swallowing medications resort to modifications to facilitate intake (86, 87). The lack 
of available data on the prevalence of this practice in the older community-dwelling 
cohort is of concern given that patients or their carers may be inappropriately 
modifying medications without involving their healthcare professionals in the 
decision making process (224).  
 
This review has highlighted concerns about the methods used to modify medicines 
and how the modified medicines are subsequently administered. Modifying 
medications may affect the physical and chemical stability of the drug, the clinical 
performance of the drug may be affected through an increase or decrease in 
bioavailability, which may lead to increased adverse effects or toxicity or decreased 
efficacy (110, 206, 225, 226). These changes could potentially affect clinical 
outcomes for patients. In addition, the altered medicine is frequently administered 
in food vehicles (227). The interaction of medicine and vehicle should be considered 
as the vehicle chosen may not be considered an inert excipient in all cases. Previous 
research has shown that administration of medication in food vehicles can alter the 
stability, potency, dissolution and bioavailability of the medication (107, 108, 228). 
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The effect is dependent on the physical and chemical properties of the drug and the 
food vehicle and therefore, any guidance issued regarding compatibility with food is 
both drug and food specific.  
 
All of the studies investigated the modification of solid ODFs (102, 217-220). Studies 
on the modification of oral liquid dosage forms were not found. Liquid dosage 
forms are frequently recommended for patients with difficulty swallowing (104, 
229). However, liquids can be problematic in patients with dysphagia due to the risk 
of aspiration (230). To overcome this, liquids are frequently modified by using 
thickening agents (72), with an average of 8.3% of residents (range 0% to 28%) in 
skilled nursing facilities receiving thickened liquids (231). However, there is a 
paucity of data on whether liquid ODFs are routinely thickened for patients with 
dysphagia. Thickened liquids can significantly impair drug dissolution and 
bioavailability (115, 232), which could potentially have clinical implications due to 
sub-therapeutic drug levels. The magnitude of the effect is both thickener and drug 
specific with a number of factors including the physicochemical characteristics of 
the drug and thickening agent and the viscosity of the resultant liquid contributing 
to the effect on drug dissolution and hence bioavailability in-vivo. Therefore, 
general guidance on the use of thickening agents when administering liquid dosage 
forms cannot be issued. Further investigations are necessary to identify how 
frequently oral liquid medications are thickened, what medications are thickened 
and what thickeners are used. In tandem with this, research on the consequences 
of such modifications is necessary to clarify the potential impact that thickeners 
78 
 
may have on the therapeutic response and to assist healthcare professionals in 
making informed decisions about the most appropriate form of the medication to 
administer. 
 
2.6.2 Implications for practice 
Adherence to medication regimens is associated with improved health outcomes, 
with the risk of mortality amongst patient with good adherence approximately half 
that of poorly adherent patients (233). The majority (69%) of patients with difficulty 
swallowing solid ODFs in a general population admitted to not taking a tablet or 
capsule due to difficulty swallowing the dosage form (87). Therefore, difficulty 
swallowing oral medicines can result in poor adherence to prescribed treatments 
which can negatively impact on health outcomes.  
 
Patients with dysphagia are more likely to experience a medication administration 
error than those without (234). The rate of medication administration errors in four 
hospitals in the UK was found to be 21.1% amongst patients with dysphagia 
compared to 5.9% in patients without dysphagia; with incorrect preparation of 
medicines being the most common error observed for patients with dysphagia 
(234). Therefore, there is a clear need to optimise the administration of medicines 
to older patients with swallowing difficulties to minimise the occurrence of errors 
that could potentially lead to patient harm and poor outcomes for patients. This 
review serves as a starting point from which further research can be undertaken. 
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2.6.3 Limitations 
There are a number of limitations associated with this systematic review. Firstly, 
only a small number of relevant studies were eligible for inclusion. The 
characteristics, methodologies, assessment measures and reported outcomes 
varied significantly between eligible studies which hindered efforts to compare 
results across the studies. Finally, the review only included full text articles in 
English, and different medication administration practices may be evident in 
countries where English is not the first language.  
 
2.7 Conclusions 
Difficulty swallowing ODFs and ODF modifications are reported as being 
commonplace amongst older patients. Despite this generally accepted reality, the 
evidence to support such contentions is negligible. Anecdotally, and from the 
limited evidence available, this is an issue that needs to be addressed. Guidance to 
healthcare professionals on the administration of medicines to patients with 
difficulty swallowing advises that healthcare professionals should consider using 
alternative medications or alternative routes of administration. It is acknowledged 
that if no alternative exists, the ODF may need to be altered however, this “should 
be reserved as a last-resort” (104). Other commentators advise that the practice of 
manipulating medicines should not be accepted but rather patient-centred 
formulations should be developed (63). However, in the interim, healthcare 
professionals, patients and carers are tasked with ensuring that older patients 
receive necessary medication which often necessitates the modification of ODFs 
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due to a lack of suitable alternatives or due to cost considerations. It is evident that 
research is needed to determine: the prevalence of ODF modification; what 
medicines are commonly being modified and; what are the methods of 
modification that are used. The information obtained can be used to alert the 
pharmaceutical industry to develop new products that will meet the needs of older 
patients with swallowing difficulties, as recommended by Stegemann et al. (63). In 
addition, this research will facilitate the targeting of appropriate interventions to 
ensure that the administration of medicines to older patients is optimised and to 
provide healthcare professionals with evidence based recommendations. 
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3.1 Abstract 
3.1.1 Background 
The modification of ODFs can potentially alter drug safety and efficacy in vivo and 
can have significant legal implications for healthcare professionals in the event of 
any adverse events. Despite this, modifications are undertaken to facilitate the 
administration of prescribed doses and to overcome challenges administering 
medication to patients with difficulty swallowing intact dosage forms.  
3.1.2 Aim 
The aim of this systematic review was to synthesize the available qualitative 
evidence on the knowledge, attitudes and beliefs of adult patients, healthcare 
professionals and carers about ODF modifications. 
3.1.3 Methods 
A systematic search of PubMed, Medline (EBSCO), EMBASE, CINAHL, PsycINFO, 
Web of Science, ProQuest Databases, Scopus, Turning Research Into Practice (TRIP), 
Cochrane Central Register of Controlled Trials (CENTRAL) and the Cochrane 
Database of Systematic Reviews (CDSR) was conducted from database inception to 
September 2015. Citation tracking and searching the references lists of included 
studies was also undertaken. Grey literature was searched using the OpenGrey 
database, internet searching and personal knowledge. An updated search was 
undertaken in June 2016. Studies meeting the following criteria were eligible for 
inclusion: (i) qualitative data collection and analysis methods; (ii) full-text available 
in English; (iii) included adult patients who require ODFs to be modified to meet 
their needs or; (iv) carers or healthcare professionals of patients who require ODFs 
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to be modified. Two reviewers independently appraised the quality of the included 
studies using the Critical Appraisal Skills Programme (CASP) Checklist. A thematic 
synthesis was conducted and analytical themes were generated. 
3.1.4 Results 
Of 5,455 records screened, seven studies were eligible for inclusion; three involved 
healthcare professionals and the remaining four studies involved patients. Four 
analytical themes emerged from the thematic synthesis: (i) patient-centred 
individuality and variability; (ii) communication; (iii) knowledge and uncertainty 
and; (iv) complexity. The variability of individual patient’s requirements, poor 
communication practices and lack of knowledge about ODF modification, when 
combined with the complex and multi-faceted healthcare environment, 
complicated decision-making regarding ODF modification and administration.  
3.1.5 Conclusions 
This systematic review has highlighted the key factors influencing the knowledge, 
attitudes and beliefs of patients and healthcare professionals about ODF 
modifications. The findings suggest that in order to optimise ODF modification 
practices, the needs of individual patients should be routinely and systematically 
assessed and decision-making should be supported by evidence-based 
recommendations with multidisciplinary input. Further research is needed to 
optimise ODF modification practices and the factors identified in this review should 
be considered in the development of future interventions. 
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3.2 Introduction 
Medication represents one of the most common and most important therapeutic 
interventions of modern medicine. However, the key to optimising drug therapy is 
ensuring that the right patient receives the right drug at the right dose by the right 
route at the right time (235). Although ODFs, such as tablets and capsules, are 
preferred by both healthcare professionals and patients, modifications may be 
necessary to facilitate administration of the right dose or to allow administration 
via the oral route. ODF modifications can be defined as, “any alteration of an oral 
dosage form that can be performed at the point of administration” (66). These 
modifications are undertaken to facilitate medicine administration to patients with 
difficulty swallowing the intact dosage form (e.g. crushing tablets or opening 
capsules) or to facilitate fractional dosing (administration of part of an ODF to allow 
administration of a lower dose e.g. splitting tablets). Studies have shown that 
between 24.1% and 31.0% of all tablets prescribed for adult patients in primary 
care are split prior to administration (96, 97), with data from LTC facilities indicating 
that 35.4% of older adults receive at least one split medication (100). ODF 
modifications to overcome swallowing difficulties are also prevalent, with up to one 
third of all instances of medicine administration, to older patients in LTC facilities, 
involving ODF modification (236). Data from primary care suggest that between 
9.0% and 37.4% of adult patients experience difficulty swallowing tablets and 
capsules, with the majority of those affected modifying the dosage form to 
overcome these difficulties (85, 86).  
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There are a number of safety and efficacy concerns around modified medicines 
such as reduced dose accuracy, reduced drug stability and the potential to affect 
the pharmacokinetic and pharmacodynamic profile of the drug in vivo (106, 126, 
225, 237-239). Both UK and Irish guidelines advise that modifications should only be 
undertaken as a “last resort” (104) when “other methods have been considered” 
(150). In addition, there is growing concern amongst regulatory agencies about 
fractional dosing (178, 179). However, despite this, evidence shows that ODF 
modifications are a routine part of clinical practice (96, 102, 240). While 
modifications may be necessary due to a lack of appropriate licensed formulations 
(97, 100, 240), it is clear from the literature that modifications occur even in 
situations where alternative formulations are available (96, 97, 219) and/or in 
situations where the modification is expressly prohibited by the manufacturer’s 
guidelines (96, 97, 102, 219).  
 
Whilst quantitative studies have provided useful evidence and highlighted concerns 
about the practice of ODF modification, they have not elucidated the factors that 
influence the decision to modify. Healthcare professionals prescribe, dispense and 
administer modified ODFs (97, 141) and patients modify medicines, often without 
the knowledge of their healthcare providers (87, 97, 141). These quantitative 
studies suggest that both healthcare professionals and patients: experience 
difficulty when modifying medicines; display significant knowledge deficits about 
ODF modification and; have concerns about the appropriateness of modification 
(97, 102, 141, 241). Qualitative research methods can provide further insights into 
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the knowledge, attitudes and beliefs of those who modify to gain a deeper 
understanding of the factors that influence behaviour and practice. Qualitative 
studies have been undertaken to investigate ODF modifications, but to date, no 
systematic review of this literature has been conducted.  
 
3.3 Aim of the systematic review 
The aim of this systematic review was to synthesize the available qualitative 
research on the knowledge, attitudes and beliefs of adult patients, healthcare 
professionals and carers about ODF modification. 
 
3.4 Methods 
Details of the protocol for this systematic review were registered on the 
International Prospective Register of Systematic Reviews (PROSPERO) and can be 
accessed at:  
www.crd.york.ac.uk/PROSPERO/display_record.asp?ID=CRD42015023494. 
 
3.4.1 Search strategy 
A systematic literature search of the following databases, from inception to 
September 2015, was undertaken: PubMed, Medline (EBSCO), EMBASE, CINAHL, 
PsycINFO, Web of Science, ProQuest Databases, Scopus, TRIP, CENTRAL and CDSR. 
No language or date restrictions were placed on the initial search. A comprehensive 
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search strategy was devised, using index and free-text terms related to (i) patients, 
healthcare professionals or carers, (ii) medicine modification, (iii) knowledge and 
(iv) qualitative research. The search strategy was initially developed by the primary 
author (AMG) and subsequently approved by a qualified medical librarian prior to 
undertaking the searches. The search strategy is provided in Appendix 3. The 
reference lists of included studies were hand-searched to identify additional 
relevant studies. Citation tracking of included studies was also undertaken. A search 
for grey literature was completed by searching the OpenGrey database, internet 
searching and using personal knowledge to identify further potentially relevant 
sources. The initial search was undertaken in September 2015 and an updated 
search was undertaken in June 2016. 
 
3.4.2 Study selection 
Titles were screened by one reviewer (AMG) to remove studies that did not meet 
the eligibility criteria. Each abstract was independently screened by two reviewers 
(AMG-full set and LJS or AMC). The full-text of articles identified as potentially 
eligible based on the abstract were obtained and assessed independently by two 
reviewers for inclusion (AMG and; LJS or AMC) according to a priori inclusion and 
exclusion criteria. In the case of any discrepancies between reviewers at any stage, 
a third reviewer independently examined the study and following discussion, a 
consensus on inclusion was reached by all three reviewers. 
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3.4.3 Eligibility criteria 
Studies were eligible for inclusion if they met the following criteria: (i) qualitative 
data collection and analysis methods; (ii) full-text available in English; (iii) included 
adult patients (aged 18 years or older) who required ODF to be modified to meet 
their individual needs or; (iv) included carers or healthcare professionals (doctors, 
nurses, pharmacists, speech and language therapists) of patients who require ODFs 
to be modified. Whilst this thesis, as outlined in Chapter 1, is primarily concerned 
with ODF modifications for older adults, it was decided a priori that, for this review, 
qualitative studies that investigated knowledge, attitudes and beliefs about ODF 
modifications for adult patients in general would be included. The review team felt 
that perceptions and beliefs about modifications for adults were likely to be similar 
to, or at least inform, those for older adults. Therefore, particularly as this is a 
qualitative review, it was felt that use of an arbitrary age cut-off may be 
unnecessarily restrictive and result in useful concepts and insights being missed. To 
ensure the relevance of the findings to the older cohort, it was decided a priori, that 
if there was any evidence that the prominent themes differed based on the age of 
patients, the results would be presented separately. For studies undertaken using 
mixed methods, only the qualitative component was included. Debate exists as to 
whether survey data is considered qualitative or quantitative, which has posed an 
issue in previous qualitative systematic reviews (242). It was decided a priori that 
surveys would be excluded if the results were purely quantitative in nature, as 
these data lack the necessary “conceptual depth and richness” (243). This approach 
has been used previously (244). Quantitative studies, systematic reviews, meta-
analyses, meta-syntheses, editorials, commentaries, letters and conference 
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abstracts were excluded. The primary outcomes of interest were patients’, 
healthcare professionals’ and carers’ knowledge, attitudes and beliefs about the 
modification of ODF.  
 
3.4.4 Data extraction 
The data extraction form developed by NICE (212) was modified by AMG to meet 
the requirements of the systematic review. Data from the included studies were 
extracted by AMG. A second reviewer (AMC) independently verified the extracted 
data. Any disagreements were resolved by discussion and a consensus was reached 
by both reviewers.  
 
3.4.5 Quality appraisal 
The quality of the included papers was independently assessed by LJS and AMG 
using the CASP tool for qualitative research (245). The CASP tool was chosen as it 
allows for assessment of the rigour, credibility and relevance of qualitative research 
(213). In the case of disagreements between reviewers regarding study quality, 
AMC independently assessed study quality and following discussion a consensus 
was reached by all three reviewers. There is debate about the value of undertaking 
a formal quality assessment for qualitative studies (246). Therefore, for this review, 
assessment of study quality was not used to guide inclusion or exclusion of studies 
but rather to moderate the findings of the review based on the quality of the 
studies contributing to the final analytical themes. 
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3.4.6 Data synthesis 
The thematic synthesis approach, as described by Thomas and Harden (2008) (247), 
was used to synthesise the findings of the eligible studies. This approach was 
chosen as it offers the advantage of “staying ‘close’ to the results of the primary 
studies, synthesising them in a transparent way, and facilitating the explicit 
production of new concepts and hypotheses” (247). Through this process, analytical 
themes are generated that offer new interpretations that “go beyond” the results 
of the primary studies (248). The thematic synthesis approach involves three 
stages: (i) free line-by-line coding of the findings of the primary studies; (ii) 
organisation of “free codes” into descriptive themes; (iii) development of analytical 
themes (247). QSR International’s NVivo 10 Qualitative Data Analysis Software was 
used as an aid to the synthesis process (249). Initial line-by-line coding of all text 
labelled “Results” or “Findings” in eligible studies was performed independently by 
two reviewers (LJS and AMG). The coded text was compared to ensure that coding 
was assigned correctly and consistently. The generation of the descriptive themes 
was undertaken by two reviewers (LJS and AMG) during a group discussion. A third 
reviewer (AMC) independently examined and verified the descriptive themes 
generated and consensus was reached by all three reviewers.  Finally, the 
descriptive themes were used to generate analytical themes. Analytical themes 
were initially generated by two reviewers (AMG and LJS) independently, following 
this a number of group discussions were undertaken to consolidate the analytical 
themes identified.  
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3.4.7 Reporting 
This systematic review is reported in accordance with the Enhanced Transparency 
in Reporting the Synthesis of Qualitative Research (ENTREQ) guidelines (248) 
(Appendix 4). 
 
3.5 Results 
3.5.1 Study selection 
In total, 6,911 articles were identified from the database search. Following the 
removal of 1,456 duplicates, 5,455 articles remained. Following the title screen, 
5,290 records were excluded. Of the 165 articles that were examined for eligibility 
based on the abstract, 129 were excluded. The remaining 36 full-text articles were 
reviewed to identify those that met the inclusion criteria for the review. During this 
stage, 31 articles were excluded. Two additional studies were identified through 
citation tracking of the included articles; no additional records were identified from 
hand-searching the reference lists. Therefore, seven articles were included in the 
systematic review. No additional studies were identified in the updated search in 
June 2016. Figure 3.1 outlines the process of study selection. 
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Figure 3.1 Flow diagram of study selection process 
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3.5.2 Study characteristics 
The characteristics of the included studies are summarised in Table 3.1. The views 
of healthcare professionals were examined in three of the studies: one study 
included nurses (156); one included physicians (250) and; one included a mixed 
sample of healthcare professionals (157). The remaining four studies investigated 
the views of patients (251-254). All of the studies involving healthcare professionals 
were directly related to the topic of this review (156, 157, 250). For the studies 
involving patients, one study directly addressed the topic of interest (252). Of the 
remaining three studies undertaken in patient cohorts, two investigated the 
problems experienced by patients in managing their medication (253, 254) while 
one examined factors related to adherence (251). For these three articles, a 
number of the findings addressed the topic of interest and these findings were 
included in the synthesis for the review. Modifications to facilitate fractional dosing 
were discussed in three of the studies (251, 253, 254), while modifications for 
swallowing difficulties were the topic under consideration for four of the studies 
(156, 157, 250, 252). The majority of included studies focused on medications for 
older adults (156, 157, 252-254). Of the remaining studies, one included patients 
between 52 and 92 years of age (251),  while the final study investigated the views 
of physicians about medications for adults with chronic pain and dysphagia (250). 
Therefore, the findings of the review are mainly pertinent to the older cohort and 
no variation in ideas or concepts were evident based on age. 
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Table 3.1 Characteristics of included studies (listed alphabetically according to first author) 
Reference 
(Year) 
Location Participants (n) Method Analysis Aim Analytical 
Themes  
Barnes et al. 
(2006) (156) 
South 
Australia 
Registered Nurses 
(n=11)  
Semi-
structured 
interviews 
Thematic 
analysis broadly 
following 
Ekman and 
Segesten 
To explore issues concerning 
the nursing practice of altering 
medication dose forms prior to 
administration of medicines to 
residents in homes for older 
people 
Patient-centred 
individuality and 
variability; 
Communication; 
Knowledge and 
uncertainty; 
Complexity. 
Borgsteede 
et al. (2011) 
(251) 
The 
Netherlands 
Patients with type 2 
diabetes mellitus 
(T2DM) (n=20) 
Semi-
structured 
interviews 
Content 
analysis and 
constant 
comparison 
To explore both factors related 
to high and lower levels of 
adherence that patients 
experienced in their medication 
use and to reflect upon the 
findings in the context of 
patient education and shared 
decision-making. 
Patient-centred 
individuality and 
variability; 
Knowledge and 
uncertainty; 
Complexity. 
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Reference 
(Year) 
Location Participants (n) Method Analysis Aim Analytical 
Themes  
Kelly et al. 
(2009) (157) 
United 
Kingdom  
Consultant physicians; 
nurses; pharmacists; 
dietician; speech and 
language therapist and; 
a senior lecturer in 
pharmacy practice 
(n=10) 
 
Focus group Content 
analysis using 
Colaizzi’s 
method 
To identify the problems 
experienced by healthcare 
professionals related to 
administering medicines to 
patients with dysphagia and the 
solutions they use to overcome 
them 
Patient-centred 
individuality and 
variability; 
Communication; 
Knowledge and 
uncertainty; 
Complexity. 
Kelly et al. 
(2010) (252) 
United 
Kingdom 
Patients (n=11) Semi-
structured 
interviews 
Content 
analysis using 
Colaizzi’s 
method 
To understand the experiences 
of taking medication for older 
people with dysphagia 
Patient-centred 
individuality and 
variability; 
Communication; 
Knowledge and 
uncertainty; 
Complexity. 
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Reference 
(Year) 
Location Participants (n) Method Analysis Aim Analytical 
Themes  
Notenboom 
et al. (2014) 
(253) 
The 
Netherlands 
Patients aged ≥70 years 
(n=59) 
Semi-
structured 
interviews 
Coded 
according to a 
coding scheme; 
Framework 
type analysis 
To identify the practical 
problems that older people 
experience with the daily use of 
their medicines and their 
management strategies to 
address these problems and to 
determine the potential clinical 
relevance of thereof 
Patient-centred 
individuality and 
variability; 
Knowledge and 
uncertainty; 
Complexity. 
Pergolizzi Jr 
et al. (2014) 
(250) 
United 
States of 
America  
Physicians (n=34) Semi-
structured 
phone 
interviews 
Content 
analysis 
To understand the knowledge, 
attitudes, and practices of 
physicians and the beliefs of 
patients regarding the 
treatment of chronic pain in the 
presence of dysphagia 
 
 
Patient-centred 
individuality and 
variability; 
Communication. 
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Reference 
(Year) 
Location Participants (n) Method Analysis Aim Analytical 
Themes  
Tordoff et al. 
(2010) (254) 
New Zealand Patients ≥65 years 
(n=20) 
Semi-
structured 
interviews 
Grounded 
theory and 
constant 
comparison 
To explore how people aged 65 
years and older in New Zealand 
manage their medicines in their 
own homes and the problems 
and concerns they might have 
with taking them 
Patient-centred 
individuality and 
variability; 
Communication; 
Knowledge and 
uncertainty; 
Complexity. 
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3.5.3 Quality appraisal 
A summary of the results of the quality appraisal for the included studies is shown 
in Table 3.2. All of the studies provided a clear statement of the aims of the 
research, used qualitative methodology appropriately, used an appropriate 
research design and an appropriate recruitment strategy. Three of the studies did 
not provide sufficient detail about data collection (157, 250, 253); with two of the 
studies not discussing data saturation (157, 250) and one not providing detail about 
the use of a topic guide (253). Four of the studies did not address reflexivity which 
relates to the researcher considering their role and potential bias (156, 157, 250, 
253). Two of the studies did not provide sufficient detail about the data analysis 
process, particularly in relation to the number of researchers who performed the 
analysis (157, 250). Finally, one study did not state whether ethical approval had 
been obtained, did not provide participant quotations to substantiate findings nor 
discuss in detail the findings in light of existing evidence or the implications for 
practice (250).  
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Table 3.2 Quality appraisal of included studies using the Critical Appraisal Skills Programme (CASP) Qualitative Research Checklist (245) 
Quality 
Appraisal 
Criteria 
Barnes et al. 
(2006) (156) 
Borgsteede et 
al. (2011) (251) 
Kelly et al. 
(2009) (157) 
Kelly et al. 
(2010) (252) 
Notenboom et 
al. (2014) (253) 
Pergolizzi Jr et 
al. (2014) (250) 
Tordoff et al. 
(2010) (254) 
Clearly stated 
aim(s)? 
√ √ √ √ √ √ √ 
Qualitative 
methodology 
appropriate? 
√ √ √ √ √ √ √ 
Appropriate 
research 
design? 
√ √ √ √ √ √ √ 
Appropriate 
recruitment 
strategy? 
√ √ √ √ √ √ √ 
Data 
collection? 
√ √ U √ U X √ 
Reflexivity? U √ U √ U X √ 
Ethical issues 
considered? 
√ √ √ √ √ X √ 
Rigorous data 
analysis? 
√ √ U √ √ X √ 
Clear 
statement of 
findings? 
√ √ √ √ √ U √ 
Value? √ √ √ √ √ √ √ 
Legend: √ = Yes; X = No; U = Unclear
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3.5.4 Analytical themes 
Four themes emerged from the synthesis: (i) patient-centred individuality and 
variability; (ii) communication; (iii) knowledge and uncertainty and; (iv) complexity. 
 
3.5.4.1 Patient-centred individuality and variability 
The central role of the patient and the importance of recognising the inherent inter- 
and intra-patient variability emerged as a strong theme in all studies (156, 157, 250-
254). Individuality is key and variability of individual patient’s needs and 
requirements has an important role in ODF modification. Although Tordoff et al. 
(254) reported that, “Most people had no difficulty swallowing tablets”, it was clear 
from all the studies that many patients experience difficulty with medication 
administration and modification. A number of factors contribute to this variability 
including: medical conditions (156, 157, 250, 252); patient-related factors (156, 157, 
251-254); and medication-related factors (156, 157, 250-254) which can be further 
complicated by family and institutional influences on decision-making (156, 157).  
 
Many medical conditions can lead to dysphagia/ difficulty swallowing medicines 
thereby complicating medicine administration (156, 157, 250, 252) including: stroke 
(156, 252); cognitive impairment/dementia (156, 157); cancer (250); Parkinson’s 
Disease (156, 157) and; epilepsy (157). However, the variable nature of these 
medical conditions further complicates ODF administration (157, 252), as individual 
patients, despite having similar diagnoses, may have very different medication 
formulation requirements, “The first major theme is the broad spectrum of 
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dysphagia… ‘There are three different categories of patient we’ve got here which 
give us problems with dysphagia’…… each variation of dysphagia brings its own 
problems in relation to medicine administration” (157). In addition, the natural 
progression of these medical conditions means that a progressive decline in 
function is observed (157, 250, 252) or conversely, an improvement in swallowing 
capability can occur, “In the case of participants who were stroke survivors, 
swallowing could gradually improve” (252). Therefore, continuity of medication can 
be problematic with disease progression (157, 250, 252). It is clear that formulation 
choice and decisions regarding modification for individual patients are complicated 
by inherent variability; due to disease stage and severity.  
 
Individual patient-related factors were reported in all studies as being important 
regulators of how medicines are administered. These included: patient decision-
making for example choosing not to take medicines due to difficulty swallowing 
(156, 157, 251, 252) or chewing medicines (253, 254); patient medication 
preferences such as wanting to continue previous administration practices (156, 
252, 254) or preferring to modify medicines despite an intact swallow (156, 252). In 
addition, administration practices varied, not only from patient to patient, but also 
for an individual patient from administration-to-administration and from day-to-day 
(156, 252) depending on additional factors including their mood at the time of 
administration, time of day and the number of medicines being administered. 
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Medication related factors including the size (156, 251-254), texture (252), shape 
(252), taste (156, 157, 252, 253), number of medicines (156, 250-252) and viscosity 
of oral liquids (157) were reported by patients and healthcare professionals as 
impacting on medication suitability and patient acceptability. However, the 
importance of medication characteristics varied from person to person (156, 157, 
252, 254), “Small tablets were generally easier to swallow than large ones although 
one participant found small round ones the hardest to swallow. Three participants 
found large tablets difficult and two said that size and shape were irrelevant” (252). 
Therefore, the preferred formulation characteristics vary from patient to patient, 
which is a crucial factor complicating medicine administration.  
 
The reasons that patients receive modified medicines may not be solely related to 
the individual patient’s needs, requirements or preferences. Family members’ 
influence on healthcare professional’s decision-making was discussed in two studies 
(156, 157). This influence may result in healthcare professionals making decisions 
based on family member’s priorities rather than patient’s preferences, “… [some] 
families tend to pill count and cost monitor and many of them prefer us to press on 
with the tablets and crush them rather than the [liquid] alternative which they 
prefer not to pay for … [t]here have been occasions where we’ve disregarded the 
resident’s request and favoured the family’s insistence in relation to the crushing of 
medication” (156). Institutional and professional issues were also discussed as 
important factors influencing medicine administration practices. Barnes et al. (156) 
highlighted the pressure placed upon nurses to ensure prescribed medicines are 
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administered, “All but one nurse presented the need to ensure that prescribed 
medications were administered as the dominant imperative”, along with the 
pressure to complete medicine administration in a timely manner, “Thus, the 
overall organizational requirements, including completion of the medication round, 
often took precedence over attending to individual needs of particular residents”  
(156).  
 
Numerous options were discussed to overcome difficulties with formulations 
including: changing the formulation, for example to oral liquids (156, 157, 250, 
252); discontinuing unnecessary medications (157, 254); using various coping 
strategies e.g. the chin-tuck position, or using food or various liquids to facilitate 
intake (252-254) or; modifying ODFs (156, 157, 250-254). It was noted that 
alternative formulations were often not available (156, 250) or there was a lack of 
knowledge about the availability of alternatives (156, 252). However, even in 
situations where alternative formulations were available, other problems arose 
including: cost (156, 157, 250); unsatisfactory formulation characteristics (157) and; 
poor patient acceptability (157, 252). Therefore, these issues can result in 
alternatives not being fit for purpose and modifications of ODFs are preferable or 
necessary. 
 
104 
 
3.5.4.2 Communication 
The importance of communication was a recurring theme in the majority of 
included papers (156, 157, 250, 252, 254). While communication plays an important 
role in the optimisation of medicine administration and modification practices, poor 
communication and lack of communication presents a significant barrier that may 
negatively influence medicine administration. Two distinct lines of communication 
were seen; communication between patients and their healthcare professionals 
and communication between healthcare professionals. 
 
Communication between patients and their healthcare professionals 
Communication between patients and their healthcare professionals also 
influenced modification practices and the selection of appropriate alternatives that 
avoided the need for modification. In general, patients had a positive view of their 
healthcare professionals (157, 252). However, there were examples of poor 
communication between patients and healthcare professionals, which negatively 
impacted upon medication adherence; “One man, finding it hard to break his 
aspirin tablets into quarters as prescribed, asked his GP [General Practitioner] to 
change them to the type he’d had in hospital. ‘I’ve told him but he don’t take any 
notice’ ” (254). Good communication and continuity of care were important to 
patients, with locums unpopular as they are unfamiliar with the patient and their 
needs and preferences, “Key points were the need for GP continuity and the 
recognition that locums…are a drawback…So I thought, ‘Don’t call the locum!’” 
(252), “Variability of pharmacist was also identified as a problem, even when the 
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patient went to the same pharmacy: ‘Also, where we go it always seems to be a 
different pharmacist. You never see the same ones. There doesn’t seem to be a 
consistent one there’” (252).  
 
One of the barriers to effective communication seems to focus on the healthcare 
professional’s reactive, rather than proactive, approach to patient’s difficulties or 
preferences (157, 250, 252). This is compounded by the observation by Barnes et al. 
(156) that individual patient’s medication formulation requirements are not 
routinely or systematically assessed. As a result, healthcare professionals are 
unaware of patient’s requirements and make decisions about medicines for their 
patients without fully appreciating their needs. This was particularly true in the case 
of pharmacists with patients reporting that different formulations were dispensed 
without the patient’s views being sought, “Participant 3’s pharmacist had changed 
the formulation of one of his medicines from a smooth-coated, torpedo-shaped 
tablet to a chalky form that he found difficult to take, and he put the change down 
to the tablets being cheaper” (252). However, communication should ideally be a 
two-way process and patients admitted that they often neglected to inform their 
healthcare professionals about the difficulties they experience with medications 
(157, 252). This may be due to many reasons: (i) aphasia (157); (ii) carers collecting 
medicines (252); (iii) patient’s lack of knowledge that alternative formulations may 
be available (252) or; (iv) patients being unwilling to question healthcare 
professional’s decisions (157, 252).  
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Communication between healthcare professionals 
Extensive inter-professional communication to discuss individual patient’s needs 
was reported in two studies (156, 157), “We speak to the pharmacist for him to 
have a look at what medications they’re on to see if those can actually be crushed 
before we actually give them crushed… [t]he (pharmacist) will… give us a suggestion 
as to what tablet, what alternatives we can use…and then we discuss it with the 
medical officer…” (156). However, this inter-professional communication often 
takes place on an informal basis rather than being a routine and systematic process, 
“Nurses were concerned that they were working in an information vacuum, due to 
limited information resources and informal communication with other healthcare 
professionals” (156). While on the whole, communication and information sharing 
between healthcare professionals was noted as an aid to decision-making, a key 
issue, highlighted by Kelly et al. (157), centred on ‘data flow’ with necessary 
information not being available to the appropriate individual in a timely fashion. 
Data flow problems arose due to deficits in communication practices, for example, 
prescriptions tended not to specify the necessary formulation or that a patient had 
dysphagia (157) and communication between specialists and primary care was 
problematic (252). The varying expertise of the different members of the 
multidisciplinary team (MDT) further compounded these communication deficits, 
“Even if medicine charts do contain information on dysphagia there are problems 
identifying a common language… Thus, as identified by the speech and language 
therapist: ‘We are not always sure what we should say...’ ” (157). Therefore, the 
input of many different healthcare professionals was often necessary to make the 
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most appropriate decision, but the lack of a formal communication process hinders 
this. A formal, systematic process of communication between healthcare 
professionals would ensure that all the necessary information is available for 
decision-making and would facilitate information and expertise sharing on a routine 
basis. 
 
3.5.4.3 Knowledge and uncertainty 
Knowledge about medicine modification and administration was an important 
theme that emerged from the synthesis. Although confidence in one’s knowledge 
and abilities was reported by one nurse, “...I rely on my own knowledge of 
medication, which has always been quite comprehensive because I’ve always 
dispensed medication and I’m quite experienced” (156), it was clear that overall 
there was a significant knowledge deficit and uncertainty about medicine 
modification and administration amongst both healthcare professionals (156, 157), 
“… you’re participating in a practice that you’re really not totally au fait with” (156) 
and patients (251, 252), “One of the issues that participants identified was their 
own lack of knowledge” (252). This knowledge deficit arose due to a lack of 
information and guidance related to medicine modification, particularly for 
healthcare professionals (156, 157). It was noted by Kelly et al. (157) that the 
availability of formal guidance or information from the manufacturers is limited as 
modifications generally represent an off-licensed use of the formulation, “…absence 
of information because medicine formulations are frequently altered in order to 
administer them to dysphagic patients and so are given outside licence” (157). This 
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was reiterated by Barnes et al. (156) who highlighted the deficits of commonly used 
resources, “We have a series of medication resources, but not necessarily associated 
with the crushing of tablets, more associated with what the tablets are for” (156). 
 
Consequently, the lack of explicit information resources results in a reliance on 
informal information provided by healthcare professionals or continuation of 
previous medication modification and administration practices. For healthcare 
professionals, seeking the advice and recommendations of other members of the 
MDT was commonly undertaken (156, 157), “…the nurses reported discussing 
individual resident’s medication needs with pharmacists and doctors” (156). 
However, although generally helpful, it was noted that different healthcare 
professionals have different priorities with the result that nurses reported receiving 
conflicting advice which complicated decision-making, “When the nurses sought 
advice about how to decide between the various options with which they were 
faced, they were sometimes given varying and contradictory advice. Different 
professional disciplines (nursing, medicine and pharmacy) that are involved in the 
provision of residential care had conflicting views about what should be done” 
(156). However, it was acknowledged that no one healthcare professional has all 
the knowledge and expertise necessary to make an informed decision for individual 
patients, “… the knowledge related to dysphagia and medication that falls within 
each professional’s sphere of expertise” (157). Therefore, MDT involvement is vital 
to ensure that all necessary expertise is available. Healthcare professionals also 
relied on their previous experience and practice to guide decision-making, “Nurses 
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tend to put their own interpretation on how things are done – governed by perhaps 
their social background in nursing, by their experience in nursing, by their academic 
experience in nursing” (156). The lack of a standard knowledge base, reliance on 
previous practice and varying interpretation of guidance, led to varying and 
inconsistent practices.  
 
Patients were very reliant on information provided by healthcare professionals 
(251, 252), “...you follow his [the doctor’s] advice... The pharmacy provides those 
big information sheets, with everything written clearly. Well you read everything” 
(251). Therefore, healthcare professionals have an important role in providing 
information, knowledge and skills to patients, formally through the provision of 
verbal and written instructions but also informally, through observation of 
healthcare professional’s practice (157, 252). However, both healthcare 
professionals (157) and patients (252) acknowledged that inconsistent practice by 
healthcare professionals led to patient confusion regarding best practice, “… each 
time a different nurse gave it [the medicine] they gave it in a different form… so how 
the patient was meant to learn which form they should do when they go home … it 
would very confusing I would imagine” (157). Similarly to healthcare professionals, 
patients also relied on their previous experience and reported the use of various 
coping mechanisms to overcome difficulties with their medications including using 
food, warm fluids or the chin tuck position to facilitate swallowing and using tablet 
devices or learned techniques to facilitate fractional dosing (251-254).  
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Due to this knowledge deficit, patients and healthcare professionals expressed 
concerns, fears and worries about modifying medicines, including concerns about 
the accuracy of fractional dosing (251, 253), the effect of the modification on the 
pharmacological action of the drug including absorption, the pharmacokinetic 
profile and adverse effects (156, 157, 252). There were also concerns about the 
methods used to modify medicines including the potential for cross-contamination 
(157). Conversely, some healthcare professionals expressed apprehension about 
not modifying medicines as this may lead to medicine discontinuation or choking 
(156, 157).  
 
3.5.4.4 Complexity 
Complexity was a key theme that emerged from the synthesis. Although complexity 
was a factor associated with the themes discussed previously, the overall 
complexity associated with nearly every aspect of decision-making for ODF 
modification ensured its importance as an analytical theme. This complexity was 
particularly related to the need to balance the advantages and disadvantages 
associated with modification and the complexity of the healthcare structure. 
Medicine modification was seen to be both necessary and advantageous as it: (i) 
facilitated administration of vital medicines (156, 252); (ii) promoted adherence 
(157, 252) and; (iii) overcame some of the concerns regarding choking (156) or 
medicine discontinuation due to difficulty swallowing (157). It also facilitated the 
administration of the correct dose for individual patients (253). However, there was 
a conflict between these advantages and the accepted disadvantages of 
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modification (including the lack of information (156, 157), difficulty modifying 
medicines (251, 253, 254), the unlicensed nature of administration (157), the 
impact on nursing workload and time management (156), the taste of modified 
medicines (156, 157, 252) and concerns around the efficacy and safety of modified 
medicines (156, 157, 252, 253)). This conflict must be negotiated by healthcare 
professionals and patients. Decision-making was complicated, as shown by the 
observation by Kelly et al., “Although both problems and solutions were discussed 
by the group, they were not separate issues because a solution in one area could be 
a problem in another” (157), which highlights the dilemma faced when trying to 
balance the conflicting aspects of medicine administration and modification. This 
leads to professional, therapeutic and ethical dilemmas.  
 
This “complex” environment contributes significantly to the challenge of optimising 
ODF administration practices. Barnes et al. (156) summed up the situation, “This 
complex and ‘messy’ environment meant that the implementation and evaluation 
of the process of alteration of medications, rather than being systematic and 
orderly, was often ad hoc”. This complexity arises due to a number of inter-related 
factors: the lack of a systematic, proactive assessment of patient’s needs; the 
absence of clear, explicit evidence-based guidance for staff and patients; the 
informal communication structures and; the hierarchical structure of the healthcare 
system.  
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3.6 Discussion 
This systematic review synthesised the available qualitative research evidence on 
the knowledge, attitudes and beliefs of patients and healthcare professionals about 
the modification of ODFs. Key challenges include; the variability of individual 
patient’s requirements, poor communication practices and lack of knowledge which 
when combined with the multi-faceted healthcare environment complicate 
decision-making regarding ODF modification and administration. Although there 
were a limited number of eligible studies, particularly involving patients, the 
strength of this review lies in the fact that the synthesis included studies 
investigating the perspectives of both healthcare professionals and patients. This 
provides a deeper understanding of the challenges encountered from prescribing 
right through to medication-taking behaviour. In addition, the diverse nature of 
patients in the included studies is a strength of the systematic review as it highlights 
the range of experiences encountered. The similarity of findings between studies 
adds to the validity of the findings and highlights key areas that need to be 
addressed. However, it also served to elucidate differences in the knowledge, 
beliefs and priorities of patients and healthcare professionals which may give rise to 
misunderstandings and conflict in practice.  
 
This review highlights that ODF selection for patients is complicated by the variable 
nature of patient’s needs and preferences, which is influenced by the interplay 
between patient’s medical conditions, patient’s preferences, formulation 
characteristics as well as external influences including family input. Whilst it is 
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widely accepted and recommended that healthcare providers treat the patient as 
an individual and “for services to be tailored to respond to the needs, preferences 
and values of the patient” (255), the continual move towards clinical guidelines, 
protocols and treatment algorithms has raised concerns about the standardization 
of medical care at the expense of individualised patient-centred care (256). While 
there are on-going efforts to ensure that patient’s preferences are considered in 
the implementation of evidence-based guidelines, it is clear from this synthesis that 
variability of patient disease state and preference is a major factor that must be 
considered when choosing appropriate formulations. Therefore, communication, 
between patients and healthcare professionals and between different healthcare 
professionals, is vital. This review has also illustrated however, that poor 
communication between patients and their healthcare professionals is widespread 
and results in poor awareness of patient’s needs. This finding is consistent with 
previous studies that report that patients do not discuss their difficulties with 
medication with their healthcare professionals and healthcare professionals do not 
routinely enquire about these difficulties (86, 87). There is a clear need for the 
routine evaluation of patient’s ODF requirements prior to the prescribing, 
dispensing and administration of medication. This echoes the findings of the 
quantitative systematic review in Chapter 2, which called for the development and 
routine use of a validated screening tool to identify patients with difficulty 
swallowing medication (236). Use of such a tool may help to overcome the current 
communication deficit and informal, ad-hoc assessment process. Communication 
between members of the MDT, particularly at transitions of care, was also shown to 
be suboptimal, which is in-line with previous literature (223). Continuity of 
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healthcare at transitions of care is a major challenge facing the healthcare system 
(257). Again, a formal, systematic process of communication may help to address 
this, as structured communication has been shown to improve the effectiveness of 
information transfer and communication between healthcare professionals (258).  
 
In order to make appropriate decisions for individual patients, healthcare 
professionals require timely access to evidence-based information. A clear issue 
that emerged from the synthesis is the lack of information about the 
appropriateness of ODF modifications which created a knowledge deficit and 
subsequent concern amongst healthcare professionals. Given that patients rely on 
their healthcare professionals to provide advice about medication use, this 
invariably results in a lack of knowledge amongst patients about ODF modifications. 
Previous research has shown an absence of explicit information to support clinician 
decision-making regarding modifications (96). The absence of accurate, evidence-
based information contributes to the concerns of patients and healthcare 
professionals and the complexity of decision-making. Improved education regarding 
ODF modification may be one method of improving knowledge; however this needs 
to be supplemented by increased availability of information about the potential 
consequences of modification of medicines. 
 
This review has highlighted the complexity associated with ODF modifications and 
the challenges of optimising ODF administration. Interventions to reduce 
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inappropriate tablet splitting have focused on the prescriber (259, 260). Both 
studies reported that the implementation of a computerised decision support and 
warning system reduced the frequency of inappropriate splitting, with Hsu et al. 
(260) reporting a substantial effect on prescribing behaviour. However, Quinzler et 
al. (259) reported that half of all alerts were not acted on by the physician despite a 
more suitable formulation being available in 82% of cases. Bourdenet et al. (261) 
investigated if recommendations on crushing tablets could lead to an improvement 
in crushing practices. Following the implementation of these recommendations, 
significant reductions in medicine crushing and inappropriate crushing were seen. A 
study by Hanssens et al.(262) found that a two-day training program improved 
nurses’ knowledge about medicine administration for patients with swallowing 
problems and feeding tubes, however, the impact of this improvement in 
knowledge on practice was not assessed. The results of this synthesis suggest that a 
complex, multi-faceted intervention will be required to optimise ODF modification 
practices and future interventions should be cognisant of the findings of this 
review. Any intervention or quality improvement initiative must consider all the 
factors and challenges encountered by patients and healthcare professionals in 
daily practice. This review has served to highlight some of the prominent 
influencing factors. A gap in the literature is the absence of qualitative research 
investigating carers’ perceptions of ODF modification. Further research 
investigating the views of healthcare professionals and patients is also necessary 
given the limited evidence available. In particular, given the observation that many 
patients without any clinical evidence of dysphagia are modifying ODF without the 
knowledge of their healthcare professionals, further research directly focusing on 
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ODF modification from the perspective of patients is required. Only one such study 
has been reported to date. 
 
The results of the synthesis suggest that to optimise ODF modification and 
administration practices, input is needed from patients and all members of the 
MDT. The needs of patients should be routinely and systematically assessed when 
medications are prescribed and dispensed. Decision-making should take into 
consideration the individual needs of the patient but reliable and pertinent 
information from drug manufacturers, guidelines and recommendations from 
healthcare colleagues are needed to support this.  
 
There were a number of limitations associated with this review. For three of the 
studies involving patients the review topic was not the sole focus of the studies, 
therefore, not all the findings were relevant for inclusion in the synthesis. The 
inclusion of English language articles only, may hinder the generalizability of the 
findings.  
 
3.7 Conclusions 
Through the synthesis of the existing qualitative literature, the findings of this 
systematic review have highlighted that the key factors influencing the knowledge, 
attitudes and beliefs of patients and their healthcare professionals about ODF 
modifications are: patient-centred individuality and variability; communication; 
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knowledge and uncertainty and; complexity. These factors can act as both barriers 
and facilitators to medicine administration and modification. It is evident from the 
synthesis that the individual needs of patients should be routinely and 
systematically assessed and that decision-making should be based on evidence-
based recommendations with multidisciplinary input. Further research is needed to 
optimise ODF modification practices and the findings of this synthesis should inform 
the development of future interventions. 
 
3.8 Acknowledgements 
We would like to acknowledge Mr. Joe Murphy, Medical Librarian, for his assistance 
with the search strategy. 
 
 
 
 
 
 
 
 
 
118 
 
Chapter 4: The modification of oral dosage forms for older 
adults: a retrospective audit of practices in an Irish aged care 
facility 
 
 
Publication three: 
Mc Gillicuddy A, Kelly M, Sweeney C, Carmichael A, Crean AM, Sahm LJ. 
Modification of oral dosage forms for the older adult: An Irish prevalence study. 
International Journal of Pharmaceutics. 2016;510(1):386-93. 
doi:http://dx.doi.org/10.1016/j.ijpharm.2016.06.056  
 
 
 
 
 
 
 
 
 
119 
 
4.1 Abstract 
4.1.1 Background 
Administering ODFs to older patients can be complicated by age-related changes in 
the swallowing mechanism and pharmacokinetic and pharmacodynamic changes 
that alter drug sensitivity. These age-related changes may result in the modification 
of ODFs to facilitate administration or to individualise dosing e.g. crushing or 
splitting tablets or opening capsules. These physical alterations may invalidate the 
product licence and can potentially affect drug quality, safety and efficacy.  
4.1.2 Aim 
The aim of this study was to investigate the appropriateness of ODFs for older 
adults by determining the prevalence of ODF modifications in an aged care facility 
(ACF) in the Munster region of Ireland. Secondary aims included identifying the 
most commonly modified medicines and the evidence-base for these modifications. 
4.1.3 Methods 
Ethical approval was granted for this retrospective, descriptive study by the Clinical 
Research Ethics Committee of the Cork Teaching Hospitals. The study was 
conducted in a 63 bed ACF in the Munster region of Ireland between April and 
August 2015. Patients were eligible for inclusion in the study if they were: (i) aged 
≥65 years and (ii) were resident in continuing care (CC) on the 31st of December 
2014 or were admitted for respite care (RC) between October and December 2014. 
Drug charts and medical notes for eligible patients were obtained. Details of all 
medications administered to patients were recorded. ODF modifications were 
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examined to determine if they were evidence-based: defined as complying with the 
terms of the Product Licence or one of two best practice guidelines (BPGs). 
4.1.4 Results 
In total, 111 patients were included in the study (mean age (standard deviation 
(SD)) 83.0 years (7.8); 66.7% female). Of the study cohort, 35.1% of patients (n=39) 
received at least one modified medicine. Medicines were most commonly modified 
to facilitate fractional dosing (82.0%) followed by to overcome swallowing 
difficulties (10.3%). Sixty-eight instances of medicine modification were undertaken 
for 32 medicines. Of these 68 modifications, 35.3% were authorised in the product 
licence. Of the 44 unlicensed modifications, 14 complied with BPGs. Therefore, 
44.1% of modifications were not evidence-based. 
4.1.5 Conclusions 
This study highlights that clinicians routinely have to tailor commercial ODFs to 
meet older patients’ needs despite the lack of an evidence-base for almost half of 
these modifications. The main factor contributing to the need to modify these 
medications appears to be the lack of appropriate, licensed dosage forms. 
However, reimbursement policies may also play a role. Research is needed to 
optimise medicine administration and to provide clinicians with much needed 
evidence to support their daily practice. 
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4.2 Introduction 
Despite accounting for between 12 and 18% of the population of developed 
countries, people aged 60 years and over, consume approximately 50% of all 
prescribed medicines and are responsible for 60% of medication-related costs (49). 
Given the projected growth in the older population (199), healthcare systems are 
tasked with optimising medication use in an environment of increasing demand and 
expense. Provision of optimum medical care to older patients involves the 
consideration of a number of specific age-related challenges including 
pharmacokinetic and pharmacodynamic changes and increased susceptibility to 
adverse effects (8, 94). Pharmacists’ involvement in strategies to increase the 
appropriateness of medicine use for older patients have shown favourable results 
(263-265), but as the healthcare system moves towards a more multidisciplinary 
approach, pharmacists need to continue to add value to MDTs. Pharmacists are 
recognised experts in medicine and have a unique understanding of all aspects of 
medication use, from formulation to use in a clinical setting. One area where 
pharmacists’ specialised knowledge could be used is in the optimisation of 
medication administration by aiding the selection of appropriate dosage forms for 
the individualised needs of patients. 
 
The oral route of drug administration is preferred as it is the simplest, most 
convenient and safest route of administration (65). Solid ODFs are favoured as they 
facilitate accurate drug dosing, in a manner that ensures the chemical and physical 
stability of the drug (65). However, for certain patients with individualised needs, 
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ODFs may prove problematic (266). Solid ODFs (e.g. tablets and capsules) may need 
to be modified for fractional dosing or to overcome actual or perceived swallowing 
difficulties. ODF modification appears to be quite prevalent in the community 
setting with between 59% (86) and 68% (87) of patients with difficulty swallowing 
medication modifying the ODF to facilitate administration. Tablet splitting is also 
common, with just under one in four tablets prescribed in a German study being 
split prior to administration (96). However, as identified in Chapter 2, there is a 
dearth of specific studies investigating medicine modification for older adults (236). 
Given that the prevalence of dysphagia increases with increasing age (72) and is 
higher in nursing home residents (63), difficulty swallowing oral medicines is likely 
to complicate ODF administration to older adults in ACFs. Older patients represent 
a heterogeneous cohort with a diverse range of pharmacokinetic and 
pharmacodynamic changes that may further complicate dosing. Therefore, ODF 
modifications may be required to meet the individual needs of older patients: to 
facilitate fractional dosing and /or to overcome difficulty swallowing medication. 
There is a clear need, as discussed in Chapter 2, to investigate the proportion of 
older adults receiving modified ODFs and to determine which medications are most 
frequently modified. This chapter aims to address this literature deficit using 
preliminary evidence from an Irish setting.  
 
As previously discussed, ODFs are becoming increasingly complex as dosage forms 
control factors including the: (i) rate; (ii) extent; (iii) site of drug release and; (iv) 
drug stability, both in the dosage form and the gastrointestinal tract (65). If these 
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ODFs are modified to facilitate fractional dosing, the administered dose may not be 
accurate (128) and the method of modification may affect dosing accuracy (237). 
Modifications for fractional dosing or swallowing difficulties may affect the physical 
and chemical stability of the drug or the clinical performance of the drug through 
an increase or decrease in bioavailability, which may lead to adverse effects or 
toxicity or decreased efficacy (106, 110, 225, 226). These changes could potentially 
affect clinical outcomes for patients. In addition, the taste of the modified medicine 
may be an issue, which could impact on patient acceptability and adherence (156, 
157, 252). In Chapter 3, it was evident that a lack of information resources about 
ODF modification resulted in a knowledge deficit about the practice which gave rise 
to uncertainty and concern amongst healthcare professionals. In addition to 
examining current ODF modification practices, it is vital that the evidence-base for 
these modifications is investigated to determine if clinicians are supported in their 
decision-making.  
 
There is a growing acceptance that the needs of the older patient must be 
considered in the design, formulation and evaluation of medicines (64). The EMA 
have highlighted the importance of investigating if the specific needs of the older 
patient are being met and identifying the issues that should be addressed to ensure 
that medicines that are developed are suitable for older patients (267). By 
investigating the use of oral medicines in routine clinical practice, the needs of the 
older adult can be elucidated and drug development adapted to meet these needs. 
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4.3 Aim and objectives 
The overall aim of this study is to investigate if practice-based evidence shows that 
there is a deficit of patient appropriate and patient-centred drug formulations for 
older patients. To achieve this goal, the primary objective of this study was to 
determine the prevalence of ODF modifications for older patients in an ACF, by 
pharmacist-led drug chart review. The secondary objectives were to identify the 
most commonly modified medicines, along with the accompanying rationale and 
the presence or absence of an evidence-base for these modifications.  
 
4.4 Methods 
4.4.1 Ethical approval 
Ethical approval for the study was obtained from the Clinical Research Ethics 
Committee of the Cork Teaching Hospitals, Cork, Ireland (Appendix 5). 
 
4.4.2 Study design and setting 
This retrospective, descriptive study was undertaken in an ACF in the Munster 
region of Ireland between April and August 2015. The ACF comprises a 63-bed unit 
with two distinct patient cohorts: CC patients and RC patients. CC patients are long-
term residents and generally have high dependence levels. RC patients are 
admitted for one or two weeks respite care and are generally reflective of a less 
dependent, community-dwelling population. A research pharmacist (AMG), not 
employed at the ACF, was responsible for data collection.  
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4.4.3 Inclusion criteria 
Patients were eligible for inclusion if they met the following criteria: 
 Aged ≥ 65 years 
 Resident in a CC bed on the 31st of December 2014 or 
 Admitted to a RC bed in the last quarter of 2014 (October to December 
2014). 
 
4.4.4 Data collection 
For all eligible patients, drug charts and medical notes were obtained. Using a 
standardised data collection form, the researcher recorded demographic details for 
each patient (age, gender, category of admission and details of previous swallowing 
assessments).  
 
Details of all drugs administered during 2014 (for CC patients) and in the last 
quarter of 2014 (for RC patients) were recorded. Medicines charted for “when 
required” (PRN) use were only included if the medication was administered. The 
following medication details were recorded: (i) name; (ii) dose; (iii) formulation; (iv) 
strength; (v) route of administration; (vi) instructions for ODF modifications on the 
drug chart and; (vii) initiation and discontinuation dates. In addition, AMG used her 
professional judgement to decide whether a modification would have been 
necessary, based on the dose prescribed, e.g. 12.5mg quetiapine necessitates 
halving of a 25mg tablet. A second pharmacist (MK), experienced in working in a 
126 
 
medication dispensing role in Ireland, analysed 20% of patient records to make an 
independent judgement as to whether a modification would have taken place and 
to allow determination of the inter-rater agreement. Any discrepancies were 
discussed and a consensus was reached about the likelihood of ODF modification. 
 
Medications were categorized using the Anatomical Therapeutic Chemical (ATC) 
classification system. Analysis included recording the number of medications 
administered to patients. For changes in strength or brand of a medication, the 
medication was counted once only. If the formulation changed e.g. from immediate 
release to sustained release, this was recorded as two different medications. For 
non-chronic medications e.g. antibiotics, each non-consecutive administration was 
counted separately. 
 
The evidence-base for the modification was assessed by determining whether the 
modification complied with the terms of the product licence, using the SPC or 
“Patient Information Leaflet” for each formulation. If the modification complied 
with the product licence it was considered to be a “Licensed Modification”. If the 
modification was not authorised using these sources, the modification was checked 
against two BPGs: “The NEWT Guidelines for Administration of Medication to 
Patients with Enteral Feeding Tubes or Swallowing Difficulties” (159) and; the 
“Handbook of Drug Administration via Enteral Feeding Tubes” (160). The 
modification was considered to be evidence-based if it was recommended in at 
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least one of these guidelines. Figure 4.1 details the process of determining whether 
the modification was evidence-based. 
 
 
Figure 4.1 Decision process for determining if a modification was evidence-based 
 
4.4.5 Statistical analyses 
Data were analysed using IBM’s Statistical Package for the Social Sciences (SPSS) for 
Windows, Version 22.0 (IBM Corp., Armonk, NY). Descriptive analysis was 
undertaken for categorical variables and reported as percentages. Mean and SD 
were recorded for normally distributed numeric variables, and median and 
interquartile range (IQR) were reported for non-parametric data.  
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Associations between categorical variables were assessed using Pearson’s Chi-
square test, Yates continuity corrected Chi-square test or Fisher’s Exact test as 
appropriate. The inter-rater agreement between pharmacists for the need for ODF 
modification was measured using Cohen’s Kappa statistic. The guidelines proposed 
by Landis and Koch (268) were used to interpret the strength of agreement 
between raters. P values <0.05 were considered to be statistically significant. 
 
4.4.6 Reporting 
This study is reported in accordance with the “Strengthening the Reporting of 
Observational Studies in Epidemiology” (STROBE) guidelines (269) (Appendix 6). 
 
4.5 Results 
4.5.1 Patient demographics 
In total, 111 patients met the inclusion criteria for the study: 41 in CC and 70 in RC. 
Initially, 117 patients were identified based on the admission criteria; 5 were 
excluded as they were aged <65 years and one was excluded as no drug charts were 
available. Available drug charts were sourced for the 111 included patients. For five 
CC patients, not all drug charts were available. The available charts were treated as 
the full record for these patients. The mean age of study participants (SD) was 83.0 
(7.8) years. The demographic details of the study cohort are summarised in Table 
4.1. 
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Table 4.1 Demographic details of study cohort 
  CC (n=41) RC (n=70) Total (n=111) 
Gender Male 26.8% 37.1% 33.3% 
Female 73.2% 62.9% 66.7% 
Age 65-75 years 19.5% 14.3% 16.2% 
76-85 years 43.9% 51.4% 48.6% 
86-95 years 29.3% 31.4% 30.6% 
≥ 96 years 7.3% 2.9% 4.5% 
Evidence of 
Swallowing 
Assessmenta 
Yes 26.8% 20.0% 22.5% 
No 73.2% 80.0% 77.5% 
Legend: CC = Continuing Care; RC = Respite Care; a = Evidence from patient’s notes 
that they previously had their swallow assessed/ had a recommendation for altered 
consistency food/ fluid 
 
There were no statistically significant differences between the CC and RC groups 
based on gender (χ²yates (1) = 0.817, p=0.366), age range (χ² (3) = 1.918, p=0.590) 
nor evidence of previous swallowing assessment (χ²yates (1) = 0.355, p=0.551). 
 
To assess the inter-rater reliability, records for 20% of patients (n=23) were 
examined by a second pharmacist who made a judgement regarding the 
requirement for medicine modification. There was very strong agreement between 
raters for the need for modification (k = 0.893, p<0.005). The kappa statistic of 
0.893 indicates “almost perfect” agreement (268). 
 
130 
 
4.5.2 Medication use in the study cohort 
The median number of medicines administered to the study cohort during their 
admission was 13 (IQR 9-19). The median number of oral medicines administered 
was 11 (IQR 7-13). There was no statistically significant difference in the likelihood 
of medicine modification for those receiving less than five medicines during their 
admission compared to those who received five or more medicines (p=0.551, 
Fisher’s Exact Test). 
 
4.5.3 Modification of medicines 
Of the 111 patients, 35.1% (n=39) received at least one modified medicine. 
Medicines were significantly more likely to be modified for CC residents than for RC 
patients (χ²yates (1) = 8.542, p<0.05). The proportion of patients receiving at least 
one modified medicine based upon category of admission is shown in Table 4.2. 
 
Table 4.2 Proportion of patients receiving at least one modified medicine according to 
category of admission 
Oral Medicines Modified CC (n=41) RC (n=70) Total (n=111) 
Yes 53.7% 24.3% 35.1% 
No 46.3% 75.7% 64.9% 
Legend: CC = Continuing Care; RC = Respite Care 
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No significant associations were observed between medicine modification and age 
(χ² (3) = 1.942, p=0.585), gender (χ²yates (1) = 0.044, p=0.833) nor evidence of 
previous swallowing assessment (χ²yates (1) = 0.667, p=0.414). 
 
Of the 39 patients who received modified medicines, the majority (69.2%) received 
one modified medicine, 17.9% received two, 7.7% received four, 2.6% received five 
and the remaining 2.6% received 10 modified medicines. The most common reason 
for modifying medicines for patients in the study cohort was to facilitate fractional 
dosing (82.0%). Other reasons included swallowing difficulties (10.3%) and 
percutaneous endoscopic gastrostomy (PEG) administration (5.1%). A low 
percentage of patients (2.6%) had medicines modified to facilitate both fractional 
dosing and to overcome swallowing difficulties. 
 
Table 4.3 provides a breakdown of the most commonly modified medications 
according to ATC classification system. Medicines affecting the CNS were most 
frequently modified. Quetiapine; an atypical antipsychotic, was the most commonly 
modified medication accounting for 23.5% of all incidences of modification.  
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Table 4.3 Most commonly modified medicines according to ATC classification 
ATC Code Classification No. of modified 
medicines 
No. of instances 
of modification 
% 
Alimentary Tract and 
Metabolism 
4 8 11.8% 
Blood and Blood Forming 
Organs 
2 2 2.9% 
Cardiovascular System 
(CVS) 
11 15 22.1% 
Central Nervous System 
(CNS) 
14 41 60.3% 
Anti-infectives for 
Systemic Use 
1 2 2.9% 
Total 32 68 100% 
 
4.5.4 Evidence-base for modifications 
Of the 68 instances of ODF modification, 35.3% of modifications complied with the 
terms of the product licence. Therefore, almost two thirds (64.7%) of all 
modifications were outside the terms of the product licence. Figure 4.2 details the 
proportion of modifications that were licensed according to the reason for 
undertaking the modification. 
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Figure 4.2 Licensing status of modifications categorised by reason for modification (n=68) 
 
Of the 68 instances of medicine modification, 44 did not comply with the terms of 
the product licence. Of these 44, there were 14 that were permitted in at least one 
of the two BPGs. Therefore, 44.1% (n=30) were outside the terms of the product 
licence and were not recommended in either BPG. Table 4.4 details the unlicensed 
modifications and the evidence-base for these modifications. 
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Table 4.4 Evidence-base for unlicensed modifications 
Medication Modification Incidence 
(n=44) 
Comply 
with BPG 
Reason for BPG 
non-compliance  
Available solid ODF 
strengths 
Alternative 
Formulation 
(Licensing Status)* 
Quetiapine  Administer 12.5mg 
(halve a 25mg tablet) 
14 (20.6%) X 1 25mg, 100mg, 200mg 
and 300mg tablets 
Oral Solution or 
Suspension 
(Unlicensed) 
Quetiapine Crush 25mg tablet 2 (2.9%) √ N/A 25mg, 100mg, 200mg 
and 300mg tablets 
Oral Solution or 
Suspension 
(Unlicensed) 
Trazodone Open 100mg capsule 1 (1.5%) √ N/A 50mg and 100mg 
capsules 
150mg tablet 
Oral Solution 
(Licensed but not 
marketed) 
Diazepam Administer 1mg 
(halve a 2mg tablet) 
1 (1.5%) X 2 2mg, 5mg and 10mg 
tablet 
Rectal Solution 
(Licensed); 
Oral Solution or 
Suspension 
(Unlicensed) 
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Medication Modification Incidence 
(n=44) 
Comply 
with BPG 
Reason for BPG 
non-compliance  
Available solid ODF 
strengths 
Alternative 
Formulation 
(Licensing Status)* 
Alprazolam Administer 125mcg 
(halve a 250mcg 
tablet) 
4 (5.9%) X 2 0.25mg, 0.5mg and 
1mg tablets 
Oral Suspension 
(Unlicensed) 
Amitriptyline  Crush 25mg tablet 1 (1.5%) √ N/A 10mg and 25mg 
tablets 
Oral Solution 
(Unlicensed) 
Escitalopram  Crush 10mg tablet 1 (1.5%) X 3 5mg, 10mg, 15mg, and 
20mg tablets 
Oral Drops 
(Licensed but not 
marketed) 
Venlafaxine Crush 75mg tablet 1 (1.5%) √ N/A 37.5mg and 75mg 
(immediate release) 
tablets 
Oral Solution 
(Unlicensed) 
Riluzole Crush 50mg tablet 1 (1.5%) √ N/A 50mg tablet No Alternative 
Warfarin Crush 1mg or 5mg 
tablet 
1 (1.5%) √ N/A 1mg, 3mg and 5mg 
tablets 
Oral Suspension 
(Unlicensed) 
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Medication Modification Incidence 
(n=44) 
Comply 
with BPG 
Reason for BPG 
non-compliance  
Available solid ODF 
strengths 
Alternative 
Formulation 
(Licensing Status)* 
Spironolactone  Administer 12.5mg 
(halve a 25mg tablet) 
1 (1.5%) X 1 25mg, 50mg and 
100mg tablets 
Oral Suspension 
(Unlicensed) 
Pravastatin  Crush 20mg tablet 1 (1.5%) √ N/A 10mg, 20mg and 40mg 
tablets 
No Alternative 
Bumetanide Administer 0.5mg 
(halve a 1mg tablet) 
3 (4.4%) X 2 1mg and 5mg tablets Oral Liquid or 
Injection 
(Licensed but not 
marketed) 
Amlodipine Crush 10mg tablet 1 (1.5%) √ N/A 5mg and 10mg tablets Oral Solution or 
Oral Suspension 
(Unlicensed) 
Rosuvastatin Crush 5mg tablet 1 (1.5%) √ N/A 5mg, 10mg, 20mg and 
40mg tablets 
No alternative 
Midodrine Administer 1.25mg 
(halve a 2.5mg tablet) 
1 (1.5%) X 2 2.5mg and 5mg tablets No  alternative 
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Medication Modification Incidence 
(n=44) 
Comply 
with BPG 
Reason for BPG 
non-compliance  
Available solid ODF 
strengths 
Alternative 
Formulation 
(Licensing Status)* 
Bisoprolol  Administer 0.625mg 
(halve a 1.25mg 
tablet) 
1 (1.5%) X 1 1.25mg, 2.5mg, 
3.75mg, 5mg, 7.5mg 
and 10mg tablets 
Oral solution 
(Unlicensed) 
Timolol and 
bendroflumethiazide 
Administer 5/1.25mg 
(halve a 10/2.5mg 
tablet) 
1 (1.5%) X 1 10/2.5mg tablet No alternative 
Slow Sodium Administer in Yoghurt 1 (1.5%) X 4 600mg tablet No alternative 
Macrogol Administer half a 
sachet 
2 (2.9%) X 1 13.8 gram adult sachet 
6.9 gram paediatric 
sachet 
No alternative 
 
 
 
Nitrofurantoin Open 50mg capsule 2 (2.9%) √ N/A 50mg and 100mg 
tablets 
50mg and 100mg 
capsules 
Oral Suspension 
(Unlicensed) 
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Medication Modification Incidence 
(n=44) 
Comply 
with BPG 
Reason for BPG 
non-compliance  
Available solid ODF 
strengths 
Alternative 
Formulation 
(Licensing Status)* 
Donepezil Crush tablet 2 (2.9%) √ N/A 5mg and 10mg tablets Orodispersible 
Tablet 
(Licensed but not 
marketed); 
Oral Solution 
(Unlicensed) 
Legend: BPG = Best Practice Guideline; 1 = Fractional dosing not recommended; 2 = Score line is only to facilitate breaking for ease of 
swallowing and not to divide into equal doses, therefore, dose cannot be guaranteed; 3 = Disperse do not crush; 4 = Swallow whole with 
water; N/A = Not applicable as the modification was recommended in BPG; X= Did not comply with BPG; √ = Complied with at least one BPG; * 
= Refers to the marketing/licensing status in the Republic of Ireland; Unlicensed= Product licensed outside the Republic of Ireland or a product 
manufactured in a "specials” laboratory (270) 
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4.6 Discussion 
The aim of this study was to determine the prevalence of ODF modifications for 
older patients in an ACF. ODF modifications were frequently undertaken, with over 
one third of residents receiving at least one modified medication. Almost half of all 
necessary modifications were not detailed in current evidence-based guidelines. In 
accordance with previous literature (220, 261), medicines affecting the CNS were 
modified most frequently, followed by drugs acting on the CVS, which indicates that 
these commonly prescribed medication classes, do not meet the needs of older 
patients and further research investigating this is necessary.  
 
There is a lack of comparable evidence on the prevalence of ODF modifications for 
older adults. Previously, an Australian study reported that 18% of older patients 
received crushed tablets (102), while 32.3% of patients in a French study received 
crushed tablets or opened capsules (103). In contrast, in this study, any physical 
alteration of a dosage form, including fractional dosing, was included. Therefore, 
the prevalence of capsule opening and tablet crushing in this study setting is lower, 
but the overall prevalence of ODF modification is higher (35.1%) due to the 
inclusion of fractional dosing. Paradiso et al. (219) found that medicine modification 
was significantly more likely in high-care facilities compared to low-care facilities 
which concurs with the finding that the more dependent CC population were more 
likely to receive modified medicines than the RC cohort. 
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Studies and guidelines (63, 102, 271) have recommended that ODF modifications 
are best avoided due to the clinical and legal risks they pose and research has 
repeatedly called for further staff education and training to improve knowledge 
about the practice (102, 156, 272). However, in order to reduce the prevalence of 
ODF modifications, as observed in this and previous studies (102, 219, 220, 234), it 
is important to firstly consider and address the key factors that give rise to ODF 
modification.  
 
The most common reason for modifying medication in this study was to facilitate 
fractional dosing. Previous research only considered crushing tablets or opening 
capsules (102, 103, 219, 220), with studies investigating tablet splitting considering 
this in isolation (96, 97). Fractional dosing has not been addressed extensively in the 
literature. However, age-related pharmacokinetic and pharmacodynamic changes 
may alter dosing requirements (89, 92, 93), leading physicians to “start low and go 
slow” (273), which may necessitate fractional dosing. Fractional dosing has also 
been proposed as a cost containment measure (274). This study represents a novel 
investigation as any alteration of an ODF was included. The majority of 
modifications for fractional dosing were unlicensed. Modifications for fractional 
dosing could affect dosing accuracy (237) and/or the pharmacological action of the 
drug in vivo. This would depend on factors including the therapeutic index of the 
drug and the characteristics of the formulation. However, to administer the 
appropriate dose for individual older patients, clinicians often need to prescribe 
fractional doses of ODFs (273). This highlights that the dosing requirements of older 
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adults are not being fully met by commercially available ODFs. Regulatory agencies 
are increasingly considering the issue of tablet splitting, with both the FDA and the 
EMA issuing guidelines related to the splitting of scored tablets to facilitate 
fractional dosing (178, 179). However, these guidelines are nonbinding 
recommendations, and in the case of the European guidelines relate to paediatric 
medicines. Therefore, a consensus effort is required to evaluate fractional dosing 
and how it relates to older patients. 
 
In this study the most frequent ODF modification was the halving of 25 mg 
quetiapine tablets. This is a commonly reported modification for older adults (101, 
275) and this modification arises due to a clear and unmet need. Unique patient 
factors undoubtedly contribute to this and have been discussed; i.e. 
pharmacokinetic and pharmacodynamic changes (8, 63, 236). Other studies have 
found that modifications may also arise due to the culture within the institution 
including prescribing, dispensing and administration practices and communication 
and MDT engagement (261, 262, 276). Alternatives to ODF modification 
recommended in the BPGs include unlicensed formulations or alternative medicines 
(104). However, the cost of alternatives can be prohibitive (157). The unlicensed 
formulation alternative for 12.5 mg quetiapine is an oral suspension. This product is 
over 10 times the cost of the halved tablet for 30 doses. Decisions regarding 
medicine use are increasingly dependent on budgetary considerations. Unlike 
quetiapine tablets, quetiapine suspension in the Irish setting is not funded under 
the GMS scheme, which entitles the patient to receive the drug at a substantially 
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reduced price, presenting a significant barrier to the use of this alternative. In 
addition to the cost/reimbursement challenges of these alternative formulations, 
many of these formulations are unlicensed with consequent implications for the 
prescriber (277) and the formulations may be difficult to source (156, 278). 
 
However, direct and indirect costs need to be considered when evaluating the cost-
effectiveness of expensive alternatives compared to modifying ODFs. It has been 
shown that administering a modified medication takes twice as much time as a 
non-manipulated drug (279), with consequent implications for nursing workload. 
Additionally, the cost of any deleterious consequences of inappropriate 
modifications must also be considered. In tandem with this, the potentially 
increased risk of medication errors also needs to be evaluated given the 
observation by Kelly et al. (234) that patients with dysphagia experience a 
significantly higher risk of errors compared to patients without dysphagia. Further 
research is needed to assess the cost-effectiveness of the various options. 
 
In addition to the patient factors and budgetary factors discussed, other 
environmental/cultural factors can also contribute to ODF modification. Other 
studies have suggested that a lack of communication between the various 
healthcare professionals providing care for patients (156, 280), and between 
patients and their healthcare professionals (86, 87, 157), may present a barrier to 
optimisation of ODF administration for individual patients. This study site is unique 
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due to the presence of an on-site medical team and pharmacy, which is unusual in 
an ACF setting. Strict policies regarding the modification of ODFs for swallowing 
difficulties are in place, with a pharmacist reviewing all potential administration 
options. Decisions regarding modification are then made following consultation 
between the medical, pharmacy and nursing teams. The clinical implications of the 
modifications were not formally investigated in this study as it is beyond the scope. 
However, the observed modifications are considered by the authors to be unlikely 
to affect patient outcomes. In contrast, previous studies have reported that ODF 
modifications that could potentially affect patient outcomes/ lead to adverse 
reactions were observed (102, 219). This suggests that MDT involvement and 
detailed policies, as are in place in this study site, can help to ensure that ODF 
modification practices are optimised in so far as possible in situations where there 
is a lack of an evidence-base to support these modifications.  
 
This study highlights that clinicians have no choice but to routinely tailor 
commercial ODFs to meet the needs of older patients. The lack of an evidence-base 
to support the modifications necessary to meet older patient’s needs was of 
concern: over two-thirds of all modifications were unlicensed placing a substantial 
legal burden on the healthcare professionals involved (146, 208). Medication use 
involves balancing the risks associated with the medication and the benefits to be 
gained from treatment. Clinicians may determine that the need for treatment 
outweighs concerns regarding the unlicensed use of the medicine. However, given 
the lack of an evidence-base for 68% of the unlicensed modifications, further 
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research investigating common ODF modifications is required to provide clinicians 
with this evidence-base to support their decision-making. Ideally, clinicians would 
have access to data on the pharmacokinetic profile of modified medicines to allow 
evaluation of the potential clinical consequences of modification. The NEWT 
guidelines are, “a compilation of theoretical, practical and anecdotal information 
from a variety of sources” (159). In some, but not all, cases it may be supported by 
pharmacokinetic data possessed by the pharmaceutical marketing authorisation 
holder. Pharmaceutical companies are only required to provide information on the 
licensed use of medicines. If available, this pharmacological information would 
facilitate clinician decision making, however, issues around legal responsibility for 
any harms would need to be addressed. 
 
A key issue also highlighted from this study is that commercially available, licensed 
ODFs are not meeting the needs of older adults from dosing or swallowing 
perspectives. These ODFs are routinely marketed based on the results of clinical 
trials that exclude older patients (95, 170, 281). There is a clear need for 
researchers, regulators and the pharmaceutical industry to prioritise engaging with 
older patients to facilitate the development of ODFs that meet the needs of this 
expanding patient cohort. A regulatory approach akin to that previously 
implemented to facilitate the development and accessibility of medicinal products 
for use in the paediatric population (282) may be required to achieve this aim. To 
ensure that the needs of older adults can be met, a key step will involve engaging 
with relevant stakeholders including older patients, their carers and healthcare 
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professionals in order to ascertain their needs, priorities and preferences around 
oral medicines. 
 
The generalisability of the study results to other ACFs in Ireland and internationally 
is limited by inclusion of one site. In addition, the CC patients at this site are a highly 
dependent, frail population. However, the respite patients are more representative 
of a community-dwelling older population. There are limited data available on ODF 
modifications for older adults, and this is the first study in an Irish setting. This 
study represents a pilot study. The study was undertaken as a retrospective review, 
with the advantage that a large amount of data was obtained. However, there are 
limitations with this method: modifications may have occurred that were not 
recorded on the drug chart, there is no information about how the modifications 
were performed or how the modified medication was administered. Therefore, the 
prevalence of ODF modifications may be underestimated. Using the results 
generated in this study, a prospective study of medicine administration will be 
undertaken to detail how medicines are modified and subsequently administered. 
 
4.7 Conclusions 
This study provides practice-based evidence that ODF modifications are frequently 
necessary to meet the needs of older patients. Almost half of these modifications 
are not supported by a recommendation in BPGs. Modifications were most 
commonly undertaken to facilitate fractional dosing, followed by to facilitate 
146 
 
administration. The factors contributing to the necessity to modify ODFs for older 
adults are multifaceted. While the lack of availability of appropriate, licensed 
dosage forms is a major factor, other factors also play a role such as prevailing 
budgetary and reimbursement policies. To address the needs of older patients’, 
further research is warranted; to identify problematic medications and any clinical 
implications of modifying medicines but also to address the factors contributing to 
this practice.  
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5.1 Abstract 
5.1.1 Background 
Oral medicines are frequently modified to meet the needs of older adults. However, 
these modifications can have clinical, legal and/or ethical implications. Nurses, in 
acute and long-term care settings, bear responsibility for medicine administration 
and hence, perform these modifications.  
5.1.2 Aim 
The aim of this study was to investigate the knowledge, attitudes and beliefs of 
nurses about ODF modification for older adults. 
5.1.3 Methods 
A qualitative study was conducted using semi-structured, face-to-face interviews 
with nurses providing care to older adults in 16 purposively selected care settings in 
the Munster region of Ireland; 4 acute care (AC) and 12 long-term care (LTC) 
settings. Nurses were recruited by convenience sampling at these sites. Interviews 
were conducted between March 2016 and February 2017. Interviews were audio-
recorded and transcribed verbatim. Data were analysed thematically. Interviews 
were conducted until no new themes emerged using the Francis method. 
5.1.4 Results 
Eighteen nurses participated (83% female, 67% LTC, 33% AC, median age 38.0 years 
(IQR 32.5-52.0)). Three major themes: modifying – a necessary evil; nurses’ role as 
patient advocate and; modifying – we are working very much as a team; and two 
minor themes: fractional dosing; and covert administration; emerged from the 
data. Nurses viewed ODF modifications as being a routine and necessary 
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occurrence in older patient care due to limitations of available formulations and the 
presence of age-related challenges in drug administration. Nurses’ knowledge of 
residents’ requirements ensured that they advocate for those with individualised 
formulation needs, however nurses rely on pharmacists for information about 
modifications. Nurses expressed a desire for supports including increased education 
and ward-specific, pharmacist-developed recommendations on common 
modifications.  
5.1.5 Conclusions 
This study has provided useful insights into the views of nurses regarding ODF 
modification for older adults. The unique and varied formulation requirements of 
older adults must be acknowledged. Increased engagement by healthcare 
professionals, the pharmaceutical industry, regulatory agencies and policy-makers 
is required to facilitate the development of age-appropriate formulations. In the 
interim, practical interventions, informed by the findings of this study, are required. 
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5.2 Introduction 
Medication administration is guided by a number of principles, with the ultimate 
aim of ensuring that the right medication is administered to the right patient at the 
right dosage, in the right form and at the right time (150, 283). Given the global 
trend towards an aging population (199, 284, 285), combined with the high rates of 
medication use amongst the older cohort (49, 201), there is widespread recognition 
of the need to optimise medication use for older adults (8, 286). However, various 
age-related changes, including dysphagia (67, 74, 80) and altered pharmacokinetics 
and pharmacodynamics (89, 92), can complicate the administration of the right 
form or the right dose of oral medication, resulting in ODFs being modified to meet 
the needs of older adults. Modifications of ODFs are of concern for healthcare 
professionals as they can potentially affect therapeutic outcomes for patients and 
adverse events have been reported as a consequence of medicine modification 
(106, 206).  
 
Data from international literature has demonstrated that ODF modifications are 
undertaken to overcome difficulty swallowing (102, 103, 219, 287) and to facilitate 
fractional dosing (100) for older adults. The retrospective review of drug charts in 
an Irish ACF, described in Chapter 4, found that 35% of residents received at least 
one modified ODF during their admission (240). Whilst many of the factors that 
influence the need to modify will be similar across different countries, healthcare 
structures and settings, there may be nuanced, context-specific variables that 
influence the requirement to modify ODFs. Based on the modifications documented 
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in Chapter 4, various factors contributing to the need to modify medications in an 
Irish setting were postulated including supply and reimbursement issues (240). 
However, there is a limit to the insight that can be gained using quantitative 
research methods alone and other factors may play a substantial role in influencing 
daily practice. 
 
Qualitative study methodologies can be used to gain a deeper understanding of the 
factors that influence this practice in healthcare (288). A number of qualitative 
studies have investigated medicine modification (156, 157, 252), however, as 
discussed in the systematic review of qualitative literature described in Chapter 3, 
there is a need for further research in this area given the limited number of studies 
(289). Whilst, “The activities associated with medication management involve the 
nursing, midwifery, medicine and pharmacy professions and the patient/service 
user” (150), ultimately nurses bear responsibility for medicine administration and 
therefore, perform modifications and administer modified medicines, in acute and 
long-term care settings. Despite this, only two previous qualitative studies 
investigated nurses views about medicine modification: an interview study 
conducted with nurses working in nursing homes in Australia (156) and; a focus 
group study from the UK, which investigated the experiences of ten healthcare 
professionals (including five nurses) of the challenges encountered in administering 
medication to patients with dysphagia (157). Neither study considered ODF 
modifications to facilitate fractional dosing. Investigation of the views and 
experiences of nurses about ODF modification will provide an insight into the 
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factors influencing this practice and the challenges encountered by nurses and 
patients on a daily basis. Increased understanding of these factors will aid the 
identification of potential areas for prioritisation for intervention and further 
research. Factors unique to the Irish healthcare setting may also be elucidated. This 
study will contribute to, and further develop, the evidence base in this area, given 
the inclusion of nurses working in acute and long-term care and investigation of all 
types of ODF modifications, including fractional dosing. 
 
5.3 Aim of the study 
The aim of this study was to examine the knowledge, attitudes and beliefs of nurses 
about the modification of ODFs for older adults (aged ≥65 years). 
 
5.4 Methods 
5.4.1 Ethical approval 
Ethical approval for this study was granted by the Clinical Research Ethics 
Committee of the Cork Teaching Hospitals, Cork, Ireland (Appendix 7). 
 
5.4.2 Study design 
Semi-structured interviews were conducted with nurses who provide care for, and 
administer medicines to, older adults (aged ≥65 years) within the Munster province 
in the south of the Republic of Ireland (290). Semi-structured interviews were 
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chosen as rich, in-depth, detailed accounts of participant’s experiences, 
perspectives and opinions can be generated and one-to-one interviews are 
particularly suited for discussing sensitive issues, such as individual nurse’s 
medicine administration practices (288).  
 
5.4.3 Study setting and sampling 
Purposive sampling, which involves actively selecting the most productive sample 
to answer the research questions (291), was utilised for site identification. A 
sampling matrix of important variables was developed to ensure that the range of 
sites providing care for older patients were included. LTC settings from each 
category (public, private and voluntary (publicly funded but governed by a religious 
or charitable organisation)) (25); both with and without specialist dementia units 
(SDUs) were actively sampled (292). Previous research has shown that ODF 
modifications are more common in high dependency units (219). According to the 
Department of Health, the public nursing home sector in Ireland has the highest 
proportion of maximum dependent older people at just over 60%, compared to 
private nursing homes where almost 35% of residents are maximally dependent 
(293). Therefore, the funding category of the LTC site was used as a surrogate 
descriptor for dependency. In addition, ODF modifications have been shown to be 
more common in dementia care units (102), providing the rationale for this 
variable. In the AC setting, both acute geriatric hospital wards and acute stroke 
wards were sought as previous studies have demonstrated that modifications are 
commonly undertaken in wards of these types (261, 287). Interview participants 
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were identified by convenience sampling of nurses within the purposively selected 
sites. Where possible, two of each type of care site, and at least one nurse from 
each site were sought for inclusion in the study. For one category of LTC site, only 
one such facility was available in the geographical area in which the study was 
conducted. 
 
The Medical Director or Director of Nursing at each of the purposively identified 
sites was contacted by telephone or e-mail and provided with details of the study. 
The person in charge approached individual nurses to identify potential 
participants. The inclusion criterion for interview participants was any nurse who 
provides care for, and administers medicines to, older adults (aged ≥65 years) at 
the purposively selected sites. Whilst healthcare assistants are also commonly 
employed in acute and long-term care settings in Ireland, their responsibilities 
centre on personal care and do not usually extend to medication administration. 
Therefore, in an Irish setting, nurses are responsible for medicine administration, 
providing the rationale for choosing nurses as the interview participants for this 
study. It was highlighted to nurses that participation was voluntary and no incentive 
for participation was offered. When a nurse expressed an interest in participating, 
the primary researcher (AMG) followed up with a telephone call to arrange a 
convenient time for the interview. 
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5.4.4 Data collection 
The topic guide was developed by the authors based on a review of the literature 
(289), observations from a prevalence study (240) and the authors’ practical 
knowledge of the research area. The topic guide was modified following piloting 
with an experienced geriatric nurse who provided feedback on the content and 
language. This pilot interview was not included in the analysis. The topic guide 
underwent iterative revision throughout the study, to ensure that emerging themes 
were captured in subsequent interviews. Table 5.1 provides a summary of the topic 
guide. 
 
Table 5.1 Summary of topic guide for interviews 
Medicine administration to older adults 
Experience of medicine modification and medicine administration to older adults 
Knowledge about ODF modification 
Attitudes and beliefs regarding ODF modification 
Factors influencing practice 
Decision-making 
Information sources/ resources used 
Healthcare professionals and their involvement 
Desire for any further resources/ supports 
 
All semi-structured interviews were conducted by AMG, a research pharmacist with 
training in qualitative research methods and qualitative interviewing techniques. 
No relationship was established between the interviewer and the participants prior 
to study commencement. The interviews were conducted in a private area at the 
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participant’s workplace between March 2016 and February 2017. Only the 
interviewer and participant were present during the interview. All participants 
provided written informed consent for participation. Prior to initiating the 
interview, participants completed a demographic data collection form which 
recorded details including: participant’s gender; age; qualifications; length of time 
working with older patients and; details of any specific training undertaken in 
medicine administration. The interviews were audio-taped and transcribed 
verbatim by AMG. Transcripts were not returned to participants for comment and 
repeat interviews were not conducted. The interviewer recorded any relevant field 
notes after conducting the interview. 
 
The method used by Francis et al. (294) was used to determine when data 
saturation had been reached. An initial analysis sample of fifteen and a stopping 
criterion of three were specified a priori. The initial analysis sample was determined 
based on the pre-specified stratification factors in the sampling matrix, which 
sought to recruit at least one nurse from each purposively selected study site. The 
stopping criterion of three required that a further three consecutive interviews 
were conducted, in which no new concepts emerged, to confirm that data 
saturation had been achieved.  
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5.4.5 Analysis 
The “Thematic Analysis” approach, as described by Braun and Clarke (295), was 
used to analyse the data. The data (transcripts) were inputted into QSR 
International’s NVivo 10 Qualitative Data Analysis Software to facilitate analysis 
(249). Thematic analysis involves six phases: (i) familiarisation with the data, (ii) 
generation of initial codes, (iii) searching for themes, (iv) reviewing themes, (v) 
defining and naming themes and (vi) producing the report (295). Data 
familiarisation began at an early stage with data transcription, reading and re-
reading of the data. Open coding (phase 2) was undertaken by one author (AMG) to 
generate initial, non-hierarchical codes. These initial codes were then categorised 
and re-ordered to generate potential themes. The next step involved reviewing and 
refining the themes generated in phase 3. The fifth stage involved further analysis 
to refine the themes and to generate clear definitions and names for each theme. 
The final stage involved drafting of the report. Participants were not asked to 
provide feedback on the study findings.  
 
To ensure that codes were applied consistently, a co-author (MK) independently 
coded a random sample of three interview transcripts. The inter-rater reliability 
between coders was determined by calculating the Kappa Coefficient for interviews 
coded by AMG and MK. The Kappa Coefficient measures the level of agreement, 
and ranges from 0 to 1; with 1 indicating perfect agreement and 0 indicating no 
agreement (268). In addition, each of the co-authors (LJS, AMC and MK) read six 
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interview transcripts to assess if the themes were reflective of the interview 
content, to further ensure the confirmability of the findings.  
 
5.4.6 Reflexivity 
The research team sought to address reflexivity during the design of the study. All 
four authors are pharmacists, and all are female. Two are academic staff members 
(one in Clinical Pharmacy Practice and one in Pharmaceutics) and at the time of the 
study, the other two researchers were PhD students (both in Clinical Pharmacy 
Practice). None of the researchers were employed at any of the study sites and they 
had no prior relationship with any of the nurses who participated in the study. All 
members of the research team have been involved in research investigating ODF 
modifications for older adults. The research team discussed their preconceptions 
and thoughts about the research area and all felt, based on their previous 
experience, that medicine modification was likely to be encountered by nurses in 
older patient care. However, all members of the research team acknowledged that 
they were unaware of the challenges encountered when physically performing 
medicine administration and modification as none had any previous practical 
experience in this area. Therefore, the views of nurses were given primacy and an 
inductive approach was seen to be most appropriate. 
 
5.4.7 Reporting 
This study is reported in accordance with the “Consolidated Criteria for Reporting 
Qualitative Research” (COREQ) guidelines (296) (Appendix 8). 
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5.5 Results 
5.5.1 Characteristics of interview participants 
Eighteen interviews were conducted. The interviews ranged in length from 7 
minutes 19 seconds to 31 minutes 41 seconds, with a mean interview duration (SD) 
of 16 minutes 29 seconds (6 minutes 21 seconds). Twelve of the interviewed nurses 
worked in LTC and six worked in AC. Of the nurses who participated in the study, 
83% were female. The median age of participants was 38.0 years (IQR 32.5-52.0). 
Seventeen nurses provided details about their experience caring for older people 
and the median length of experience in geriatric nursing was 8.0 years (IQR 5.0-
11.5). Table 5.2 describes the characteristics of the interview participants. 
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Table 5.2 Characteristics of interview participants (n=18) 
Characteristic  n (%) 
Gender Male 
Female 
3 (17%) 
15 (83%) 
Age groups 20-29 years 
30-39 years 
40-49 years 
50-59 years 
60-69 years 
1 (6%) 
10 (56%) 
2 (11%) 
4 (22%) 
1 (6%) 
Nurse profession  Staff nurse 
CNM 1 
CNM 2 
Assistant Director of Nursing 
Nurse (not specified) 
4(22%) 
1 (6%) 
5 (28%) 
1 (6%) 
7 (39%) 
Care Setting (n=16) Public LTCF with SDU (n=2) 
Public LTCF without SDU (n=2) 
Voluntary LTCF with SDU (n=1) 
Voluntary LTCF without SDU (n=2) 
Private LTCF with SDU (n=3) 
Private LTCF without SDU (n=2) 
Geriatric Ward in Acute Hospital (n=2) 
Stroke Ward  in Acute Hospital (n=2) 
2 (11%) 
2 (11%) 
1 (6%) 
2 (11%) 
3 (17%) 
2 (11%) 
4 (22%) 
2 (11%) 
Medicine administration training 
completed 
Yes 
No 
17 (94%) 
1 (6%) 
Medication administration training mentioned included: on-site medication 
management training courses, refresher courses, on-line training, undergraduate 
training, pharmacy-provided training 
Legend: CNM = Clinical Nurse Manager; LTCF = Long Term Care Facility; SDU = 
Specialist Dementia Unit 
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5.5.2 Inter-coder reliability 
A Cohen’s Kappa score of 0.924 was obtained which demonstrated aligned thinking 
between coders. In addition, following review of the themes in relation to interview 
content, all authors agreed that the themes generated were representative of the 
content of the interviews. 
 
5.5.3 Themes 
Three major themes emerged from the data: modifying - a necessary evil; nurses’ 
role as patient advocate; modifying- we are working very much as a team. In 
addition, two minor themes emerged: covert administration and; fractional dosing. 
In order to comprehensively discuss nurses’ views on the topic of medicine 
modification, these two minor themes will be briefly addressed. 
 
5.5.3.1 Major themes 
Modifying - a necessary evil 
Modifications of ODFs were viewed by participants as being a routine and necessary 
part of clinical practice and were undertaken on a daily basis as part of drug rounds, 
“That would be a daily basis” (Nurse 12, AC). It was strongly felt that the older 
cohort in particular require modified medicines more frequently, “To be honest I 
think that modifying medicines is a necessity, especially in elderly patients” (Nurse 
2, LTC), “It would be very common here in the unit. It’s a geriatric ward... it would be 
very common I suppose here because of our patient group” (Nurse 10, AC). 
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Participants discussed a number of different types of modifications that they 
encountered, including tablet crushing, capsule opening, tablet splitting, dispersing 
or dissolving tablets and mixing medications with food. However, the modification 
that was reported as being most common was tablet crushing, “In 95% of cases 
when we are talking about modifying medicines we are talking about crushing” 
(Nurse 5, LTC). The necessity to modify medications was seen to be an inevitable 
part of older patient care and participants highlighted common reasons for this 
including: swallowing difficulties or dysphagia, medical conditions with dysphagia as 
a sequela, patient preference or difficulty with large dosage forms, family input and 
formulation characteristics. Overall, age-related swallowing difficulties and 
dementia were the most commonly implicated reasons for ODF modification. It was 
clear from the interviews that formulation suitability is extremely individualised, 
“all patients are so different… so you’d be looking at lots of different types of 
medications… whatever fits in with the individual patient” (Nurse 9, AC) and it is 
vital that each patient’s needs are assessed on a regular basis due to the potential 
for fluctuations in formulation suitability, “…you can see progressively the swallow 
or the level of cognition fluctuates, that affects the swallow and it’s something that 
you are looking at and thinking, oh my god [sic], this patient actually was taking 
oral tablets a matter of weeks ago and now it’s a case of that we’re dispersing them 
and giving them different suspensions… we are just keeping an eye out for ourselves  
[nurses watch for changes in patient’s ability to take different medication 
formulations]” (Nurse 9, AC).  
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Participants reported that alternative formulation options are investigated when 
patients experience difficulty with solid ODFs. Options discussed included changing 
the route of administration or the formulation of the medication e.g. liquid 
formulations, transdermal patches, dispersible tablets etc. The availability of 
appropriate alternative formulations was satisfactory for certain classes of 
medications e.g. antibiotics and anti-dementia medications; and participants 
expressed that in many instances the use of these alternatives was preferable to 
modifying solid ODFs. However, there was an almost universal acknowledgement 
that there were significant limitations associated with alternatives that often 
resulted in modifications of ODFs being required or even preferred including: lack 
of availability or difficulty sourcing alternatives; cost; alternatives not being covered 
on reimbursement schemes; difficulties administering large or small volumes; and 
issues with the viscosity of the liquids that may increase the risk of aspiration, 
“…then we have liquid forms, again it’s hard to give liquid form medications to 
people with swallowing difficulties because of aspiration” (Nurse 13, LTC). 
 
Participants expressed a wide variety of attitudes and beliefs about ODF 
modifications. As stated, it was clear that the majority of participants felt that 
modifications were a routine part of practice. Participants highlighted a number of 
benefits of modifying ODFs including ensuring that vital medications are 
administered and overcoming concerns about not modifying medications e.g. the 
risk of choking or discontinuation of necessary medication, “Your choice is … crush 
the medicine which is what we do… or give the medication in its uncrushed form and 
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run the risk of the person choking on it or not give the medicine at all and then, you 
know, the risk of the illness that’s treating” (Nurse 5, LTC). However, 
notwithstanding the general acceptance of modifications as a routine occurrence, 
participants reported numerous concerns about modifications including: inaccurate 
dosing, altered drug absorption or effectiveness, potential interactions with food 
vehicles used for administration, possible cross-contamination issues, occupational 
hazards for nurses due to exposure to powdered drugs and the unlicensed nature 
of the modified medicines, “Sometimes I question it because… you crush all the 
tablets, they are all kind of going into one, you know, one dust…so are you 
modifying you know… the chemistry or what the tablet actually does because each 
tablet is made up individually… Plus, I don’t know are they getting the full dose of 
what they should be getting, because obviously there is going to be residue inside in 
the crush pouch that you can’t ever get out, and also… some in the yoghurt, or in 
the yoghurt tin or whatever you mix it in. So am, I’d say they probably don’t always 
get the right dose” (Nurse 13, LTC). An additional issue identified by nurses was the 
time-consuming nature of modifications, which impacted on nurses’ time and work-
load, on the patient receiving the modified medicine and on other patients in the 
ward, “It definitely affects nurse’s time…we have a resident here … it takes twenty 
minutes to finish only that patient because everything needs to be crushed 
individually and you have to give everything individually. So it takes a good bit of 
time from you… that will affect the other patients as well… time is everything” 
(Nurse 1, LTC).  
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Overall, it is clear that nurses’ view modifying ODFs as being a key part of their 
medication administration role. Whilst nurses were aware that modifications may 
not be appropriate and did express concerns about the effect of modifications on 
drug action, it is accepted that to meet the many individualised and varied needs of 
older patients, ODF modifications are a necessity, “Look it’s essential….it’s a 
necessary evil… I’m all for modifications because it’s necessary” (Nurse 4, LTC)   
 
Nurses’ role as patient advocate 
Medicine administration was acknowledged by participants as being a key aspect of 
their role and nurses viewed medicine administration as their area of expertise. 
However, from the interviews, it was clear that the responsibilities of nurses extend 
far beyond simply modifying and administering the medication. Nurses are at the 
frontline of healthcare provision and play a central role in every aspect of patient 
care related to ODF modification. Nurses: identify when patients are experiencing 
difficulty swallowing medications; arrange review by appropriate healthcare 
professionals; highlight patient’s requirements and needs to other healthcare 
professionals, especially doctors and pharmacists when prescribing and dispensing 
and; communicate and liaise both with and between members of the MDT. 
Therefore, the input of nursing staff is crucial in the area of medicine modification, 
“Very much nurse led…” (Nurse 6, LTC). The importance of nurses knowing their 
patients was central to this, “…one of the huge advantages of working in care of the 
older person in long-term settings is that you really get to know the patient…” 
(Nurse 7, LTC). Nurses, particularly in LTC, know the patients, and therefore their 
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preferences and requirements, extremely well, “The most important thing is to 
know the person, know each individual” (Nurse 8, LTC). Nurses are also alert to 
subtle changes in the patient that may suggest that the patient is experiencing 
difficulty, “… as their medical condition changes… they’ve become unwell and we 
know that, you know, they’re coughing a lot or that their swallow has changed or 
that they’re not able for their big medications, it’s because we know our patients so 
well I suppose” (Nurse 17, LTC). Participants did acknowledge that although some 
healthcare professionals do consider patient’s formulation requirements, 
particularly those who know the patient or geriatric specialists, overall there was a 
reliance on nurses to communicate patient’s formulation requirements. Nurses 
were cognisant of this responsibility and were particularly aware of highlighting this 
to out-of-hours doctors, “Especially [out-of-hours GP service] you have to be there 
on top of them saying no, this person is liquid, this person is, you know, suspension 
or whatever” (Nurse 6, LTC) and locum nursing staff. Nurses also shoulder 
responsibility for liaising between the various members of the MDT and 
communicating various recommendations within the team as often the MDT 
members communicate through the nursing staff rather than directly, “The 
pharmacist will do a review, the pharmacist leaves instructions, I communicate 
them to the GP” (Nurse 17, LTC).  
 
It was evident that care provision in the area of medicine modification is very much 
nurse-led and nurses play a central role in this area. Nurses appeared to be 
confident in exercising these responsibilities and at the centre of this was their 
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acknowledgement that knowing the patient and developing a good relationship 
with them is a key component of their role. This allows nurses to act as an advocate 
for their patients. For nurses, acting as an advocate for their patients is an intrinsic 
component of their professional responsibility and identity “…none of them can 
speak for themselves, so you have to have somebody that knows them to be able 
to...” (Nurse 8, LTC).  
 
Modifying – we are working very much as a team 
Nurses believed that decision-making around medicine modification requires the 
input and expertise of many different members of the MDT. Nurses repeatedly 
highlighted the importance of ensuring that modifications are safe and appropriate 
“So we’d always make sure that if we’re crushing tablets that it’s safe to do so” 
(Nurse 18, AC). Nurses, throughout the interviews, demonstrated knowledge that 
certain formulations should never be modified e.g. sustained-release and enteric 
coated preparations, which was based on their previous experience with such 
medications, “We’d know as well… the slow release, long acting, enteric coated or 
retard medicines… that we couldn’t be crushing them” (Nurse 14, LTC). Ultimately 
however, nurses acknowledged that drug formulations and modification 
appropriateness was not their area of expertise, “We would always seek external 
advice for that because that’s not our area of expertise” (Nurse 7, LTC), and that 
they always sought information and advice prior to modifying oral medicines, “I 
always say it, I’m not a pharmacist and I’m not a doctor and I think it’s something 
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that, I’m very cautious by nature anyways, am, so it’s something I always double 
and triple check” (Nurse 9, AC).  
 
The main information source for nurses about ODF modification and the availability 
of alternative formulations was the pharmacist, “It is always the pharmacy” (Nurse 
7, LTC). Nurses reported relying on information provided by the pharmacist, “If I 
have any concerns I always ring the pharmacist and I always go by their directions…  
but always check with the pharmacist” (Nurse 2, LTC), “That would be a rule that we 
just don’t go off modifying the tablets ourselves, we have to do it in liaison with the 
pharmacy department so that we know… the patient is getting the benefit of the 
medication, it is not altering the effectiveness of the drug and that it’s safe for the 
patient” (Nurse 10, AC). In general, nurses had very positive views of pharmacists, 
“Our pharmacists are excellent. They are very accommodating to us” (Nurse 3, LTC) 
and pharmacists were seen to be the most knowledgeable member of the MDT in 
relation to modifications, “On a Sunday or a bank holiday, you could discuss it with 
the medical team on call but often... regs [registrars] will tell you really to refer to 
the pharmacy department as soon as possible because I suppose, they’ve the most 
knowledge in relation to medication, the altering and modifying of them” (Nurse 10, 
AC). One nurse did express dissatisfaction with the support provided by a pharmacy 
in the past, “There was one pharmacy alright that were a bit slack that I worked 
with” (Nurse 6, LTC). However, this reliance on pharmacists did present challenges 
in the AC settings when the pharmacy department is closed, “We don’t have any 24 
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hour pharmacy… you know so it may not be appropriate forms, it could be whatever 
you can get” (Nurse 15, AC). 
 
Nurses did mention a number of reference sources e.g. the British National 
Formulary (BNF), the Monthly Index of Medical Specialities (MIMS) and SPCs, 
however, these resources did not provide information related to medicine 
modification “And it’s not really in the MIMS either… it doesn’t say whether you can 
crush it or not” (Nurse 16, LTC). In one AC setting, a ward-specific guideline on 
medicine modification was developed by the pharmacy department which was 
mentioned as a useful resource available at the moment of medication 
administration, “Just definitely, that do-not-crush book, that’s like our bible here” 
(Nurse 12, AC). 
 
The attitudes of interview participants differed regarding the need for more 
resources and supports. Many of the participants expressed satisfaction with the 
supports and systems in place in their workplace. The majority of participants 
reported that they had very good working relationships with other members of the 
MDT and they valued a collaborative approach to decision making in which their 
opinions were listened to and accepted, “We have a very good working relationship 
but generally they don’t question, they accept, you know, our judgement on it I 
suppose” (Nurse 5, LTC). Notwithstanding this finding, some participants did discuss 
a number of potential methods of improving multidisciplinary collaboration 
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including: the MDT meeting to review and discuss patient’s needs and greater 
consideration being given to patient’s formulation requirements by doctors and 
pharmacists when prescribing or dispensing, “I suppose, as a multidisciplinary, 
sitting down as a nurse, GP and pharmacist together… there isn’t enough 
constructive reviewing of that, it’s very much the GP does the monthly round, the 
script goes to the pharmacist, the pharmacist sends it up and the follow up really is 
the nurse” (Nurse 7, LTC). Some participants also expressed a desire for auditing of 
their medication administration practices, “I suppose observing how we are doing it 
because again, you can’t constructively say right, that’s the correct procedure unless 
you actually observe it yourself” (Nurse 7, LTC). A number of other suggestions were 
mentioned including: more education and training from pharmacists and availability 
of a pharmacy-developed, site-specific formulary or online database on commonly 
encountered modifications, “I think all nurses should be given extra pharmacy 
education, especially in specialist areas where we are doing a lot of modifications” 
(Nurse 9, AC), “A pharmacy-led manual on the ward where, whatever amount of 
medications they can go through, whether they state whether this medication could 
be crushed or halved or dissolved in water or whether, you know, it is readily 
available in that particular hospital in liquid form” (Nurse 10, AC). Nurses also 
stated that increased availability of alternative formulations and increased 
recognition by the pharmaceutical industry of the formulation challenges 
encountered by older patients on a daily basis would be welcome, “…older people 
are the greatest consumers of medicines but many of these medicines are tested on 
people... they are young and they are fit and they are not people who normally 
consume those medicines… so you are effectively trialling the drugs on a cohort of 
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people who are very different physiologically and in other regards from the people 
who are going to be consuming them. So that’s another area for researchers... to 
give some consideration to” (Nurse 5, LTC). 
 
5.5.3.2 Minor Themes 
Fractional dosing  
Fractional dosing involves the administration of part of a dosage form e.g. half a 
tablet, to facilitate the administration of a lower dose. Whilst score-lines are often 
present on tablets, in many instances these score-lines do not divide the tablet into 
equal doses but rather allow tablets to be split to facilitate swallowing. When 
participants were asked to discuss the common modifications they encountered in 
practice and the reasons for undertaking modifications, none of the participants 
volunteered fractional dosing. While splitting tablets was commonly mentioned, 
this was to overcome difficulty swallowing large tablets rather than for fractional 
dosing. However, when participants were specifically asked about modifications for 
fractional dosing, it was viewed as being frequently undertaken for older patients, 
“Yeah, daily … some of the medication that we give out on a daily basis doesn’t 
come in a dose that’s prescribed” (Nurse 11, AC). Fractional dosing was felt to be 
necessary for older adults due to a combination of increased sensitivity to higher 
doses and a corresponding lack of commercial formulations that meet these dosing 
requirements, “I see a lot more of it here [fractional dosing on a geriatric ward]…you 
would find that they’re constantly altering doses because some of them might be 
too severe, patients don’t react well and it’s always finding the fine balance to keep 
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some of the patients on an even keel” (Nurse 9, AC), “…splitting the tablet because 
the form, the dosage wouldn’t be available, especially with the anti-hypertensive 
tablet, we always split it or quarter it” (Nurse 1, LTC). Drugs acting on the CNS, 
especially quetiapine (an atypical antipsychotic), and the CVS were the most 
commonly implicated medications, “Seroquel … comes in a 25 mg tablet. That has 
to be split for 12.5. Yet 12.5 is the most common dose… but there is no 12.5 
available” (Nurse 6, LTC). Fractionally dosed medications were often supplied pre-
split by the pharmacy which seemed to account for nurses not considering this a 
modification as they did not physically perform the modification themselves, “The 
pharmacy will do the alteration if they are required, we don’t do it at floor level no” 
(Nurse 17, LTC). In addition, there was a general belief that scored tablets are 
designed to be split in two for fractional dosing, “I mean many tablets as you know 
are scored to be divided in two” (Nurse 5, LTC). However, some nurses did report 
checking with pharmacy colleagues if fractional dosing was appropriate, even for 
scored tablets. While overall, participants did not have many concerns about 
administering fractionally dosed medications, particularly if the pharmacy had split 
the tablets in advance or the tablets were scored, a number of concerns were 
raised including inaccurate dosing, wastage and difficulties splitting tablets, “How 
accurate is the dose?… like, as somebody said to me ‘I gave him the big half’. Yeah, 
that says everything” (Nurse 6, LTC). Overall, participants’ attitudes to the 
modification of ODFs for fractional dosing were distinct from attitudes to 
modifications due to swallowing difficulties or patient preference. This appeared to 
be related to lack of knowledge about the purpose of score lines on tablets and 
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different attitudes towards modifications when tablets are pre-split by the 
pharmacy. 
 
Covert administration  
The modification of ODFs to facilitate covert administration was mentioned by a 
number of participants and it would be remiss not to address this as a separate 
theme. A number of participants acknowledged that covert administration was 
commonly undertaken in the past, particularly for patients with dementia or 
agitated patients, “Now I would admit, I’m a long time in the profession, certainly 
that has happened in the past” (Nurse 5, LTC). The majority of participants who 
discussed covert administration stated that it was not undertaken at their site of 
employment, “Now, it’s not actually done in this hospital” (Nurse 6, LTC) and that it 
is no longer commonly encountered. The ethical implications of covert 
administration and the importance of respecting patient’s wishes was a major 
factor influencing this, “Oh no, no, we would never… if a patient refuses that’s it… 
the law as you may know, says no means no. And no even means no from somebody 
who is cognitively impaired” (Nurse 5, LTC). There was an acknowledgement that 
very occasionally, covert administration occurs but that this is undertaken in strict 
adherence to detailed policies and guidelines on covert administration, following 
discussion with all members of the MDT and the patient’s family and taking the 
importance of the medication into consideration, “We have a policy around it and I 
suppose it would have to be in the person’s best interest whether they need the 
tablet or not” (Nurse 16, LTC). The main challenge discussed by nurses relating to 
174 
 
covert administration was the ethical dilemma that arose when trying to balance 
respecting patient’s wishes and providing optimal medical and pharmacological 
care to individual patients.  
 
5.6 Discussion 
This study has identified the knowledge, attitudes and beliefs of nurses about the 
modification of ODFs for older adults using qualitative, semi-structured interviews. 
Three major themes emerged from the data: modifying – a necessary evil; nurses’ 
role as patient advocate; modifying – we are working very much as a team. The 
findings of this study provide important insights that will enable us to better 
understand ODF modification practices and the challenges that need to be 
addressed to optimise formulation suitability for older adults.  
 
From the results of this study, it is clear that nurses view ODF modifications as 
being a necessity in the care of older patients. Whilst a myriad of factors 
contributed to this, one of the most important influences was the belief that 
formulation suitability is extremely individualised and varies significantly between 
patients due to e.g. medical conditions, patient preference, severity of dysphagia 
and the clinical status of the patient. This finding concurs with the qualitative 
systematic review on the views of healthcare professionals and patients about ODF 
modification which found that patient-centred individuality and variability was a 
key driver of ODF modification (289). Whilst it was noted that alternatives to solid 
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ODFs are often simply not available, it was also highlighted that modifications are 
often preferred due to unsatisfactory properties of available alternative oral liquid 
formulations such as: viscosity and the consequent risk of aspiration; expense; 
difficulties sourcing and; difficulties administering the necessary volume. These 
reported challenging properties of alternative formulations echo the findings of 
previous qualitative studies (156, 157). This study further develops the evidence 
base through the inclusion of nurses working in both acute and long-term care 
settings and also by investigating modifications to facilitate fractional dosing which 
have been neglected in qualitative literature thus far. Data from quantitative 
studies have demonstrated that modifications are prevalent (102, 219, 240, 297), 
and alternative formulations are often unavailable or unsatisfactory (240, 278) 
which confirms the beliefs expressed by nurses about modifications. However, 
despite this reality, guidance provided to healthcare professionals generally advises 
that modifications should be avoided (104, 150). It is clear that this advice can be 
difficult for healthcare professionals to adhere to given limitations of currently 
marketed ODFs.  
 
The nurses’ role as patient advocate was a strong theme present throughout the 
data. Familiarity with, and knowledge of, the patient ensures that nurses have a 
vital role in identifying patients’ difficulties with oral formulations and liaising with 
other healthcare professionals to address any issues. Previous studies have found 
that inadequate communication practices result in lack of awareness of patient’s 
formulation requirements (236, 289). This study has found that for patients in LTC 
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and AC settings, nurses’ knowledge of the patient allows them to act as an advocate 
on the patient’s behalf which helps to overcome this communication deficit. This is 
particularly true in LTC given the length of stay. On acute geriatric wards, nurses 
spend more time on direct nursing care compared to many other ward types (298) 
and have more direct patient contact than any other healthcare professional, 
facilitating the development of the nurse-patient relationship. A key tenet of 
nursing care and the subject of much nursing literature is the concept of “knowing 
the patient” (299, 300). The importance of the nurse-patient relationship has been 
suggested as being an important contributor to the individualisation of care 
provision and potentially improved patient outcomes (300, 301). This finding has 
important implications for other members of the MDT who should be encouraged 
to consult with nurses as they “know” the patient prior to prescribing and 
dispensing medications for this cohort. A more formal, proactive review of patients, 
in the presence of all necessary members of the MDT, was also mentioned as a 
possible method to optimise formulation suitability for individual patients in the 
absence of satisfactory alternative dosage forms. An approach such as this would 
not only ensure that all necessary expertise was available but would also allow 
other healthcare professionals to benefit from the nurses knowledge of the 
individual and decrease the time spent by nurses in communicating 
recommendations from one healthcare professional to another. Administrative 
tasks such as these can be time-consuming for nurses which takes time away from 
direct patient care (302). The importance of a patient advocate needs to be 
recognised by healthcare professionals, which has particular implications for 
community-dwelling patients. Studies have previously reported that healthcare 
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professionals are frequently unaware of the difficulties with medication intake 
experienced by community-dwelling patients (86, 87, 222), which highlights the 
importance of enquiring about difficulties, either from the patient themselves or a 
suitable advocate who knows the patient e.g. a carer.  
 
Some nurses in this study expressed a desire for resources and supports that would 
help them in their day-to-day practice. Nurses were reliant on pharmacists for 
information provision regarding the appropriateness of ODF modification and 
satisfaction with pharmacists’ role was generally expressed. In addition, while not a 
major source of information, nurses also expressed satisfaction with the role of the 
doctor in their workplaces, who support nurses by ensuring that modifications are 
authorised on drug charts. Some nurses did express a desire for further education 
and training on the pharmacological and pharmaceutical implications of 
modification, and while they did acknowledge that this was not their area of 
expertise, some felt that increased knowledge would facilitate nurses to be more 
empowered in this area. There were variations in nurse knowledge displayed which 
may serve as starting points for educational interventions, particularly in the area of 
capsule opening and fractional dosing. Knowledge about the purpose of the score-
line on tablets differed, with some nurses assuming that this score-line was to 
facilitate fractional dosing and therefore, divided the tablets into two equal halves. 
This has been identified as an issue previously (175) and regulatory agencies are 
becoming more concerned about the presence of non-functional score lines on 
tablets (178, 179). This may highlight a potential role for education of nurses on 
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relevant, fundamental aspects of pharmaceutics (dosage form design). Nurses 
seemed to express a preference for pharmacists to deliver such educational 
programmes. Another possible intervention suggested by nurses was the use of a 
pharmacist-developed, site-specific guidance document which would provide 
recommendations on commonly encountered modifications within the care setting. 
One study site had such a resource and the participant found this to be extremely 
useful in their daily practice. Bourdenet et al. (261) found that the implementation 
of good practice recommendations and the development of a list of medications 
that should not be modified resulted in a significant reduction in the number of 
patients receiving crushed medication and a significant reduction in crushing of 
drugs that should not be modified. Whilst practical interventions such as this should 
be developed and evaluated in an attempt to support nurses and patients 
administer medications in the short-term, ultimately there is a need to increase the 
availability of licensed formulations that meet the needs of the older adult. Nurses 
advocate for individual patients in daily practice however, the older cohort requires 
advocates to highlight their needs to industry, regulatory agencies and policy-
makers, to encourage the development of age-appropriate formulations. 
Optimisation of formulation suitability for older adults will require a thorough 
understanding of the challenges of administering medication to older adults. The 
literature abounds with commentaries on the age-related challenges in medication 
administration (8, 63, 168). A growing body of evidence from clinical practice is 
required to quantify the breadth of the problems encountered. However, to truly 
understand the challenges encountered, the views of healthcare professionals, 
patients and carers need to be heard to ensure that any potential solutions 
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developed reflect the priorities and needs of end-users  and therefore, will be of 
maximal benefit (194). This study adds to the existing evidence-base on the views 
of nurses about ODF modification (156, 157). In addition to the potential 
interventions discussed above, further research should investigate the views of 
patients and their informal carers in community settings where there may be 
limited healthcare professional input into decision-making around ODF modification 
(86, 87). This research should seek, not only to identify the main challenges 
encountered by this cohort, but also to determine the “ideal” formulation 
characteristics from the perspectives of patients, carers and healthcare 
professionals. 
 
There are a number of strengths associated with this study. The use of semi-
structured interviews allowed for in-depth, detailed accounts of participants’ 
experiences and perceptions to be elucidated (288). The data were analysed 
thematically (295), using an inductive approach to coding which produced rich 
findings that were firmly rooted in the data. The timeframe of the study also 
facilitated an iterative approach to data collection and analysis which allowed a 
thorough interrogation of the data. The transferability of the study findings may be 
questioned given that the interviews were conducted in one geographical area in 
Ireland. However, the use of the sampling matrix helped to ensure that the views of 
nurses working in a variety of care settings were elucidated which helped to 
overcome this limitation. In addition, the findings cohered with the limited 
evidence from other qualitative and quantitative studies which further confirms the 
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transferability of findings. Social desirability is another potential limitation of the 
study. Participants were aware that the interviewer was a pharmacist and that the 
research team were all based at a School of Pharmacy. Therefore, participants may 
have given socially desirable answers. Whilst it is difficult to eliminate this bias, the 
research team had discussed this prior to undertaking the study and felt that it 
would be unethical not to disclose the research team’s background. However, this 
was balanced by highlighting to participants that the research team were interested 
in hearing, and gaining a greater understanding of, the views and experiences of 
nurses. Social desirability did not appear to emerge as a significant issue given the 
honest, forthcoming nature of the interviews, with both positive and negative 
experiences with pharmacy colleagues being reported and discussed. In addition, 
nurses were asked to describe the procedure followed in their institution when 
medications were required to be modified for patients. Nurses, in different 
institutions, all described the input of pharmacists and the role they played. The 
role of the pharmacist was similar across all institutions included in the study, so it 
is likely that this reflects the true role that pharmacists play in an Irish setting. The 
length of the interviews ranged from 7 minutes to 31 minutes. The shortest 
interview was conducted on an extremely busy ward in an acute hospital, which is 
likely to have contributed to the brevity of this interview. However, useful insights 
were still gained in this interview. The interviews focused on ODF modification, 
which was clear to participants from the information leaflet for the study. 
Therefore, from the outset, the interviews focused on medicine administration and 
modification for older adults. Therefore, very detailed insights into this topic were 
gained from what could be considered to be relatively short interviews. The authors 
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feel that the interviews provided comprehensive coverage of the topic and 
therefore the length of the interviews has not impacted on the quality or depth of 
findings of the study. It was not possible from the detail provided in the completed 
data collection forms to ascertain the primary nursing qualification of all 
participants due to variability in how nurses completed the data collection form. 
Regardless of qualification, all of the interview participants would be required to 
demonstrate their competency to, and register with, the Nursing and Midwifery 
Board of Ireland and adhere to the relevant national guidelines on medicine 
administration. In addition, the number of years working in care of older patients 
was recorded but not the total number of years since qualification, as the former 
was of more interest for the purposes of this study. No variation in ideas or 
responses was observed between participants based on age, qualification type or 
length of experience in older patient care. However, previous research has 
investigated how nursing competence relates to length of clinical experience (303). 
Whilst in this study, similar themes and insights were gained irrespective of length 
of experience in older patient care, future research should consider qualification 
type and time since qualification to investigate whether this affects practice. 
 
5.7 Conclusions 
This study has provided a useful insight into the knowledge, attitudes and beliefs of 
nurses on the modification of ODFs for older adults. Modifications of ODFs are 
viewed as unavoidable in care of the older person, due to limitations of available 
formulations. Nurses had a number of concerns about modifications and valued 
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input from other healthcare professionals, particularly pharmacists. Nurses’ 
knowledge of individual patients ensures that nurses have a vital role to play in 
identifying and assessing patients experiencing difficulty with oral medicines and in 
communicating with other healthcare professionals. The unique and varied 
formulation requirements of older adults must be acknowledged by healthcare 
professionals, academics, regulatory agencies, the pharmaceutical industry and 
policy makers to promote the development of more age-appropriate formulations. 
Further research will be central to the development of these formulations, both to 
ascertain the prevalence of the practice and the most problematic drugs/ 
formulations and to identify the priorities and needs of end-users. In the interim, 
practical interventions and guidance should be developed, taking into consideration 
the themes that were identified in this study. 
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6.1 Abstract 
6.1.1 Background 
ODF modifications can potentially affect drug safety and efficacy; however, this is 
dependent on factors including the medication, the dosage form, the method of 
modification and the subsequent method of administration. There are a lack of data 
describing ODF modifications, particularly the methods of modification and 
administration, in an Irish setting. In order to identify priority areas for intervention, 
there is a requirement for a thorough investigation of current ODF modification and 
administration practices in ACFs in Ireland. 
6.1.2 Aim 
The aim of this study was to elucidate ODF modification and administration 
practices in ACFs in Ireland using undisguised, direct observation of drug rounds.  
6.1.3 Methods 
Undisguised, direct observations of medication administration to older patients on 
13 wards in 5 ACFs in Ireland was undertaken between May 2017 and August 2018. 
Patients who met the following criteria were eligible to be included in the study: (i) 
resident in the ACF; (ii) aged ≥65 years; (iii) received medication from nurses during 
drug rounds and; (iv) written, informed consent for inclusion was provided (by the 
patient or their next-of-kin if the patient lacked the capacity to consent). 
Demographic and medical details about included patients were recorded from the 
patients’ medical records. The drug round observations were undertaken by one 
researcher who recorded details including: the name, dose, dosage form, route and 
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method of administration of medication, as well as details of any ODF 
modifications. 
6.1.4 Results 
Medicine administration to 141 patients (63.8% female, mean age (SD) 83.96 years 
(7.26)) was observed. In total, 44.7% of patients received at least one modified solid 
ODF during the observed drug rounds. Amongst patients who received modified 
medicines (n=63), 46.0% had medicines modified to overcome swallowing 
difficulties, 41.3% to facilitate fractional dosing and 12.7% required medicines to be 
modified for both reasons. There were 178 modifications observed for 71 different 
medications, with drugs acting on the CNS the most commonly modified. Of these 
178 modifications; 81.5% were unlicensed, and just under half of these unlicensed 
modifications were authorised in the BPGs. Modified medicines were most 
frequently administered using food vehicles or thickened fluids, while almost one-
fifth of non-modified solid ODFs and liquid ODFs were administered with thickened 
fluids or in food vehicles.  
6.1.5 Conclusions 
This study has provided insights into ODF modification and administration practices 
in ACFs in Ireland. ODF modifications are commonly required to tailor oral 
medicines to meet the swallowing capabilities and dosing requirements of older 
adults. Whilst many of the modifications were neither authorised in the product 
licence nor BPGs, the majority of administration practices were optimised within 
the limitations of currently marketed formulations. Further research is needed to 
improve medication formulation suitability for older adults and the findings of this 
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study, by describing the current reality of medication administration, should inform 
the direction of this research. 
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6.2 Introduction 
This thesis investigates ODF modifications for older adults, particularly as they 
relate to the Irish setting. Following the systematic review of the quantitative 
literature described in Chapter Two, it was found that there are limited data on ODF 
modifications for older adults, with none from an Irish setting (236). To address this 
gap, a retrospective review of drug charts in an ACF was undertaken (Chapter Four), 
which suggested that ODF modifications are common in Ireland (240). However, 
there were limits to the depth of information that could be gained from this study 
given the retrospective nature of data collection. In addition, as highlighted in 
Chapter Two, there are a number of limitations of the published literature 
investigating ODF modifications, particularly relating to how data collection was 
performed and how the study findings were presented (102, 219, 220, 236).  
 
In Chapter Three, the qualitative literature on ODF modifications was systematically 
reviewed (289). Following on from this systematic review, and informed by the 
findings of the retrospective review of drug charts, the views and opinions of nurses 
responsible for administering medicines to older adults in Ireland were sought. It 
was clear that modifications were viewed by nurses as being both common and 
necessary for older patients, and there was a perception that there was often no 
alternative to modifying ODFs. In addition, a number of nurses suggested that 
observations of drug rounds would be useful, both to audit practice and to gain an 
understanding of the challenges encountered by nurses, “I think really it should be 
audited… observing how we are doing it because again, you can constructively say 
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‘right that’s the correct procedure’” (Nurse 7), “With respect I would say 
pharmacists maybe need to be aware of the challenges at ground level… I mean if 
you were to have been able to come in earlier this morning and come on a drug 
round with me and see, and be physically beside me and see why it is that I had to 
crush so and so’s medicines. And come in and see that individual and see for 
yourself that this is why” (Nurse 5).  
 
Internationally, a number of quality improvement studies have sought to optimise 
ODF modification practices (260, 261, 280, 304-306). These studies were predicated 
on the assumption that the modifications that were being undertaken were 
inappropriate and arose due to poor prescribing, dispensing and/or administration. 
However, whether similar interventions would be warranted or useful in an Irish 
setting could not be determined without gaining a greater understanding of ODF 
administration practices. Therefore, following consideration of the findings of 
Chapters Two, Three, Four and Five, this study was designed in an attempt to 
provide more detailed information on ODF modification practices in an Irish setting, 
in order to address the identified gaps in the literature and to inform the direction 
of future research and potentially, interventions. 
 
6.3 Aim and objectives 
The primary aim of this study was to elucidate ODF modification and administration 
practices in ACFs in Ireland using undisguised, direct observation of drug rounds. To 
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achieve this aim the following objectives were defined: to determine the 
prevalence of ODF modifications for older adults in a sample of ACFs in Ireland; to 
identify the most commonly modified medicines; to determine the methods of 
modification used; to describe the methods of administration of medicines and; to 
determine if there is an evidence-base to support decision-making around ODF 
modification.  
 
6.4 Methods 
6.4.1 Ethical approval 
Ethical approval to conduct this study was granted by the Clinical Research Ethics 
Committee of the Cork Teaching Hospitals, Cork, Ireland (Appendix 9). During the 
observation of drug rounds, nurses were observed preparing and administering 
medicines and patients were observed taking medications. Therefore, written 
informed consent for observation was obtained from nurses and patients (or the 
patient’s next-of-kin if the patient lacked the capacity to consent). The researcher 
did not actively participate in the drug round, but rather was present as an 
observer. It was within the terms of the ethical approval however, that if the 
observer, a qualified pharmacist, witnessed any potential errors that represented a 
significant risk to the patient (e.g. wrong dose, wrong drug or wrong patient) the 
observer would intervene. This approach has previously been used in a number of 
studies involving the direct observation of medicine administration (234, 297). 
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6.4.2 Study design 
This study was an undisguised, direct observation of drug rounds in five ACFs in the 
Munster region of Ireland. 
 
6.4.3 Study setting and sampling 
The study was conducted on thirteen wards in five ACFs in the Munster region of 
Ireland. As previously described, the aged care or “nursing home” sector in Ireland 
includes public, private and voluntary nursing homes, with the public nursing home 
sector providing care for a more highly dependent patient population (293). 
“Specialist Care Units for People with Dementia”, also known as “Specialist 
Dementia Units” (SDUs), are a feature of the Irish nursing home sector and they are 
a model of long-term residential care established to provide specialist care to small 
groups of people with dementia (292). Given that previous research has suggested 
that ODF modifications are more common in high dependency units (219) and 
patients with dementia are also more likely to receive modified medicines (102), 
the sampling strategy for this study sought to ensure that at least one ACF from 
each funding category was represented. In addition, a number of SDUs were also 
sought for inclusion in the study.  
  
The Director of Nursing or the Medical Director at the purposively selected ACFs 
was provided with an information letter or e-mail outlining the purpose of the 
study. A member of the research team followed up the invitation letter with a 
telephone call or visit to discuss, and provide further information about, the study. 
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Following agreement to participate, a suitable timeframe for the conduct of the 
study was arranged. Patients were provided with an invitation letter and 
information leaflet about the study and those who wished to participate provided 
written, informed consent. The medical/nursing team at the study site identified 
patients who were unable to provide informed consent, and in this instance, if 
possible, the patient’s next-of-kin were contacted and supplied with the invitation 
letter and information leaflet for the study. If the patient’s next-of-kin provided 
written, informed consent, the patient was enrolled in the study. Nurses who were 
observed administering medication also provided written, informed consent to be 
observed.  
 
6.4.4 Inclusion criteria 
Patients were eligible for inclusion in the observational study if they met the 
following criteria: 
 Aged ≥65 years old; 
 Resident in an ACF included in the study; 
 Were administered medication during drug rounds; 
 Provided written, informed consent for participation. 
In the event that a patient lacked the capacity to provide informed consent, the 
patient’s next-of-kin could provide informed consent for participation on their 
behalf. The decision as to whether a patient had capacity to consent was made by 
the medical/ nursing team at the ACF. 
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Nurses were eligible to be observed in the study if they met the following criteria: 
 Administered medication to older adults in a participating ACF; 
 Provided written, informed consent to be observed. 
 
6.4.5 Data collection 
Data collection and the observation of drug rounds were performed by one 
researcher (AMG), a qualified pharmacist. Data collection began at the first site in 
May 2017, and sites were recruited on a phased basis thereafter, with the final 
observations being completed in August 2018. Each participant in the study was 
assigned a unique study number. The researcher completed a standardised data 
collection form for each participant, using data retrieved from the participant’s 
medical records. The following data were collected: type of ward; category of 
admission; gender; date of birth; medical conditions; documented diagnosis of 
dysphagia; any relevant recommendations regarding food texture and fluid grade 
and; Barthel Index Score (if available) (307). For the swallowing recommendations, 
wherever possible, the recommendations regarding food and fluid consistency 
were reported in accordance with the preferred terminology in the “Consistency 
Descriptors for Modified Fluids and Food Consensus Document”, issued by the Irish 
Association of Speech and Language Therapist and the Irish Nutrition and Dietetic 
Institute (308). The Barthel Index Score was used as a surrogate descriptor of 
patient dependence; higher scores indicating greater levels of independence (307). 
For the drug rounds, observations were conducted over a full day (including 
morning, lunch, evening and night-time drug rounds) with the goal of observing a 
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full day of medication administration for each participating patient. However, in 
some instances it was not feasible to observe every administration for each patient 
e.g. due to patient absences from the ward for appointments, lack of access at 
certain drug rounds in the ACF etc. During the drug round, the observer shadowed 
the nurse as s/he prepared and administered medications for participating patients. 
A standardised data collection form was used to record details of the drug round 
including: the time; the names of medications administered; the dose; dosage form 
type and route of administration; whether the medication was modified; the 
method of modification; whether the modification was authorised on the drug 
chart and; the method of administration of both modified and non-modified 
medications. Only medications that were administered were included for analysis in 
the study, i.e. medications refused by the patient, “when required” (PRN) 
medications charted but not administered or medications that were administered 
by nurses but not witnessed by the researcher were not included in the analysis. 
 
The approach used in Chapter Four to assess the evidence-base for the 
modifications (Figure 4.1) was also used for this study. Briefly; the first step 
involved assessing if the modification was licensed, in which case it was an 
evidence-based modification. Unlicensed modifications were considered to be 
evidence-based if they were recommended in at least one of, “The NEWT 
Guidelines for Administration of Medication to Patients with Enteral Feeding Tubes 
or Swallowing Difficulties” (159) or the “Handbook of Drug Administration via 
Enteral Feeding Tubes” (160).  
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6.4.6 Statistical analyses 
Data analyses were performed using IBM’s SPSS for Windows, Version 22.0 (IBM 
Corp., Armonk, NY) and Microsoft Excel (2010). Descriptive analysis was 
undertaken. Continuous variables were described by means and SDs for normally 
distributed data and by medians and IQRs for non-parametric data. Categorical 
variables were described by counts and percentages. Associations between 
categorical variables were investigated using Pearson’s Chi-square tests, or Yates’ 
Continuity Corrected Chi-Square tests as appropriate. Independent samples t-tests 
and Mann-Whitney U tests were used to investigate differences between groups 
for normally distributed and non-parametric continuous variables respectively. P-
values <0.05 were considered to be statistically significant. The analysis was 
primarily conducted at the patient level. The researcher recorded details of all 
medicines that were observed being administered to study participants. The total 
number of medications administered to each individual patient, based on the active 
ingredient, was calculated. For the analysis, if medications were administered to 
one patient multiple times over the course of the day, the medication was only 
counted once. A similar approach was used if ODFs were administered more than 
once in the day, with the exception of different strengths or formulation types, 
which were counted separately.  
 
6.4.7 Sample size 
Assuming that the prevalence of ODF modification for older adults in ACFs is 35.1% 
(based on the findings of the retrospective review of drug charts reported in 
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Chapter 4 (240)), it was estimated that a sample size of 351 patients would be 
required to determine the prevalence with 95% confidence to within ± 5%. 
 
6.4.8 Reporting 
This study is reported in accordance with the “Strengthening the Reporting of 
Observational Studies in Epidemiology” (STROBE) guidelines (269) (Appendix 10). 
 
6.5 Results 
6.5.1 Patient demographics 
The Medical Director or Director of Nursing at eight ACFs were contacted, informed 
about the purpose of the study and invited to participate. Of these, two did not 
reply to the invitation to participate, while six agreed to participate. However, a 
suitable time for the conduct of the study could not be arranged at one of these 
sites, therefore, the study was conducted in five ACFs (2 public, 2 private and 1 
voluntary). Of 267 patients who met the inclusion criteria in these 5 nursing homes, 
informed consent for participation was obtained for 141 patients (73 patients and 
68 next-of-kin). Figure 6.1 provides an overview of the study recruitment process.  
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Figure 6.1 Overview of study recruitment process 
 
The administration of medicines to 141 patients (63.8% female, mean age (SD) 
83.96 years (7.26)) was observed during this study. All of the study participants 
were admitted for long-term care; 17 to SDUs and 124 to regular nursing home 
wards. Table 6.1 provides demographic details of the study cohort. 
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Table 6.1 Demographic details of patient cohort (n=141) 
Variable  n (%) 
General Demographic Details 
Gender 
Male 51 (36.2%) 
Female 90 (63.8%) 
Nursing Home Category 
Public with SDU (n=1) 5 (3.5%) 
Public without SDU (n=1) 33 (23.4%) 
Private without SDU (n=2) 49 (34.8%) 
Voluntary with SDU (n=1) 54 (38.3%) 
Nursing Home Ward Type 
SDU 17 (12.1%) 
Non-SDU ward 124 (87.9%) 
Age Range (n=139) 
65-75 years 18 (12.9%) 
76-85 years 67 (48.2%) 
86-95 years 45 (32.4%) 
≥96 years 9 (6.5%) 
Swallowing Details 
Documented Dysphagia 
Diagnosis 
Yes 9 (6.4%) 
No 83 (58.9%) 
Unclear 49 (34.8%) 
Recommendations 
Regarding Swallowing 
Yes 56 (39.7%) 
No 83 (58.9%) 
Unclear 2 (1.4%) 
Food Texture 
Recommendations (308) 
Texture A 20 (14.2%) 
Texture B 15 (10.6%) 
Texture C 16 (11.3%) 
Texture D 1 (0.7%) 
Texture dependent on time of day 1 (0.7%) 
No food recommendation despite 
swallow review 
5 (3.5%) 
No review of swallow 83 (58.9%) 
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Variable  n (%) 
Fluid Grade 
Recommendations (308) 
Grade 1 12 (8.5%) 
Grade 2 14 (9.9%) 
Grade 3 2 (1.4%) 
Normal fluids 23 (16.3%) 
Thickened fluids (not specified) 3 (2.1%) 
Use of special cup 1 (0.7%) 
No fluid recommendations despite 
swallow review 
3 (2.1%) 
No review of swallow 83 (58.9%) 
Medical Conditions 
Documented Diagnosis of 
Dementia 
Yes 60 (42.6%) 
No 70 (9.6%) 
Cognitive impairment 11 (7.8%) 
Documented Diagnosis of 
Stroke 
Yes (in past 6 months) 1 (0.7%) 
Yes (>6 months previously) 21 (14.9%) 
Transient Ischaemic Attack 7 (5.0%) 
No 112 (79.4%) 
Legend: SDU = Specialist Dementia Unit. 
 
In a number of instances there was uncertainty in the medical notes regarding the 
patients’ swallowing difficulties. Two patients had a diagnosis of dysphagia 
recorded in their medical notes however no recommendations regarding food and 
fluid were present. For subsequent analysis, these two individuals were categorised 
as having dysphagia but not having a documented swallowing recommendation. In 
contrast, 49 individuals had recommendations regarding food texture and/or fluid 
grade but dysphagia was not a documented medical condition in their medical 
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notes. In this case, for subsequent analyses, these 49 individuals were classified as 
being likely to have dysphagia. The median number of chronic medical conditions 
(IQR) experienced by the study cohort was 5 (3-7). A Barthel Index Score was 
available for 137 patients and the median score (IQR) was 9 (3-14). 
 
6.5.2 Medication use amongst the study cohort 
The median number of drug rounds observed for each patient was 2 (IQR 1.5-2.5, 
range 1-4). The administration of medicines to any patient was not observed on 
more than one occasion at any time-point i.e. each patient was only observed for 
one morning drug round, one lunch time drug round, one evening drug round and 
one night time drug round. The median number of medicines that were observed 
being administered to patients, based on the active ingredient, was 8 (IQR 5-11), 
while the median number of oral medicines was 7 (4-10). Oral dosage forms were 
the most commonly prescribed formulations with participants receiving a median 
of 7 ODFs (IQR 4.5-10), of which solid ODFs were the most common (median 6 (IQR 
4-9)).  
 
6.5.3 ODF modifications 
During the drug rounds, modified ODFs were observed being administered to 44.7% 
(n=63) of the study cohort. Amongst the group of patients who received modified 
medicines, 29 patients (46.0%) had medicines modified to overcome swallowing 
difficulties, 26 (41.3%) received fractionally dosed medicines, while a further eight 
patients (12.7%) had medicines modified to facilitate fractional dosing and to 
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overcome swallowing difficulties. For the majority of patients (96.8%), the 
modifications were expressly authorised on the drug chart by the prescriber, with 
only two patients receiving modified medicines that were not expressly authorised. 
For one of these patients, although the modification was not authorised, it was 
licensed and consequently the nurse did not require prior authorisation from the 
prescriber. The other patient received multiple modified medicines but only one of 
these modifications had not been authorised. Therefore, only one medication in the 
study was modified without the expressed authorisation of the prescriber. 
 
The median number of modified solid ODFs administered to patients was 2 (IQR 1-
4). Figure 6.2 provides a breakdown of the number of modified solid ODFs 
administered to patients. 
 
Figure 6.2 Breakdown of the number of modified medicines received by patients (n=63) 
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The association between medicine modification and various patient characteristics 
was investigated. Medications were significantly more likely to be modified for 
patients with dysphagia (χ²yates (1) = 5.139, p<0.05) and for those with a 
documented swallowing recommendation (χ²yates (1) = 6.703, p<0.05). A diagnosis 
of dementia or cognitive impairment was found to be potentially associated with 
modification (χ²yates (1) = 3.830, p=0.05). Neither gender (χ²yates (1) = 0.206, p=0.650) 
nor stroke (χ²yates (1) = 0.024, p=0.878) were found to be associated with medicine 
modification. Independent samples t-tests were used to compare the age of those 
who received modified medicines to those who did not receive modified medicines. 
There were no statistically significant differences between these two groups based 
on age (t (137) = -0.756, p=0.451). A Mann-Whitney U Test demonstrated a 
statistically significant difference in the Barthel Index Scores between those who 
received modified medicines (median = 5.0, n = 60) compared to those who did not 
(median = 11.0, n = 77), (U = 1398, z = -3.964, p<0.001, r = 0.34).  
 
Analysis was undertaken to examine modifications for fractional dosing and 
swallowing difficulties separately. It was found that none of the above variables 
were associated with modifications for fractional dosing. In contrast, modifications 
to overcome swallowing difficulties were associated with dysphagia (χ²yates (1) = 
15.992, p<0.001), the presence of swallowing recommendations (χ²yates (1) = 17.867, 
p<0.001) and a diagnosis of dementia or cognitive impairment (χ²yates (1) = 9.076, 
p<0.01). In addition, a statistically significant difference was seen in the Barthel 
Index Scores of those who required medicines to be modified to overcome 
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swallowing difficulties (median = 2.5, n = 34) compared to those who did not 
require such modifications (median = 11.0, n = 103), (U = 872, z = -4.388, p<0.001, r 
= 0.37). 
 
During this study, modifications including tablet crushing, capsule opening and 
tablet splitting were observed. Tablet crushing was performed for 33 patients, with 
between 1 and 9 tablets crushed for these individuals. The Silent Knight Tablet 
Crusher®, which consists of an individual, disposable plastic pouch into which 
tablets are placed, prior to crushing using the crushing device (309), was used to 
crush tablets for 32 of the patients who received crushed medicines. The remaining 
individual had medications crushed using a commercial twist-type crushing device. 
Capsules were opened to overcome swallowing difficulties for 14 individuals, with 
these patients receiving between 1 and 3 opened capsules. Tablet splitting was also 
commonly observed, with split tablets administered to 36 individual patients: 31 
patients had tablets split for fractional dosing; 2 to overcome swallowing difficulties 
and; 3 had tablets split due to the necessity to administer a fractional dose as well 
as to overcome swallowing difficulties. A variety of tablet-splitting techniques were 
employed, including the use of a commercial tablet splitter, having tablets pre-split 
by the pharmacy or the nurse breaking the tablets by hand. Four patients who 
received more than one split medication had medication split using different 
techniques. Figure 6.3 provides details on the methods used to split tablets for 
patients (n=36) in the study. 
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Figure 6.3 Methods used to split tablets for patients (n=36) 
 
Seventy-one different medications were observed being modified during the study, 
with 178 separate instances of modification of these medications being recorded. 
The modified medications were classified according to the ATC code and it was 
found that drugs belonging to the “Nervous System” anatomical group were most 
frequently modified (Table 6.2). Given that analysis was conducted at the patient 
level, when a medication was observed being modified more than once in the day 
for an individual patient (e.g. at the morning and night time drug round), this was 
only counted as one instance of medicine modification.  
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204 
 
Table 6.2 ATC classification of modified ODFs 
ATC Code Classification 
(arranged alphabetically) 
No. of modified 
medicines 
No. of instances 
of modification 
% of all instances 
of modification 
Alimentary Tract and 
Metabolism 
10 22 12.4% 
Blood and Blood Forming 
Organs 
10 20 11.2% 
Cardiovascular System 15 33 18.5% 
Central Nervous System  27 90 50.6% 
Systemic Hormonal 
Preparations 
1 5 2.8% 
Anti-infectives for Systemic 
Use 
2 2 1.1% 
Genito-urinary and Sex 
Hormones 
3 3 1.7% 
Respiratory System 3 3 1.7% 
Total 71 178 100% 
 
The frequency of medicine modification was also examined at the individual 
medication level. Table 6.3 documents the top twelve most commonly modified 
medications and the reasons for these modifications. 
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Table 6.3 Most commonly modified medications and the reason for modification 
Drug Instances of 
modification 
Reason for Modification 
FD SD Both SD and FD 
Quetiapine 16 9 5 2 
Paracetamol 13 0 13 0 
Memantine 9 0 8 1 
Aspirin 8 0 8 0 
Bisoprolol 6 0 6 0 
Trazodone 5 0 5 0 
Mirtazepine 5 3 2 0 
Lorazepam 5 1 3 1 
Senna 5 0 5 0 
Nebivolol 5 4 1 0 
Levothyroxine 5 0 5 0 
Calcium and 
Vitamin D 
5 0 5 0 
 
6.5.4 Evidence-base for modifications 
The 178 instances of modification that were observed during the drug rounds were 
examined according to the criteria described in Chapter Four for assessing the 
evidence-base for the modifications. Modifications were considered to be 
evidence-based if the modification was authorised in the product licence or 
alternatively if it was recommended in one of two BPGs. Figure 6.4 provides a 
breakdown of the evidence-base for the observed modifications.  
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Figure 6.4 Evidence-base for observed modifications  
 
Of the 75 modifications that were neither licensed nor recommended in best 
practice guidelines, the majority (70.7%) were undertaken to overcome swallowing 
difficulties, 25.3% were to facilitate fractional dosing and 4.0% involved an initial 
modification to administer a fractional dose, followed by a subsequent modification 
to overcome swallowing difficulties. 
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6.5.5 Methods of administration of medicines 
Details of how modified and non-modified ODFs were administered to patients 
were recorded during the drug rounds. Table 6.4 provides further details on how 
the various ODFs were administered to individual patients. 
 
Table 6.4 Method of administration of ODFs to individual patients 
Administration vehicle n % 
Modified ODFs (n=63 patients) 
With water or other thin liquid 23 36.5% 
With custard 17 27.0% 
With yoghurt/ petit filous 12 19.0% 
With thickened fluids e.g. Swalloweze® and water 6 9.5% 
With nutritional supplement e.g. Forticreme Complete® 2 3.2% 
With very thickened flavoured water 2 3.2% 
With yoghurt in morning, very thickened water at night 1 1.6% 
Liquid ODFs (n=80 patients) 
Administered directly to the patient 66 82.5% 
Thickened prior to administration 8 10.0% 
Administered in food vehicle e.g. custard, petit filous 6 7.5% 
Non-modified solid ODFs (n=118 patients) 
With water or other thin liquid 92 78.0% 
In food vehicle e.g. petit filous, custard, yoghurt 14 11.9% 
With thickened fluids 9 7.6% 
Chewable medicines- chewed by patient 3 2.5% 
Legend: petit filous = fromage frais; a smooth fresh cheese with a thick yoghurt 
consistency. 
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In all instances where a food vehicle was used to administer medication, a small 
quantity of the food vehicle was used, and the purpose of the vehicle was to 
facilitate medicine administration rather than a meal being used for administration 
of medication. Similarly, when a nutritional supplement was used, it was prescribed 
for the patients on the drug chart and a spoon of the nutritional supplement was 
used to administer the medication. The medication was not added to, or mixed in 
with, the full quantity of the nutritional product. 
 
6.6 Discussion 
Through the direct, undisguised observation of medication administration in ACFs, 
detailed insights into ODF modification and administration practices in an Irish 
setting were gained. Modifications were found to be extremely common, with 
44.7% of all patients receiving at least one modified solid ODF. Both modifications 
to overcome swallowing difficulties and to facilitate fractional dosing were 
prevalent, with approximately one-quarter of patients requiring medicines to be 
modified for these reasons. This study contributes to the literature on ODF 
modifications for older adults by providing comprehensive data from an Irish 
perspective as well as affording greater insights into the reasons modifications are 
required and which medications are most commonly altered. However, particularly 
novel is the level of detail that was obtained regarding the methods of modification 
and methods of administration of both modified and non-modified medicines which 
aids in the comprehension of the challenges encountered in administering 
medicines to older adults. 
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The findings of this study broadly concur with previously published studies on tablet 
crushing and capsule opening (102, 103, 219, 220), as well as the limited reports on 
fractional dosing (100). Prevalence of medicine modification was found to be higher 
in this study than in the retrospective review of drug charts in Chapter 4, which may 
be due to the inclusion of less-dependent, respite patients in the retrospective 
study (240), whereas in the current study only long-term care patients were 
included. However, as was reported in Chapter 4, ODF modifications were slightly 
less common in Ireland compared to international reports (100, 103, 219), which 
may stem from differences in the study settings, the organisation of healthcare or 
medication formulation availability as well as differences in the methods of data 
collection and reporting. Collectively, the findings of these studies highlight that 
across different jurisdictions, in a variety of healthcare settings, ODF modifications 
for older adults are the norm, occurring on a daily basis in order to meet the needs 
of this cohort (100, 102, 103, 219, 220, 240).  
 
An important finding, which concurs with previous studies, is that highly dependent 
patients and those with dementia or dysphagia are particularly likely to require 
modified medicines (102, 219, 310). Therefore, healthcare professionals should be 
vigilant of the need to consider formulation suitability for these individuals. 
However, a significant issue that may hinder identification and engagement with 
these patients, was the finding that dysphagia was often not expressly reported in 
patient’s medical notes, with swallowing difficulties inferred from 
recommendations regarding food and fluid administration which were reported in 
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daily care notes for healthcare assistants. The inconsistent recording and reporting 
of dysphagia and swallowing recommendations for older patients in long-term care 
facilities, in agreement with the findings of this study, has previously been 
identified as an issue (280). Inadequate communication and information sharing 
have been highlighted as barriers to the optimisation of formulation suitability for 
older adults (156, 157, 289). The absence of clearly documented, easily accessible 
information about patients’ swallowing capabilities is likely to complicate 
communication of patients’ requirements as staff members may simply be unaware 
of the difficulties experienced by patients. Jackson et al. (280) identified that 
ineffective and inefficient communication of medication related swallowing 
recommendations was a major contributor to inappropriate medication 
administration practices in two continuing care facilities for older adults. Through 
the implementation of new communication processes, which involved clearly 
documenting speech and language therapists’ recommendations on medication 
administration records and doctors’ order sheets and creating dysphagia alerts in 
the pharmacy dispensing systems, compliance with medication swallowing 
recommendations improved and inter-disciplinary communication was optimised. A 
similar approach, in which swallowing recommendations, diagnoses of dysphagia as 
well as any relevant, patient-specific difficulties with medication formulations are 
documented in patient’s medical notes, may help to encourage the routine 
consideration of formulation suitability during the prescription, dispensing and 
administration of medication to older adults. This would prove particularly useful 
for locum and agency staff. In this study, although it was clear that pharmacists 
were involved in providing recommendations regarding medicine modification and 
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doctors authorised modifications, the processes by which swallowing 
recommendations were communicated between nurses, doctors, pharmacists and 
speech and language therapists were not evaluated. Further research should 
investigate communication and information sharing around swallowing 
recommendations and medication suitability in the long-term care setting in 
Ireland, in order to identify if there is scope for alteration of practice to optimise 
communication and enhance formulation suitability for older patients.   
 
This study was designed in an attempt to address a number of the limitations of 
published literature investigating ODF modifications, as described in Chapter 2; and 
to provide greater detail on ODF modification practices than could be gained from 
the retrospective review of drug charts described in Chapter 4. In particular, 
insights into the methods of modification and administration of modified medicines 
were sought. Previous studies have reported the occurrence of concerning 
modification and administration practices (102, 219, 220), with crushing equipment 
being shared between residents, inadequate cleaning of shared equipment, and 
administration of modified medications in food in a manner which could affect 
administration of the full dose e.g. adding the medication to the patient’s meal. In 
this study, no such concerning practices were witnessed. When tablets were 
crushed, all bar one administration involved the use of a crushing device in which 
the medication was contained in a disposable plastic bag during crushing (309) 
which helped to overcome issues associated with cleanliness and cross-
contamination. Only one instance of tablet crushing involved the use of an 
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alternative crushing device, however, this device was cleaned by the nurse, both 
before and after the administration. For fractional dosing, the majority of split 
medications were split in advance by the pharmacy. However, when communal, 
commercial tablet splitters were used, they were inspected and cleaned by the 
nurses prior to use. Therefore, cross contamination and inadequate cleanliness did 
not emerge as significant concerns in this study. In addition, although a number of 
vehicles were used to facilitate the administration of modified medicines e.g. 
yoghurt, custard etc., these vehicles were used solely for the purpose of medicine 
administration and only a sufficient quantity to facilitate administration was 
utilised. No medication was observed being administered in meals, as has been 
witnessed in previous studies (102, 219, 220). 
 
As stated, the results of this study, when taken into consideration with work 
conducted by other research groups (102, 103, 219, 261, 280, 304, 305) as well as 
the findings of Chapters 2, 4 and 5, highlight the ubiquity of ODF modifications. A 
recent proliferation in the publication of reviews (311, 312) and intervention 
studies (304-306) addressing the topic of ODF modifications has been apparent. 
This increased engagement with the issue of ODF modifications for older adults is to 
be welcomed. However, the potential applicability of these recommendations and 
interventions in an Irish setting cannot be ascertained without understanding 
current practices. The value of this study is that it facilitates the assessment of the 
applicability, and likely benefits, of these recommendations, in light of real-world 
evidence from an Irish setting. Whilst the evidence from this study highlights that 
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modifications are prevalent in an Irish setting, there were numerous positive 
practices observed: the overwhelming majority of modifications were authorised by 
the prescriber, there was documented evidence of regular review of patients’ 
medication with pharmacists involved in the provision of advice regarding 
modifications, and there were fewer concerns about modification and 
administration practices than have been reported in similar studies internationally. 
However, notwithstanding these findings, modifications were still routinely being 
undertaken and for many of these modifications there was a lack of evidence-based 
information sources to facilitate decision making. A number of recently published 
reviews have described approaches that could be used as an alternative to ODF 
modification including: the use of alternative formulations of the medication, use of 
different medications from the same therapeutic class, extemporaneous 
compounding, discontinuation of unnecessary medication, or teaching patients’ 
strategies to overcome difficulty swallowing (311, 312). These approaches, where 
available, should be trialled. However, based on the findings of this study, it is clear 
that in many instances these options are unfeasible or simply unavailable. The use 
of alternative dosage forms e.g. liquids, is commonly suggested. However, liquid 
formulations are often expensive, can be difficult to source and may prove 
challenging to administer, particularly for patients with dysphagia who frequently 
require liquids to be thickened to minimise the risk of aspiration (231, 313). 
Uniquely, this study reported on the method of administration of liquid ODFs, 
finding that almost one in five administrations of liquid ODFs involved thickening 
the liquid or adding it to a food vehicle to facilitate administration. There is much 
uncertainty in the literature about the potential impact of thickeners on drug 
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dissolution and bioavailability (116, 232). For both solid and liquid ODFs, there is a 
lack of evidence to recommend the use of a particular food vehicle or thickening 
agent for administration of specific medication. In some instances, drug companies 
may provide some information on compatibility with certain foods e.g. Xarelto 
(rivaroxaban) tablets are licensed to be crushed and mixed with water or apple 
puree (314). Given the lack of information about the appropriateness of various 
food vehicles and thickening agents, despite their routine use for medication 
administration, there is a need for further research in this area. Recently, an inert 
gel, Gloup® has been marketed as an aid to tablet swallowing (315). The 
manufacturers state that Gloup® has no known interactions with medications. 
However, there was no evidence of the use of this vehicle in the sites included in 
the study. Further investigation of the utility of such a product in the LTC setting 
should also be undertaken. 
 
In addition, many of the liquid dosage forms that were recommended as 
alternatives to modification in the BPGs were unlicensed formulations. Therefore, 
in the hierarchy of options, modifying a licensed dosage form is often preferred to 
using an unlicensed or extemporaneously compounded formulation. As regards the 
recommendation for deprescribing or withdrawal of unnecessary medication, there 
was evidence from the medical charts that patients’ medication regimens were 
regularly reviewed by doctors and pharmacists. Deprescribing, particularly for older 
adults, has become a key focus of research in recent years and the evidence base to 
support the benefits of deprescribing is growing (316, 317). However, it is 
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commonly reported that physicians have concerns about deprescribing and can be 
hesitant to withdraw medications (318, 319). It is vital that necessary medications 
are not withheld or withdrawn from older adults inappropriately. In general, it can 
be difficult for healthcare professionals to make decisions on the risk-benefit profile 
of deprescribing. However, in the case of deprescribing due to swallowing 
difficulties, the absence of an evidence-base on the appropriateness of modification 
is likely to further complicate the decision-making process for healthcare 
professionals who seek to make informed decisions about the risks and benefits 
associated with deprescribing versus modification. 
 
As regards intervention studies; the majority have focused on ODF modifications as 
a medication error, either at the prescribing or more frequently, at the 
administration level (261, 304-306). As a result, these studies have aimed to 
optimise ODF modifications by reducing the occurrence of inappropriate 
modifications. Various strategies have been used including: staff education (280, 
304-306), the development and dissemination of guidelines or do-not-crush lists 
(261, 305, 306) or altering practices or processes e.g. implementing warning labels, 
computerised decision support systems and new protocols (280, 304, 305). 
However, thus far, the evidence from an Irish setting, as outlined in this and 
previous chapters (Chapters 4 and 5), suggests that the predominant challenges are 
not that inappropriate modifications are routinely being undertaken, but rather 
that the medications that are available are not fit for purpose and must be modified 
in order to meet the requirements of older patients. In addition, of the 
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interventions that were evaluated in these studies, many were being implemented 
in some form in the ACFs in Ireland e.g. the vast majority of modifications were 
authorised by the prescriber, with evidence of review of patients’ medication and 
modifications by pharmacists. It is likely that the stringent regulation of the nursing 
home sector in Ireland contributes to optimisation of these practices.  
 
Whilst there appears to be a growing acceptance of the need to engage with the 
issue of swallowing difficulties with medication intake amongst older adults, 
medicine modification to facilitate fractional dosing is still a neglected 
consideration. This study adds to the data on this issue which was first highlighted 
in the retrospective audit study (240). Modifications for fractional dosing were 
required for almost one-quarter of all patients, which is similar to the proportion 
requiring modifications for swallowing difficulties. Many of these modifications 
were not licensed. Therefore, despite a similar prevalence, there is a paucity of 
recommendations on modifications for fractional dosing compared to modifications 
for swallowing difficulties. No specific patient characteristics were found to be 
associated with fractional dosing, which potentially suggests that it is common 
across all older patients. Whilst there is debate surrounding the clinical 
consequences of modifications for fractional dosing, with many suggesting that it is 
unlikely to cause patient harm (135-137), this study clearly highlights that the 
dosing requirements of older adults are being neglected in the development of oral 
medications. Whilst the modification itself can represent an off-licence use, it 
should also be noted that the dose prescribed may also be off-licence if it is below 
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that recommended in the SPC. This was the case for many of the fractionally dosed 
medications administered in this study. This is an important finding for regulators 
and for the pharmaceutical industry as it clearly demonstrates the urgent 
requirement for consideration of the needs of older adults in the drug development 
and authorisation process, to support healthcare professionals in ensuring that 
patients receive necessary medication, at a dose that will provide therapeutic 
benefit without resulting in adverse effects. 
 
One of the most pertinent outcomes from this study is that it provided detailed 
information on the reality of medication administration to older adults. It is clear 
that medicines are frequently being modified to meet older patients’ requirements. 
However, even in situations where solid ODFs are being administered whole, they 
are often being administered with thickened fluids and in food vehicles to 
overcome difficulties with medication intake. In addition, liquid ODFs are also being 
thickened and administered in food to ensure patient safety. There needs to be an 
acknowledgement of the challenges associated with administering medication to 
the older cohort and a concerted effort must be made to take this reality into 
consideration when designing, developing and authorising medications. This 
research should serve as a starting point for acknowledging the reality faced by 
doctors when prescribing, pharmacists when dispensing, nurses when 
administering and patients when taking medications.  
 
218 
 
There are a number of limitations associated with this study. The study was 
conducted in five ACFs in one geographical area in Ireland. Therefore, the 
generalisability of the study findings to other sites may be questionable. In an 
attempt to overcome this limitation, ACFs from each funding category (public, 
private and voluntary) were included in the study. In addition, the stringent 
regulation of long-term care facilities in Ireland, and the requirement to meet 
national, prescribed standards on medicine modification and administration (151), 
may help ensure that the observed practices are reflective of those across Ireland. 
As a result, the findings should be transferable to other ACFs in Ireland. However, 
the generalisability of the findings internationally may be limited if different 
medication administration and management practices are implemented in other 
jurisdictions. 
 
Undisguised, direct observation of medicine administration was undertaken in this 
study. Both undisguised (234, 297) and disguised observation methods (304) have 
been used in previous studies that involved the observation of medicine 
administration. It could be argued that the use of undisguised observation is a 
limitation of the study, as the nurses may have behaved differently during the 
observed drug rounds. However, it has previously been shown that observation of 
practice does not lead to alterations in behaviour (320) and nurses have previously 
reported willingness to be observed administering medication (321). For this study, 
the research team felt that it would be inappropriate to use disguised observation. 
Previous studies that used disguised observation investigated medicine 
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administration errors (304), which was not the purpose of this study. In order to 
overcome the potential for nurses to change their behaviour, the aim of the study 
i.e. to investigate the reality of, and challenges associated with, medicine 
modification and administration for older adults, was explained in detail to the 
nurses. Nurses were also advised that they were free to decline to participate in the 
study. 
 
Given the challenges experienced with recruitment, it was not possible to reach the 
target sample size. Hence, the study is under-powered and this should be borne in 
mind when interpreting these findings. However, whilst the study did not have the 
desired number of participants, the size of the study still compares favourably with 
similar studies investigating ODF modifications (102, 219, 297). In addition, a 
significant strength of this study is the large number of observations that were 
undertaken and the inclusion of drug rounds at morning, lunch, evening and night 
time, as in previous studies individual patients were often only observed at one 
time point (102, 219, 297). Unfortunately, there were a number of challenges 
encountered in conducting this study including: difficulties arranging suitable times 
for consenting patients and next-of-kin at the ACFs; the time-consuming nature of 
the consent process and; difficulties arranging suitable times for data collection and 
the observation of drug rounds in the busy environment of an ACF. These 
challenges were not unique to this study and many literature reports have 
previously described the difficulties associated with conducting research in long-
term care settings (322-325). Therefore, further research is warranted to confirm 
220 
 
prevalence; however, this work is unlikely to be feasible using the direct 
observation method. Rather, given that this study demonstrated that in the ACFs, 
the vast majority of modifications that were undertaken were authorised, a 
retrospective audit of drug charts, which is less-time consuming and would 
circumvent the challenges associated with obtaining consent and arranging suitable 
times for observations, could be used.  
 
The findings related to the patient characteristics that are associated with medicine 
modification must be interpreted with caution as these were not the primary 
objectives of the study. However, the findings should provide direction for further 
research and investigations of medicine modification and formulation suitability for 
older adults. Whilst individuality of formulation suitability is a substantial factor 
that complicates the targeting of interventions, ascertainment of medication types 
and patient characteristics that increase the likelihood of modification may serve as 
a useful starting point for efforts to optimise formulation suitability. 
 
Finally, modifications were classed as evidence-based or not evidence-based in 
accordance with the criteria used in Chapter 4 (240). However, the clinical 
significance of the modification was not assessed as this was beyond the scope of 
the study. Some of the “evidence-based” modifications may still have the potential 
to affect clinical outcomes, particularly for NTI drugs, whilst the majority of the 
“non-evidence-based” modifications would be unlikely to result in any significant 
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patient harm. The value of categorising modifications in this manner was that it 
facilitated examination of the resources and information sources available to 
healthcare professionals when they are tasked with making decisions regarding 
medication modification for patients. Therefore, the lack of information available 
highlights the uncertainty encountered by healthcare professionals when 
prescribing, dispensing and administering medication to older patients for whom 
ODFs must be modified.  
 
6.7 Conclusions 
This undisguised, direct observation study provided important insights into ODF 
modification and administration practices in ACFs in Ireland. It is clear that ODF 
modifications are commonly required to tailor oral medicines to meet the 
swallowing capabilities and dosing requirements of older adults. Whilst many of the 
modifications lacked an evidence-base to support decision-making, the majority of 
practices were optimised within the limitations of currently marketed formulations. 
A key finding related to the method of administration of medication, with modified 
and unmodified solid ODFs, as well as liquid ODFs, routinely being administered in 
food vehicles or thickened fluids. Further research and development is needed to 
optimise medication formulation suitability for older adults and the findings of this 
study, by describing the current reality of, and challenges associated with, 
medication administration, should inform the direction of this research. 
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7.1 Abstract 
7.1.1 Background 
ODF modifications are commonly undertaken to adapt commercial formulations to 
meet the individualised needs of older adults. In the community setting, older 
adults and/or their carers make decisions about medicine administration, often 
without seeking advice or input from healthcare professionals. However, there is a 
dearth of research investigating the experiences and opinions of community-
dwelling older adults and carers about ODF modification and administration. 
7.1.2 Aim 
The aim of this study was to investigate the knowledge, attitudes and beliefs of 
community-dwelling older adults and carers of community-dwelling older adults 
about ODF modifications. 
7.1.3 Methods 
Qualitative, semi-structured, face-to-face interviews were conducted with 
community-dwelling older adults and carers of community-dwelling older adults 
who experienced difficulty swallowing ODFs, or who required ODFs to be modified 
to facilitate intake or for fractional dosing. Participants were recruited using a 
combination of purposive, convenience and snowball sampling from purposively 
selected community pharmacies throughout county Cork in Ireland. Interviews 
were conducted between May 2017 and June 2018. All interviews were audio-
recorded and transcribed verbatim. The data were analysed thematically using the 
Braun and Clarke methodology. Interviews continued until no new themes 
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emerged. The Francis method was used to determine when data saturation had 
been reached and hence governed sample size. 
7.1.4 Results 
Twenty six interviews, involving 13 patients and 13 carers, were conducted (76.9% 
female, median interview length 11 minutes 17 seconds (IQR 8 minutes 3 seconds 
to 16 minutes 23 seconds)). Four themes emerged from the data: variation in 
medical needs and preferences; balancing acceptance and resignation; healthcare 
professional engagement and; opportunities for optimising formulation suitability. 
The wide range of medical conditions and functional limitations experienced by 
community-dwelling older adults resulted in a variety of modifications being 
undertaken to accommodate the individual’s needs and requirements. Overall, 
patients and carers are quite accepting of medications and formulations prescribed 
and dispensed. Unfortunately, in some instances, when challenges arise, patients 
and their carers tend to feel resigned to coping within the constraints of the current 
medication regimen. This resignation resulted in a lack of focused communication 
with healthcare professionals about their challenges and thus, healthcare 
professionals remained unaware of the difficulties and did not offer advice or 
solutions. However, carers of patients with significant difficulties appeared to be 
more likely to engage with healthcare professionals about modifications and 
formulation suitability. 
7.1.5 Conclusions 
From this study, the views of community-dwelling older adults and their carers 
about ODFs have been elucidated. There is a clear need for healthcare professionals 
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to engage proactively with this group by advising on the availability of different 
formulations and the appropriateness of modifications. Pharmacists should offer 
workshops and supplemental training on medicines administration to those who 
care for the older adult. In addition, it would be useful to have a list of triggers that 
prompt the pharmacist to ask about ODF modifications, including both patient and 
formulation factors likely to influence acceptability. Whilst it is clear that a holistic 
approach to medication management is ideal, the disadvantage is that no single 
healthcare professional may identify this as their responsibility, therefore, as 
medication experts, it is up to the pharmacy profession to take ownership and 
become the champion of, and for, the patient. 
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7.2 Introduction 
Due to age-related pharmacokinetic, pharmacodynamic and physiological changes 
(63, 67, 89, 92, 273), ODF modifications are a reality in older patient care with 
previous research, including research conducted as part of this doctoral research 
(Chapters 2 and 4), highlighting that in older patient care settings, approximately 
one-third of all patients receive modified medicines (219, 236, 240, 261, 287). 
Despite the routine occurrence of ODF modifications, there are concerns about the 
potential effect on dosing accuracy, drug absorption and release profiles and 
therefore therapeutic outcomes or adverse events (106, 126, 127, 209). As a result, 
various interventions have sought to reduce the prevalence of ODF modifications 
(259-261, 304). However, it is clear that in many instances, there are simply no 
alternatives to modification due to an absence of suitable formulations coupled 
with a clinical need for the medication (63, 96, 97, 240). Consequently, guidance to 
healthcare professionals routinely advocates the use of alternative formulations or 
routes of administration, with the alteration of solid ODFs being “reserved as last-
resort and practised only after appropriate advice has been sought from a 
pharmacist and/or Medicines Information Centre” (104). 
 
Research investigating the views of healthcare professionals about ODF 
modifications for older adults has shown that the practice is regarded as being 
routine and necessary (156, 157, 289, 326). Reports have suggested that healthcare 
professionals’ lack knowledge about the appropriateness of ODF modifications 
(157, 158, 262). Qualitative research has provided further insights, highlighting that 
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whilst healthcare professionals were often cognisant of the potential for 
therapeutic consequences when modifying ODFs, they expressed concerns and 
uncertainty about decision-making in this area (156, 157, 289, 326). However, they 
negotiated this uncertainty through the involvement of other members of the MDT 
(156, 157, 289, 326). Therefore, when modifications are deemed necessary, they 
are considered and reviewed by a variety of healthcare professionals with the goal 
of ensuring that all modifications are safe and appropriate. Given the 
acknowledgement that the expertise and input of many different healthcare 
professionals is often required for decision-making about ODF modifications, this 
raises concerns about community dwelling older adults and their carers.  
 
The vast majority of older adults in Ireland, 94.7% of those aged ≥65 years and 
78.3% of those aged ≥85 years, are resident in private households (24). Therefore, 
the task of medication management falls to the patient and/or a carer. There are 
limited data on the prevalence of ODF modifications amongst community dwelling 
older adults. As discussed in Chapter 2, previous studies have suggested that 
approximately 14% of community-dwelling older adults experience difficulty 
swallowing solid ODFs (217, 218, 236). A study conducted in 17 community 
pharmacies found that; of customers suspected by pharmacists as potentially 
experiencing difficulty swallowing medication, 60% had difficulty taking a tablet or 
capsule and of these, 68% modified solid ODFs to facilitate administration (87). As 
regards modifications for fractional dosing, a study conducted amongst a 
community-dwelling adult population in Germany (mean age 67.3 years), found 
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that 24.1% of all tablets were split prior to administration (96). It has been reported 
that patients do not inform healthcare professionals about difficulties experienced 
with ODFs (86, 87, 252). Therefore, older adults or their carers may be modifying 
ODFs without appreciating the potential for adverse events and without the input 
of healthcare professionals. Qualitative research would help to reveal the 
knowledge, attitudes, beliefs and experiences of community-dwelling older adults 
and carers around ODF administration and modification. Ultimately, the most 
important stakeholders for any qualitative research on medication formulation 
suitability are the patients and carers who are administering medications on a daily 
basis. However, as identified in the qualitative systematic review in Chapter 3, 
research investigating the views of these key stakeholders is limited (289). Of the 
four qualitative studies involving patients that discussed medicine modification, 
only one addressed modifications in detail (252), while in the remaining three 
studies, modifications were briefly mentioned as part of broader discussions 
around medication related problems or factors that affected adherence (251, 253, 
254). No studies have investigated the views of carers in relation to ODF 
modification. Therefore, research is needed to address this gap in the literature. 
This will be vital to ensure that healthcare professionals, policy makers, regulatory 
agencies and the pharmaceutical industry are aware of the priorities and needs of 
patients and carers who are tasked with managing medication in a community 
setting. This study will provide valuable and novel insights into the issue of ODF 
administration and modification in the community setting, which should help to 
identify areas for more focused and targeted investigation.  
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7.3 Aim of the study 
The aim of this study was to investigate the knowledge, attitudes and beliefs of 
community-dwelling older adults and carers of community-dwelling older adults 
about the modification of ODFs. 
 
7.4 Methods 
7.4.1 Ethical approval 
Ethical approval to conduct this study was granted by the Clinical Research Ethics 
Committee of the Cork Teaching Hospitals, Cork, Ireland (Appendix 7).  
 
7.4.2 Study design 
Semi-structured, face-to-face qualitative interviews were conducted with 
community-dwelling older adults (aged 65 years or older), and carers of 
community-dwelling older adults, who experience difficulty swallowing ODFs or 
who require ODFs to be modified to meet their needs. Various qualitative research 
methodologies have been used in healthcare research to gain an understanding of 
the views, perceptions and priorities of patients and carers (193, 194, 327). Little is 
known about the experiences of community-dwelling older adults and carers 
around ODF administration and modification (289). Therefore, given the deficits in 
this research area, semi-structured interviews were chosen as the data collection 
method to facilitate a broad investigation of this under-explored topic whilst 
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ensuring that a detailed insight into the personal experiences and perspectives of 
individuals could be elucidated (288, 328, 329). 
 
7.4.3 Study setting and sampling 
Eligible participants for this study were: (i) community-dwelling older adults (≥65 
years) who experience difficulty swallowing ODFs or who require ODFs to be 
modified to meet their needs or; (ii) carers who provide, or have provided, care to 
community-dwelling older adults (≥65 years) who experience difficulty swallowing 
ODFs or who require ODFs to be modified. Carers included both family carers and 
employed carers. Employed carers, in an Irish setting, are commonly known as 
“home helps” and they perform essential personal care and domestic duties for 
older adults in the community (330). Home helps are primarily provided by the HSE, 
who either directly provide a home help service or contract a private provider to 
supply the necessary services (330). For the purposes of this study, modifications 
were considered to be required if they were undertaken to: facilitate fractional 
dosing; overcome swallowing difficulties; or due to patient preference to modify 
ODFs. Participants were recruited from community pharmacies throughout County 
Cork, in Ireland. A sampling matrix was developed in an attempt to ensure that the 
pharmacies and participants included would be representative of the range of 
experiences encountered by community-dwelling older patients and carers (Table 
7.1). Community pharmacies were purposively sampled to include pharmacies 
located in socioeconomically “advantaged” and “less advantaged” areas, in both 
rural and urban settings. Pharmacies were classified as: “advantaged” if they were 
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located in: “marginally above average”, “affluent” or “very affluent” electoral 
divisions and “less advantaged” if they were located in: “marginally below average”, 
“disadvantaged” or “very disadvantaged” electoral divisions based on the 2011 
Pobal HP Deprivation Index (331).  
 
Table 7.1 Sampling matrix for study 
Pharmacy Characteristics 
Modifications for 
Fractional Dosing 
Modifications for 
Swallowing Difficulties 
Advantaged areas 
Rural 
1 Patient 1 Patient 
1 Carer 1 Carer 
Urban 
1 Patient 1 Patient 
1 Carer 1 Carer 
Less advantaged 
areas 
Rural 
1 Patient 1 Patient 
1 Carer 1 Carer 
Urban 
1 Patient 1 Patient 
1 Carer 1 Carer 
Note: represents the minimum number of patients or carers from each category 
sought for inclusion in the study 
 
A member of the research team contacted the identified pharmacies, provided the 
pharmacist with an information sheet about the study and explained what the 
study would involve. Once the pharmacist agreed to participate, a suitable time for 
conduct of the study at the pharmacy was arranged. In participating pharmacies, a 
number of sampling strategies were used to recruit patients and carers including 
purposive sampling, convenience sampling and snowballing, whereby interview 
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participants were asked to suggest other potential participants. The primary 
researcher (AMG) approached patients and carers who presented at the pharmacy 
and explained the study to them. Individuals were screened for eligibility and 
eligible participants were invited to participate. Pharmacists were also asked to 
suggest potentially eligible patients and carers; a member of the research team or 
the pharmacist invited these individuals to participate in the study. This 
combination of convenience and more targeted purposive sampling was used in an 
attempt to include participants whose healthcare professionals were aware that 
they modified ODFs, as well as those who may not have previously discussed their 
requirements with a healthcare professional. During recruitment, participants were 
informed that participation was voluntary and that they were free to decline to 
participate. No incentive for participation was offered.  
 
7.4.4 Data collection 
Two topic guides were developed; one for interviews with patients and one for 
interviews with carers. The topic guides were devised based on the findings of 
Chapter 3, the systematic review of qualitative literature on medicine modification 
(289), taking into consideration the aims of this study. The general content of the 
topic guides was the same for patients and carers however the language was 
tailored to address the varied roles and perspectives of each cohort. The topic 
guides were piloted by interviewing two patients and one carer. The first patient 
interview was excluded from analysis. During the study, the topic guides underwent 
iterative refinement to ensure that any unexpected or emerging themes could be 
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investigated further. All authors reviewed and approved the initial topic guides and 
any revisions. Table 7.2 provides a summary of the content of the topic guides. 
 
Table 7.2 Summary of the interview topic guides 
Interview Topics 
Experiences of medicine administration and modification 
Decision-making around medicine modification 
Knowledge about medicine modification 
Views and knowledge about medicine formulations 
Strategies used to overcome difficulties with formulations 
Healthcare professional support and involvement 
Supports 
 
Prior to the initiation of the interviews, the purpose of the study was described to 
the participants and the interviewer explained the consent form in detail. All 
participants provided written, informed consent for participation. All interviews 
were conducted by AMG, a research pharmacist with previous training in, and 
experience conducting, qualitative research involving semi-structured interviews. 
No relationship was established between the interviewer and participants prior to 
initiation of the study. The participants were aware that the interviewer was a 
pharmacist and researcher working in the School of Pharmacy at the local 
University. The participants were informed that the research team were interested 
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in understanding the views and experiences of patients and carers about medicines 
administration and modification. The interviews were conducted between May 
2017 and June 2018 in the private consultation room at participating pharmacies, in 
the interviewee’s home or the interviewer’s home, depending on the participant’s 
preference. If participants requested the presence of an additional person during 
the interview this was facilitated. Demographic data collection forms were 
completed by participants prior to initiation of the interview. For carers the 
following details were collected: gender of carer, age and medical conditions of the 
person for whom they care and the carer’s relationship to the person for whom 
they care. For patients the following details were collected: gender, age, medical 
conditions and who looks after his/her medications. Repeat interviews were not 
conducted. Interviews were audio-recorded, anonymised and transcribed verbatim 
by AMG. Transcripts were not returned to participants for review. Detailed field 
notes were written by AMG following each interview. 
 
7.4.5 Analysis 
Data were analysed thematically according to the method described by Braun and 
Clarke (295). Transcripts were input into QSR International’s NVivo 11 Qualitative 
Data Analysis Software to facilitate analysis (332). Table 7.3 summarises the phases 
of analysis undertaken.  
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Table 7.3 Data analysis process (Adapted from Braun and Clarke (295)) 
Phase of analysis Tasks completed Research team member 
involved 
Phase 1: Familiarisation 
with data 
Transcription, reading and 
re-reading of interview 
transcripts. 
Reading of selection of 
interview transcripts  
AMG 
 
 
LJS, AC, MK 
Phase 2: Generating 
initial codes 
Initial, non-hierarchical, 
open coding of entire data 
set 
AMG 
Phase 3: Searching for 
themes 
Categorisation of codes into 
potential themes 
AMG 
Discussed with MK, LJS, 
AMC 
Phase 4: Reviewing 
themes 
Confirming themes – 
ensuring the internal 
homogeneity and external 
heterogeneity of themes. 
AMG 
Reviewed by, and 
discussed with, MK, LJS, 
AMC 
Phase 5: Defining and 
naming themes 
Further refinement of 
themes 
AMG 
Confirmed with MK, LJS, 
AMC 
Phase 6: Producing the 
report 
Production of the 
manuscript, selection of 
illustrative quotes 
AMG 
Reviewed by, and 
discussed with MK, LJS, 
AMC 
 
In this study, data analysis began at an early stage with interview transcription and 
reading and re-reading of the interviews. The research team determined a priori 
that an inductive, flexible approach to analysis would be undertaken. It was initially 
thought that the interviews for patients and carers would be analysed together 
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given the similarity of the topic guides. However, following initial coding of three 
patient and three carer interviews, the research team made the decision to analyse 
the data for patients and carers separately, in order to capture nuanced differences 
in the codes that were emerging at this stage. A flexible, iterative approach to 
analysis is a key tenet and strength of qualitative research (295, 333). It was agreed 
that in the presentation of the findings of the study, any relevant differences 
between the patient and carer groups would be fully described. The Francis method 
was used to determine when data saturation had been reached, and therefore, 
determined the sample size (294). As the patient and carer cohorts were being 
analysed separately, an initial analysis sample of ten and a stopping criterion of 
three for each cohort was agreed by the authors, once the decision to analyse the 
cohorts separately was made. Once data saturation had been achieved for each 
cohort, the findings were integrated to identify convergence and divergence of the 
themes from each cohort. 
 
To ensure aligned thinking amongst the research team, each co-author read a 
random sample of patient and carer interviews to confirm that the codes and 
themes generated were truly reflective of the interview content. Group meetings 
were held when necessary and any disagreements were resolved through 
discussion and a consensus was reached amongst all co-authors. Participants were 
not asked to provide feedback on the study findings.  
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7.4.6 Reflexivity  
Reflexivity is considered to be essential in the conduct of rigorous qualitative 
research (296, 334, 335). Reflexivity has been defined as, “An attitude of attending 
systematically to the context of knowledge construction, especially to the effect of 
the researcher, at every step of the research process” (334) and involves the 
research team acknowledging, identifying and considering their own unique role, 
perspectives, backgrounds and beliefs and how these can influence the research 
(296, 334). All four members of the research team are female pharmacists and, at 
the time of study initiation, two authors (AMG and MK) were Clinical Pharmacy PhD 
students, while the remaining authors (LJS and AMC) were academic staff 
members, at the School of Pharmacy in the local University. The research team 
have all been involved in research investigating ODF modifications for older adults 
and have previously undertaken qualitative research. The research team 
approached this study with the belief that ODF modifications are likely to be 
required for community-dwelling older adults. The research team had previously 
identified a lack of data investigating the views, experiences and beliefs of 
community-dwelling older adults and/or their carers about ODFs and modification 
practices (289). As such, the research team sought to elucidate the knowledge, 
attitudes and beliefs of these key stakeholders around ODF modifications by using a 
comprehensive sampling strategy involving broad, purposive sampling as well as 
convenience and snowball sampling, and by using an inductive approach to analysis 
to allow the priorities and views of participants to predominate. 
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7.4.7 Reporting 
This study is reported in accordance with the “Consolidated Criteria for Reporting 
Qualitative Research” (COREQ) guidelines (296) (Appendix 11).  
 
7.5 Results 
7.5.1 Study sites 
Twenty one pharmacists were approached and asked if their pharmacies would be 
part of the study. Of these, seventeen agreed to participate, one did not respond 
and three declined to participate (two cited a lack of older patients and one was 
already involved in an ongoing research project). In four of the seventeen 
pharmacies that agreed to participate, pharmacists chose to only participate in 
purposive identification of participants and not convenience sampling by a member 
of the research group at the pharmacy. However, no participants were recruited 
from any of these four pharmacies. A member of the research team (AMG) 
attended the thirteen participating pharmacies and conveniently sampled patients 
and carers attending the pharmacy. Participants were also recruited following 
purposive identification by pharmacists. 
 
7.5.2 Characteristics of interview participants 
In total, twenty six interviews were conducted: 13 with patients and 13 with carers. 
Figure 7.1 presents a flow diagram of the participant recruitment process. The 
majority of interview participants were female (76.9%). Interviews ranged in length 
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from 6 minutes 5 seconds to 35 minutes 15 seconds. The median interview duration 
was 11 minutes 17 seconds (IQR 8 minutes 3 seconds to 16 minutes 23 seconds). 
The median interview lengths were similar for patients (11 minutes 13 seconds) and 
carers (11 minutes 20 seconds). Of the 13 patients interviewed, 61.5% were female. 
The median age of the interviewed patients was 77.0 years (IQR 72.5 to 84.0). The 
majority of patients (76.9%) looked after their medication themselves, while 23.1% 
reported that a family member took responsibility for medication management on 
their behalf. Seven of the patient interviews were conducted in the private 
consultation rooms at the participating pharmacies, while six patients were 
interviewed in their homes. Three of the patients requested the presence of a 
family member during the interviews, however only the patient contributed to the 
interview. Of the 13 carers interviewed, the majority (92.3%) were female. Nine of 
the carers were related to the person for whom they cared (7 daughters, 1 
daughter-in-law, 1 husband), while four were employed as carers. Interviews were 
conducted in the consultation rooms at the participating pharmacies (n=7), at the 
carer’s home (n=4) and at the interviewer’s home (n=2). 
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Figure 7.1 Flow diagram of participant recruitment 
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7.5.3 Themes 
As discussed previously, the patient and carer interviews were analysed separately 
in order to identify any differences in themes or experiences between these groups. 
Once initial coding, categorisation and searching for themes were completed, the 
potential themes were examined and integrated to determine where similarities 
and differences lay. The themes that emerged were broadly similar, however some 
differences were seen and these are explicitly highlighted. 
 
7.5.3.1 Variation in medical needs and preferences 
It was clear from the interviews that there was substantial variation in the 
complexity of medical conditions experienced by community dwelling older adults. 
Interview participants ranged from very active, independent individuals who 
managed their medications themselves through to carers of older adults who 
required full assistance with medication as well as activities of daily living. This 
underlines the challenging context within which healthcare is provided in a 
community setting given the range of abilities, health statuses and medical 
complexities encountered by healthcare professionals in their daily practice.  
 
Unsurprisingly, given this variability in medical conditions and needs, formulation 
suitability and modification requirements were seen to differ considerably from 
person to person. Patients who required modifications to overcome swallowing 
difficulties existed on a spectrum, ranging from those who halved large 
formulations due to slight discomfort swallowing large tablets, “I find them huge… 
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so I was cutting them in half” (Patient 9), to patients who required all solid ODFs to 
be modified due to significant dysphagia which not only affected medication 
administration but also impacted on food and fluid intake, “Yeah, it [solid oral 
medicines] was all crushed” (Carer 3). One carer modified medications for 
administration via a PEG tube to a patient who was nil by mouth. Similarly, amongst 
individuals who required fractionally dosed medication, a range of experiences was 
once again seen, from those who required only a low dose of a medication to 
achieve the desired therapeutic effect through to those who required multiple 
medications to be halved as they perceived that they experienced adverse events 
on higher doses, “… a lot of my tablets were halved… they can’t give me the full 
dose because I’ve such low blood pressure and all the medications I’m on bring my 
blood pressure down” (Patient 11).  
 
Modifications to overcome swallowing difficulties are a reality for patients in the 
community. Once again, the individual nature of this phenomenon was evident 
when the reasons for modifying medications were probed. For many patients, 
particular formulation characteristics contributed to difficulty swallowing the 
dosage form e.g. the type of formulation, the size of the tablet or capsule, tablet 
shape, and tablet coating. However, considerable variability was evident with some 
participants describing formulation characteristics as detrimental to swallowing 
while others found the same characteristics to be beneficial, “A lot of the antibiotics 
that are big, I’d find you’d have to break those. Now capsules are fine, I don’t have a 
244 
 
problem” (Patient 1), “Older people who’d say, ‘oh, I can’t take them big capsules’” 
(Carer 2).  
 
A number of factors unrelated to the formulation influenced the need to modify 
ODFs including: general swallowing difficulties, often attributed to the effects of 
ageing or inherited swallowing issues; fear of choking on medication due to a 
previous bad experience; or a perception that they do not “know” how to swallow 
medications properly. Carers were particularly likely to mention medical conditions 
that affected swallowing, including stroke, dementia and Parkinson’s disease. 
Although in some instances, healthcare professionals provided advice to 
participants about modifications to facilitate intake, many participants made the 
decision to modify on their own. In contrast, modifications for fractional dosing 
were generally initiated by the prescriber with low doses being prescribed when the 
medication was started. However, in some instances the need for fractional dosing 
was only identified when the dose proved to be too high for the patient and 
resulted in the development of side effects. Whilst the doctor was generally 
responsible for making the decision regarding dosing, in some instances family 
members led the decision to decrease the dose and subsequently informed the 
prescriber who was happy to continue the lower dose, “We decided ourselves, as a 
family... that we would half a tablet because she is a very small woman and she’d 
been complaining, not complaining, but that she was constantly tired. So eventually 
we put two and two together and decided to reduce that to half a tablet… we just 
informed the doctor and he said that’s fine” (Carer 7).  
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Although modifications are commonly performed, it was evident that a wide variety 
of methods are used. Medication administration is very personal, with each 
individual patient and carer developing their own techniques and coping strategies 
to best suit their needs. Various methods to crush tablets were described including 
commercially available crushing devices, mortar and pestle, crushing between two 
spoons, crushing using a plastic bag, between a plate and a glass etc. Again, in 
administering these modified medications, patient preference governed the choice 
of administration vehicle with modified medications being administered with water, 
yoghurt, petit filous, ice-cream, jam or with breakfast. Participants reported that 
medicines were fractionally dosed using a variety of methods including breaking 
tablets by hand, using a knife, a tablet splitter, or getting the pharmacy to split the 
tablets in advance.  
 
Perhaps unsurprisingly, the “ideal” formulation differed from patient-to-patient, yet 
again highlighting the individual nature of formulation suitability and preference. In 
relation to fractional dosing, some participants expressed a desire for the 
prescribed dose to be available, which would avoid the need to modify. Others 
suggested that formulations should be made easier to halve e.g. by including score 
lines. Other participants stated that they had no issue with fractional dosing as long 
as it was performed by the pharmacist in advance. In relation to general 
preferences around ODFs, considerable variability was seen. Some participants 
expressed no preference, others preferred liquids, while others preferred tablets or 
described certain “model” tablet characteristics related to the coating, shape or size 
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of the formulation. However, there was no consensus here, as one participant said, 
“But sure I mean everybody’s different like. You know, I mean I couldn’t sort of 
legislate for somebody taking medicines, one way or another” (Patient 6). 
 
7.5.3.2 Balancing acceptance and resignation 
The views of older patients and their carers around medicines and modifications 
were elucidated throughout these interviews. In general, both patients and carers 
recognised the importance of medication in the maintenance of health and quality 
of life: “You either have that [minor side effect with medication] or you have the 
problem of… the heart, it’s one or the other, at least this way it’s keeping you going” 
(Carer 10); “Like you think you’re anti-medicines until you need a medicine and then 
you’re not anti-medicine anymore. You know, you have a different thinking” (Carer 
5); “If I have to take them, I have to take them” (Patient 3). As a result, the 
interview participants tended to be very accepting of the medications prescribed 
and formulations dispensed to them, with many expressing satisfaction with their 
current medication regimen: “I’ve no complaint with what I have really” (Patient 5); 
“Whatever the doctor prescribed she got, nothing else, good, bad or indifferent 
because we believe in, strongly, in doing what doctors tell us and that’s it” (Carer 
11). However, despite individuals expressing satisfaction with their regimen many 
voiced a desire to be on fewer medications and questioned the number of 
medications prescribed to older adults, “I’d like to reduce tablets. I was on more 
before… I’d love to have them reduced again but I mean if that’s what they say, I 
take them” (Patient 4). As the views of patients and carers were probed further, it 
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became clear that although individuals were accepting of the importance of 
medication, there was a sense of resignation and lack of autonomy, “I mean if you 
are in hospital they just give you the medication and say take it, they give you the 
tablets in the little container and they bring you in water and they maintain that you 
are going to take them like and that’s it” (Patient 6).  
 
This sense of acceptance tending towards resignation around medications was 
echoed in views about ODF modifications. Interviewees modified ODFs to facilitate 
administration of the prescribed dose, or to facilitate intake due to difficulty 
swallowing the dosage form. Participants felt that they had no option but to modify 
the medication, “But like when somebody’s elderly you just have to make the best of 
it” (Carer 1), “Well, the taste isn’t very nice, but I’d be just worried in case it won’t 
have the same, you know reaction when I take it, but there’s nothing much I can do 
only take it that way [break tablets to overcome swallowing difficulties] (Patient 1). 
Whilst some individuals had no concerns and were happy to perform modifications, 
for many individuals, modifying medications, despite being their accepted reality of 
medicine administration, was not without challenges. Concerns about fractional 
dosing mainly centred on the whether the correct dose was administered due to 
uneven splitting or fragmentation of tablet halves on storage. In addition to these 
concerns, difficulties associated with fractional dosing were described including: 
physical difficulty splitting the tablets, even if a pill splitter is used or a score line is 
present; and tablet halves fragmenting on storage. For modifications to facilitate 
intake, concerns were expressed about the accuracy of dosing due to loss of 
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medication when a modification is performed and subsequent difficulty 
administering the full dose due to drug remaining in the administration vehicle, 
“…you don’t know then are you getting a full dose even though you brought out as 
much as you could” (Patient 12). Both patients and carers noted additional 
concerns, including the potential for alterations in the action of the drug or the 
possibility that modified medicines could damage the oesophagus or stomach. Both 
groups also reported challenges around performing the actual modification and the 
palatability of the newly modified medicine. However, despite this, participants 
continued to modify as they felt this was the only viable option.  
 
This necessity to modify medications was also felt to be unlikely to change given 
that there was a lack of suitable formulations, “You could never halve them equally 
and they didn’t make the tablet in a smaller size which was an awful nuisance for 
them here in the pharmacy and for me because you know I’d be breaking and I’d 
think, well this is not a half and this is more than a half but what can you do” 
(Patient 11). It is likely that attitudes to medication i.e. that they are necessary, 
informs attitudes towards modification, which may lead to harmful modifications 
being undertaken. Whilst some individuals were knowledgeable that certain 
medication formulations should not be modified, this was not universally known or 
understood, “I saw on that medication now, ‘do not crush or chew’ and I was 
thinking like, if I have to, do I just go ahead and do it?” (Carer 12). This resulted in a 
number of participants expressing incorrect beliefs e.g. all scored tablets can be 
249 
 
divided in two to give equal doses or all capsules can be opened to facilitate 
administration.  
 
7.5.3.3 Healthcare professional engagement 
Both patients and carers discussed healthcare professionals, particularly doctors 
and pharmacists, and the role they played in healthcare provision in the community 
setting. In general, interview participants had very positive views of both 
pharmacists and doctors, “They are very good in my chemist” (Patient 9). In 
particular, continuity of care provision was valued with a preference for attending 
the same general practitioner and pharmacist. An important role centred on 
information provision, with both doctors and pharmacists seen to be an important 
source of information and advice regarding medicines and medical conditions in 
general. Whilst each healthcare professional was seen to have a distinct area of 
expertise, pharmacists were seen to be more accessible for general queries than 
GPs, however, information and healthcare provision was seen to require the 
combined input and expertise of both categories of healthcare professionals. An 
interesting point raised by one carer was the importance of having a GP and 
pharmacist who had a good relationship, as this ensured that they liaised and 
communicated on issues related to the patient, and this was seen to be the ideal 
situation, “We stayed with the same GP and pharmacist and then also the GP and 
pharmacist know each other so that all ties in, he can ring the doctor and he can, 
you know… it wouldn’t be the same if you had a pharmacist over here that didn’t 
know your GP” (Carer 5).  
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Interestingly, differences were seen between patients and carers in their level of 
engagement with healthcare professionals about ODF modifications and 
formulation suitability. Many patients reported that healthcare professionals did 
not seem to consider formulation suitability and did not enquire about patient’s 
preferred formulations or whether they experienced any issues when taking ODFs. 
However, this was unsurprising given the acknowledgement that many healthcare 
professionals were unaware of patients’ difficulties with formulations given that 
patients tended to persevere on their own, developing techniques and coping 
strategies to overcome difficulties, “Keep on till I got it down” (Patient 1). Many 
patients seemed reluctant to inform doctors or pharmacists about the difficulties 
they experienced or even simply to ask questions related to their medicine or 
health, “I don’t ask and I think afterwards why didn’t I ask him…” (Patient 3). 
Amongst pharmacists, there was a tendency to dispense the formulation prescribed 
without seeking further information from the patient, “They’d give me whatever is 
on my prescription” (Patient 7), which also hindered engagement. This tends to 
result in a vicious cycle in which the patient is left without the correct information 
and the pharmacist is blissfully unaware of their predicament. Patients appeared to 
only engage with healthcare professionals when a problem with a formulation 
became very significant and the coping strategies they used previously proved 
ineffective or if they received modified medicines during a hospital admission. 
However, in the case of modifications for fractional dosing, pharmacists appeared 
to be more proactive, offering to split the medication for patients as well as carers. 
This is likely to be due to the fact that, from the dose prescribed and formulations 
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available, it is obvious that a modification is necessary, “One of the girls there [in 
the pharmacy] told me that they’d half them” (Patient 6). 
 
In contrast to patients, carers were more likely to report that doctors and 
pharmacists were aware of the patient’s swallowing difficulties or formulation 
preferences. This was particularly true when the patients they cared for suffered 
with significant swallowing difficulties. In these instances healthcare professionals 
were more likely to consider formulation suitability and enquire about preference, 
“…their pharmacist... he was super. I mean he’d always come out and he’d say you 
know you can’t crush this… he would have been very helpful” (Carer 3). However, 
even in situations where healthcare professionals were aware of difficulties, carers 
were cognisant of the need to remind them of patient’s requirements as they 
occasionally forgot. Carers reported a sense of responsibility and advocacy which 
empowered them to ask questions and raise any concerns that they had, “I would 
question everything, I don’t have a problem… I would ring the pharmacist if I was 
having a problem with a particular tablet, would there be an alternative?” (Carer 4). 
However, this enhanced engagement was not universal, predominantly seen 
amongst carers who provided care to patients with significant needs. The views of 
those providing care for patients with fewer requirements were more in line with 
those of patients, and they were often unaware of the availability of alternative 
formulations. Therefore, lack of engagement by both patients and carers seems to 
stem from lack of knowledge about medications and formulations. This also led to 
an important observation regarding the role of carers in the community setting. 
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Both family carers and “home helps” were interviewed in this study. Although 
home helps described that their role centred on personal care and they did not 
administer medication, they were extremely knowledgeable about, not only the 
patient in general, but also the challenges they experienced when using medication. 
Carers, both family carers and home helps, were cognisant of the need to support 
and supervise older adults and stated that they would always intervene if they were 
concerned that the patient was not coping with medication management, “Like you 
visually have to keep contact with them, visual contact all the time, you can’t just 
turn away or you know, put a tablet there on the table and let them do it” (Carer 4), 
“There was a problem with her medication actually… I had to get on to the public 
health nurse” (Carer 9). Many patients in the community setting relied on their 
carers to liaise with healthcare professionals, “I would yeah [contact a patient’s 
doctor or pharmacist], and they are very good, you know. Once the patient is okay 
with you speaking to the doctor or whatever, there is no problem” (Carer 8), and to 
advocate on their behalf. This highlights the importance of the patient-carer 
relationship in the community setting.  
 
When healthcare professionals were aware of patient’s needs they were reported 
as being extremely helpful: advising about the different formulation options 
available; providing information about the appropriateness of modification; 
advising on the best methods of modification and administration. However, lack of 
engagement, both by patients and carers, and by healthcare professionals 
appeared to be a substantial barrier to formulation optimisation for older adults. 
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7.5.3.4 Opportunities for optimising formulation suitability 
The knowledge, attitudes and beliefs of participants about ODF modifications 
demonstrated a need for initiatives to support community-dwelling older adults 
and their carers in the area of formulation suitability and medicine modification. 
The majority of participants were of the opinion that more supports are required, 
with a strong preference for these supports to be delivered in the community 
setting by their regular healthcare providers. Both patients and carers felt that 
greater engagement by healthcare professionals in this area would be beneficial. 
There was a desire for healthcare professionals to enquire about patient’s 
formulation preferences and swallowing difficulties more frequently, “If the doctor 
or the pharmacist suggest, asked, like, you are prescribed a certain thing now and 
you can either have it in… whatever form, you know” (Patient 2). This was linked 
with a perceived need for more regular review of patient’s medication regimens, “I 
find that in Ireland, if you are prescribed something, you are on it for life. There is no 
follow-up… once they are prescribed it’s just a continuing process” (Carer 7). 
Notwithstanding the finding that healthcare professionals already play an 
important role in information provision, the majority of participants were of the 
opinion that information provision should be improved. Again, it was felt by both 
groups, that this information should be delivered by their regular doctors and 
pharmacists and tailored to their requirements. Topics that were suggested 
included: general information on medications; the formulations that are available; 
advice regarding the appropriateness of modifications and; how to perform 
modifications. In particular, accessible information that is consistent across all 
healthcare professionals and settings was seen to be vital as one carer previously 
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encountered inconsistencies in advice regarding PEG administration which created 
uncertainty and worry. A variety of methods of information provision were 
suggested including: information delivery at the point of prescribing or dispensing; 
leaflets and booklets on modification and; workshops or educational sessions for 
both patients and carers on administration, “Workshops that come into the 
community... and get the carers to come in for one hour and say, look this is what’s 
out on the market, do you realise that this is available and there’s an alternative 
and if you do have doubts this is who you should ask... if the workshops were open 
to everybody and not just focused on one sector” (Carer 4). Carers often described 
how, over time, they developed their own techniques and strategies to overcome 
challenges with administration and that they gradually learnt about various 
formulations that were available and who to approach for help. As such, caring for 
older adults was a learning experience, however, proactive information provision 
and education sessions, would help to empower carers to feel more confident and 
knowledgeable in this area, “Like it’s a learning curve for all of us... but you know 
small kids and old parents are very similar in that you kind of have to do so much 
and I think…it’s a life skill” (Carer 2). 
 
Most of the supports suggested centred on healthcare professionals. However, 
some participants raised the need for greater consideration of the medication 
requirements of older people by the pharmaceutical industry, “It’s a 
pharmaceutical company so they’re doing for the majority… it [a formulation] might 
suit six out of the ten, but there’s four that they’re not suiting” (Carer 4), “…if the 
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pharmaceutical industry reduced the size of their tablets, very definitely, because 
some people just can’t swallow them” (Patient 13). Increased development and 
availability of alternative formulations, such as liquids and patches or easily 
modifiable medicines, were suggested as methods of improving formulation 
suitability for older adults, “More liquids and patches and that kind of thing, that’d 
be great” (Carer 1). 
 
7.6 Discussion 
This study has examined the views of patients and carers regarding ODF 
modification. Four themes emerged: variation in medical needs and preferences; 
balancing acceptance and resignation; healthcare professional engagement and; 
opportunities for optimising formulation suitability. The findings of this study 
highlight the variability associated with the formulation requirements and 
preferences of community-dwelling older adults. While both patients and carers 
tend to be very accepting of medications and formulations as prescribed and 
dispensed, this acceptance may stem from a sense of resignation to the need to 
take the medication and the perception that there are simply no alternatives other 
than their current medication and/or modification regimen. This may ultimately 
result in a lack of engagement with healthcare professionals, with patients and 
carers adopting various coping strategies to overcome the challenges they 
encounter. As a consequence, healthcare professionals are often unaware of the 
difficulties experienced by their patients. However, the role of the carer was seen 
to be vital, with carers appearing to be more likely to engage with healthcare 
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professionals regarding formulation suitability. As a result, there is scope and desire 
for further supports and initiatives to be implemented to optimise formulation 
suitability for community-dwelling older adults. 
 
It is clear from this study that older adults in a community setting cannot be 
considered a homogenous cohort. Rather, healthcare professionals providing care 
to community-dwelling older adults encounter a wide-range of health statuses, 
medical conditions, support structures and abilities that substantially contribute to 
the complexity of healthcare provision in a community setting. Whilst ageing is 
frequently defined as a progressive deterioration of physiological function (336), 
many commentators argue that ageing itself should not be considered a 
pathological condition, commensurate with frailty and dependence (337-339). 
However, neither is active, independent living a reality for all older adults, 
particularly given that age-related physiological changes are, in themselves, risk 
factors for the development of many diseases (337-339). In reality, a wide spectrum 
is seen from independent, ambulatory individuals with excellent health through to 
individuals requiring considerable support and care from healthcare professionals 
as well as carers (338). This variation in medical complexity and care requirements 
has implications for formulation suitability and ODF modifications. This is evident 
from the wide range of experiences and views detailed by those interviewed, which 
concurs with the findings of the systematic review of qualitative literature (Chapter 
3) which reported that patient-centred individuality and variability was a key factor 
influencing the need to modify ODFs (289). Therefore, the issue of formulation 
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suitability is one that must be considered routinely. However, it is important for 
healthcare professionals to recognise that, as highlighted in the qualitative 
systematic review (289) and further emphasised in this study, medical complexity 
alone is not the only factor influencing ODF modifications.  
 
It has been established that, amongst the community-dwelling cohort, medicine 
formulation suitability varies substantially which adds to the complexity of 
optimising medical care for these patients. An important finding from this, and 
other studies, is that many patients, not just those with dysphagia, find medication 
intake challenging and resort to modifying medicines, often unbeknownst to their 
healthcare professionals (86, 87, 221, 289). It appears that healthcare professionals 
in a community-setting are more likely to consider formulation suitability for 
individuals with medical conditions with dysphagia as a co-morbidity e.g. stroke, 
dementia, Parkinson’s disease etc. This may be due to a combination of healthcare 
professionals’ awareness of the prevalence of dysphagia in these cohorts and the 
associated complications around medication intake, as well as the fact that these 
patients may have carers who take on the role of patient advocate. However, the 
literature consistently demonstrates that patients without documented diagnoses 
of dysphagia or difficulty swallowing, experience difficulty with medication intake 
and modification (86, 87, 221, 289). Therefore, relying on medical complexity alone 
to guide decisions regarding formulation suitability is likely to be insufficient to 
identify individuals who require greater support. As the population ages, and there 
is an increased preference amongst older adults to remain in the community (340), 
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which is backed by government policy (341), healthcare professionals are being 
tasked with providing care to patients with a wider variation in medical needs. 
There needs to be increased appreciation of the patient-related factors that 
contribute to complexity related to formulation suitability. Increased awareness of 
the challenges encountered by all patients and carers, in managing and 
administering medications on a daily basis, would help to ensure that all patients, 
particularly those who may not have the support or input of a carer, receive the 
optimum formulation to suit their needs. The value of this research is that the 
themes identified provide clear directions for further research and interventions, 
which take into account the substantial variability encountered in the community 
setting. 
 
Participants in this study were very accepting of medications, with the general 
consensus being that medications are necessary to maintain health and quality of 
life. Central to this appeared to be the trust that was placed in healthcare 
professionals, with participants frequently describing the need to adhere to 
doctors’ recommendations regarding treatment. However, there was a distinct 
sense of resignation to the need to take medication long-term, often despite a 
preference to be on fewer medications. Previous research has investigated whether 
patients’ beliefs about medication impact on adherence (342). It has been shown 
that higher necessity scores (i.e. a view that medications are a necessity) are 
positively correlated with adherence, whereas higher concerns about medication 
were correlated with lower adherence (343, 344). Whilst previous studies have 
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reported that difficulty swallowing medication can lead to poor adherence (84, 86, 
87), in contrast, in this study, participants’ beliefs about the necessity of medicines 
resulted in them persisting in taking formulations, even when this proved 
challenging, by developing their own coping strategies to facilitate administration. 
The beliefs of participants towards medication appeared to influence their views on 
formulation suitability and medicine modification, with the sense of acceptance and 
resignation around medicines promoting a sense of resignation towards the 
formulations prescribed and dispensed. Although the findings regarding adherence 
appeared to diverge from previous reports (84, 86, 87), in keeping with previous 
studies, difficulty taking medication resulted in many participants’ modifying 
medications (84, 86, 87). While some participants reported that they would ask 
about the availability of alternative formulations or check if the modification was 
appropriate, many undertook modifications without any appreciation that 
modifications may be inappropriate or that alternative formulations may be 
available. This may be partly explained by the observation that participants were 
resigned to the formulation prescribed and viewed the medication as being vital. 
Therefore, their primary consideration centred on administration. This finding 
reflects the view expressed by nurses in the study conducted by Barnes et al. (156) 
that the imperative is ensuring that all prescribed medication is administered. This 
raises concerns that given that the dominant imperative is to administer 
medications, inappropriate or potentially harmful modifications may be performed 
without input from healthcare professionals. Previous research has highlighted that 
many healthcare professionals are unsure of their responsibilities in relation to 
medicine modification given that numerous disciplines have distinct roles to play in 
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this area (156, 157). However, as experts in medication, with a unique 
understanding of formulation and dosage form design, pharmacists have a vital role 
to play and must engage in this area, to ensure that patients receive maximum 
benefit from their medication, while minimising potential harms.  
 
Participants in this study had positive views about their healthcare professionals, 
including doctors and pharmacists, and described that they provided excellent care 
and support to them. However, despite this, patients acknowledged that many of 
their doctors and pharmacists were unaware that: they experienced difficulty 
taking solid ODFs; they modified ODFs or; they had difficulty performing 
modifications. This echoes findings from previous research which found that 
patients do not inform healthcare professionals about difficulty taking ODFs and 
healthcare professionals do not enquire about patient preference (85-87, 221). This 
lack of engagement by patients, and some carers, with healthcare professionals is a 
serious concern and the factors contributing to this reticence to inform healthcare 
professionals about their difficulties must be addressed. The reluctance to actively 
seek assistance around formulation issues may, ironically, be related to the fact 
that patients are accepting of the healthcare provided to them because they trust 
and rely on their healthcare professionals to make decisions on their behalf. This 
passive approach, in which patients do not take an active role in decision making 
around healthcare, is reflective of a more traditional, paternalistic approach to 
healthcare professional-patient interactions (345). Perhaps the fact that the patient 
cohort was over 65 years of age may partly explain their lack of engagement as 
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older adults often have a more traditional approach to healthcare, preferring to rely 
on their healthcare professionals’ judgement (346, 347). In recent years, there has 
been a move away from this paternalistic approach to one in which shared 
decision-making is encouraged (348). It has been suggested that outcomes may be 
improved when patients participate in decision-making around medical treatment 
and care, although data are limited (349-351). Older patients in particular should be 
encouraged to become more active participants in the clinical decision making 
process and patient autonomy should be encouraged. This may help to encourage 
and empower individuals to become partners in their own care, sharing issues and 
communicating challenges with their healthcare professionals. However, research 
has also highlighted that some patients prefer not to be involved in healthcare 
decision making (346). Whilst patients and carers should be encouraged to inform 
healthcare professionals about the difficulties they experience, the onus should not 
solely be on the patient and/or carer. Healthcare professionals must be encouraged 
to consider formulation suitability at every instance of prescribing, dispensing and 
administration, particularly for patients who assume a more passive approach 
(352). In this study, patients with significant dysphagia or difficulty swallowing 
medication reported that healthcare professionals were aware of, and considered, 
their issues with formulations. However, given that individuals who do not suffer 
with dysphagia are modifying medicines routinely; healthcare professionals must be 
encouraged to ask all patients about formulation preferences and difficulties 
experienced. This may necessitate healthcare professional education, particularly to 
raise awareness of the variety of factors, not just medical conditions, which can 
impact on formulation suitability. Further research will be required to identify these 
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factors, both at the patient and formulation level. In Chapter 2, it was suggested 
that there is a need for the development of a screening tool to identify patients 
who experience difficulty taking medication (236). Routine incorporation of such a 
screening tool as part of the general consultation with a patient would encourage 
greater consideration of the formulation requirements of older adults. The 
“SWAllowing difficulties with MEdication intake and COping strategies” 
(SWAMECO) tool was developed by a research group in the University of Basel, to 
identify swallowing difficulties with medication intake thereby facilitating 
healthcare professionals to select the most appropriate formulation and to provide 
tailored counselling to reduce inappropriate modifications (353). This tool has 
recently been translated into English and undergone preliminary validation in an 
Irish community pharmacy setting (354). Further validation is required, however, 
routine use of a tool such as this may help to overcome issues associated with lack 
of engagement, thereby ensuring that healthcare professionals are aware of the 
difficulties that patients experience, which should ultimately facilitate them in 
optimising formulation suitability for their patients.  
 
Another possible reason for the lack of engagement may be related to a knowledge 
deficit around medications and formulations amongst patients and carers. It has 
been shown in this, and previous studies (84, 86, 87, 221), that patients lack 
awareness about medications and formulation types, and therefore, they may not 
enquire about the availability of alternatives due to an assumption that the 
medication dispensed to them is the only formulation available. In addition, 
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knowledge that modifications can potentially be hazardous is not commonplace. 
Therefore, patients and carers often do not realise that these modifications should 
be reviewed by a healthcare professional to ensure that they are safe and 
appropriate. There is a need for greater education of patients and carers about 
salient features of medications. However, it must be acknowledged, that some 
participants, particularly carers, described seeking alternatives or verifying if 
modifications were appropriate. This suggests that some patients and carers, 
particularly those with significant experience performing medication management 
and modification, are knowledgeable in this area. However, as described by these 
participants, caring for older patients with significant needs is a learning 
experience. As previously highlighted by Cowan (355) , experience is what makes 
the carer the expert in patient care. This provides support to the fact that 
knowledge about formulation alternatives and the supports that are available is not 
intrinsic, but rather develops over time. One carer made the analogy that caring for 
an older parent is, in some ways, similar to caring for a young child, where the carer 
undergoes a significant learning curve but expresses a willingness to advocate and 
speak out on behalf of their loved one, who may not be able to vocalise their own 
needs. Greater information and support should be provided to carers to facilitate 
them in advocating for their loved ones. At present, it appears that carers learn by 
experience, when difficulties and challenges are encountered. However, a more 
proactive approach to the provision of information and support should be 
encouraged. 
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Carers play a vital role in healthcare provision in the community setting and greater 
engagement with carers may present an additional means of optimising 
formulation suitability for older patients. Carers, particularly those caring for older 
patients with significant morbidities, reported that they informed healthcare 
professionals about formulation suitability and/or healthcare professionals 
considered formulation suitability. It was an interesting finding that carers 
appeared more likely to inform healthcare professionals about difficulties with 
formulations than patients themselves. Various studies have investigated the role 
of carers, and in particular, carers’ view of their role. As Cowan reported, carers 
have a unique knowledge of the patient’s needs and want to be viewed as an 
“expert partner” in care provision (355). In Chapter 5, it was found that nurses, in 
acute and long term care settings, advocate on behalf of their patients’, which helps 
to optimise formulation suitability. Carers in a community setting are taking on a 
similar role, and engage with healthcare professionals to act as patient advocates 
(356). Therefore, carers represent a vital resource who can help to overcome the 
lack of engagement and associated information deficits around formulation 
suitability for individual older adults. 
 
This study has provided a detailed and useful insight into the knowledge, attitudes 
and beliefs of community-dwelling older adults and their carers about the 
modification of ODFs. A key strength of this study was the inclusion of both patients 
and carers. This facilitated an in-depth investigation of the range of challenges 
encountered in the community setting. Patients who were able to participate 
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generally represented more independent, ambulatory patients who were able to 
manage medication on their own behalf. However, by including both cohorts, a 
thorough appreciation of the community care setting was obtained. Particularly 
novel was the inclusion of carers, as no previous study specifically investigated the 
views of carers around ODF modifications, despite the fact that carers frequently 
assume responsibility for medication management for community-dwelling older 
adults. Therefore, this study has addressed this significant gap in the literature. In 
addition, the use of the defined sampling strategy ensured that the full range of 
experiences and perspectives were elucidated. The large number of participants 
included in this qualitative study is also a significant strength of the study, and the 
time frame of the study allowed for in-depth analysis to be undertaken. In addition, 
providing participants with the opportunity to decide upon the location of the 
interview ensured that participants felt comfortable and at ease during the 
interview. There are a number of potential limitations associated with this study. 
The majority of participants were female and therefore, the findings may not reflect 
the male perspective on ODF modifications. However, in this study, no variations in 
views or experiences were evident between the male and female participants. The 
carer cohort, in particular, was predominantly female. However, this is likely to 
reflect the reality encountered in Ireland, as females tend to be more likely to take 
on the role of carer, both for family members and as employed carers (357, 358). 
While the transferability of the findings may be questioned given that interviews 
were conducted in one county in Ireland, the use of a sampling matrix and inclusion 
of participants from different socioeconomic regions and both urban and rural 
areas helped to overcome this limitation. It is possible that given that the 
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interviewer was a pharmacist, this may have resulted in participants providing 
socially desirable responses. However, given that no relationship was established 
with participants prior to the interviews and the participants only had knowledge of 
the interviewer in the capacity of a researcher, this would have helped to overcome 
this potential limitation. Participants were assured of the confidentiality of their 
responses and it was evident during the interviews that participants expressed their 
opinions honestly and openly.  
 
7.7 Conclusions 
From this study, the knowledge, attitudes and beliefs of community-dwelling older 
adults and their carers have been elucidated. It is clear that the diverse, 
community-dwelling older population experiences substantial variability in their 
formulation and modification requirements and preferences. Whilst good 
relationships with doctors and pharmacists were reported by both patients and 
carers, there was a sense of acceptance veering towards resignation around 
medications and formulations. This sense of resignation often resulted in lack of 
engagement with healthcare professionals, who in turn were unaware of patients’ 
formulation requirements. There is a clear need to enhance engagement with this 
cohort and various supports and initiatives are likely to be required to optimise 
formulation suitability for older adults. A key first step will involve raising 
awareness amongst healthcare professionals of the pervasiveness of challenges 
with formulations so as to encourage healthcare professionals to consider 
formulation suitability when prescribing and dispensing medications for older 
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adults. In addition, carers and patients should be provided with information about 
medications in order to enhance knowledge and encourage greater engagement 
with healthcare professionals. 
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Chapter 8: Discussion 
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8.1 Discussion 
This thesis investigated ODF suitability for older adults by examining ODF 
modifications in an Irish setting. In this chapter, the thesis, as a complete body of 
work, is discussed and the overall findings are interpreted. The chapter will begin 
with a summary of the key findings from each individual chapter, before integrating 
these findings to provide greater insights. This will involve a discussion of the 
implications of the research, taking into consideration previous literature, as well as 
healthcare policy. Following this, the overall strengths and limitations of the thesis 
will be described. Finally, recommendations for future work will be provided. 
 
8.2 Summary of findings 
The first objective of this doctoral research was to systematically review the 
quantitative and qualitative literature to provide an evidence-base to inform the 
development of research questions for the primary research studies. The 
quantitative systematic review (Chapter 2) identified that approximately 14% of 
community-dwelling older adults experience difficulty swallowing ODFs whilst 
between one-quarter and one-third of occasions of medicine administration to 
older patients in care facilities involved the modification of ODFs. However, a key 
finding was the paucity of data investigating ODF modifications amongst the older 
cohort, with only two studies assessing the prevalence of difficulty swallowing 
medicines and three investigating ODF modifications. In addition, there were issues 
associated with how direct observation studies reported the prevalence of ODF 
modifications, reporting at the level of occasions of drug administration rather than 
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at a patient level. Given the limited number of studies, the need for further 
research to investigate the prevalence and practice of ODF modification was 
identified. The qualitative systematic review (Chapter 3) identified that the variable 
and individual nature of patients’ needs and requirements is a key factor 
influencing the modification of ODFs. Optimisation of formulation suitability is 
hindered by the observation that communication, both between patients and 
healthcare providers and between different members of the healthcare team, is 
often poor, resulting in a lack of awareness of patients’ individual formulation 
needs. The review also identified that both healthcare professionals and patients 
are often uncertain about the appropriateness of modifications which stems from a 
lack of knowledge; due to an absence of easily accessible, evidence-based 
information resources. The findings of these reviews served to inform the 
generation of research questions for the primary research studies by identifying a 
number of key areas for further investigation. 
The retrospective audit of drug charts described in Chapter 4 provided the first data 
on ODF modifications for older adults in an Irish setting. This study demonstrated 
that ODF modifications are commonly required to tailor ODFs to meet the needs of 
older adults in an ACF, with 35% of patients requiring at least one medicine to be 
modified to meet their needs. A particularly novel finding was that modifications 
were most commonly undertaken to facilitate fractional dosing. This was of interest 
given the lack of consideration of the issue of dose suitability in the literature. A 
total of 68 instances of modification were recorded, of which, almost half were 
neither licensed nor recommended in BPGs. The necessity to modify ODFs 
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appeared to arise predominantly due to a lack of appropriate, licensed dosage 
forms; however, reimbursement policies also appeared to play a role. It was clear 
that clinicians lack evidence-based information sources to support decision making 
around modifications when appropriate alternatives are unavailable.  
The qualitative interview study described in Chapter 5 was designed to address 
gaps identified in previous chapters: a lack of studies investigating the views of 
nurses (Chapter 3); and to further probe the potential factors influencing ODF 
modifications in an Irish setting (Chapter 4). Three major themes: modifying – a 
necessary evil; nurses’ role as patient advocate and; modifying – we are working 
very much as a team; emerged from the data. Nurses viewed modifications as being 
a common and necessary occurrence when providing care for older adults, due to 
limitations of available formulations and the presence of age-related challenges 
around medication administration. Whilst the systematic reviews (Chapters 2 and 
3) identified that a lack of communication hinders formulation optimisation, nurses 
helped to overcome this issue by advocating on behalf of patients to raise 
awareness of their individualised needs. The nurses’ knowledge of the individual 
patient greatly facilitated this advocacy role. However, nurses expressed concerns 
and uncertainty around modifications and sought information, advice and 
reassurance from members of the MDT, particularly pharmacists, in an effort to 
overcome knowledge deficits and concerns about modifications.  
The direct observation of medicine administration (Chapter 6) undertaken in five 
ACFs sought to further develop the evidence-base on ODF modifications in an Irish 
setting and address some areas for further research identified in previous studies. 
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This study confirmed that ODF modifications are a reality for older adults in ACFs in 
Ireland with almost half of patients having at least one solid ODF modified to meet 
their needs. Modifications to overcome swallowing difficulties were more common 
than in the retrospective review. Particularly interesting were findings related to 
the methods of modification which showed that the techniques used helped to 
overcome concerns regarding cleanliness and cross-contamination. Both modified 
and non-modified ODFs were frequently administered using food vehicles and 
thickened fluids, highlighting the difficulties experienced in administering 
medications safely to older adults. 
Chapter 7, the qualitative interview study with community-dwelling older adults 
and their carers, once again highlighted the wide variability in medical needs and 
formulation requirements amongst the older cohort, which concurred with the 
results from the systematic reviews (Chapters 2 and 3), as well as the quantitative 
and qualitative studies (Chapters 4 to 6). While overall, patients and carers tended 
to be extremely accepting of their medications and the formulations dispensed, 
there was a sense of resignation towards medication which resulted in patients and 
carers persisting with formulations even when challenges were encountered. This 
resignation resulted in lack of engagement with healthcare professionals who were 
frequently unaware of the difficulties experienced by patients in a community 
setting. In contrast, carers appeared to be more likely to engage with healthcare 
professionals, informing them of patient’s formulation requirements and needs. 
Participants expressed a desire for supports to be implemented to assist them in 
managing medications in a community setting including: greater engagement and 
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information provision by healthcare professionals; delivery of workshops on 
medication and; the development of more formulations.    
 
8.3 Interpretation, and implications, of findings 
Reviews discussing potential challenges associated with oral drug administration for 
older adults continue to be published (164, 165, 182, 184, 311, 359). The principal 
contribution of this thesis has been the generation of evidence, from both long-
term care and community settings, demonstrating that ODF modifications are not 
only common, but also necessary to meet the needs of older adults. The findings 
from this thesis concur with, and add to, previous studies that have described ODF 
modifications in community (87, 217, 254) and long-term care settings (100, 102, 
156, 219, 220, 287, 297). In particular, this thesis has developed the evidence-base 
related to modifications for fractional dosing. It is now clear that modifications 
should not be considered unusual nor are they only undertaken in exceptional 
circumstances. Rather ODF modifications represent a normal, day-to-day reality for 
many older adults. The findings of this thesis should serve as the impetus for 
greater engagement with this issue through the provision of direction for future 
research. Two key areas for engagement by different stakeholder groups have been 
identified: formulation suitability and medicine acceptability by academics, the 
pharmaceutical industry and regulatory bodies and; medicines optimisation by 
healthcare professionals and academics. In particular, the findings of this thesis 
should also serve to inform the reflection paper on the pharmaceutical 
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development of medicines for use in the older population which is currently under 
preparation by the EMA (174). 
 
8.3.1 Formulation suitability and medicine acceptability 
One of the most predominant and recurring themes present throughout this thesis, 
in both the quantitative and qualitative research, was variability and individuality of 
older patients’ needs and preferences in relation to ODFs. In the qualitative studies, 
there was substantial variability around the formulation characteristics that 
contributed to difficulty with intake and/or modification, as well as the types of 
dosage forms that were preferred by patients. In addition, there was no consensus 
regarding the ideal formulation for older adults amongst patients, carers or nurses. 
In the quantitative study, forms which proved to be acceptable and usable to many, 
were unacceptable for others. This diversity concurs with previous studies that 
investigated the prevalence of difficulty swallowing ODFs amongst community-
dwelling adult patients, that reported substantial variability in the formulation 
factors that impacted on ease of intake (85, 86, 360). While none of these studies 
were conducted exclusively in an older population (85, 86, 360), they substantiate 
the finding that specific formulation characteristics contribute to difficulties with 
intake. A recent review sought to objectively investigate how the physical 
characteristics of ODFs affected oesophageal transit (182). Factors including size, 
shape, density, surface characteristics and type of formulation were found to 
impact on swallowability and oesophageal transit of tablets and capsules amongst 
adult patients (182). The authors acknowledged that literature reports pertaining to 
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older adults are limited, however, they emphasised that as difficulties are likely to 
be even more pronounced amongst the older cohort, the findings provide useful 
guidance on formulation factors that affect swallowability for the older cohort 
(182).  
 
Increasingly, medicine acceptability, “the ability and willingness of a patient to self-
administer, and also of any of their lay or professional caregivers, to administer a 
medicinal product as intended” (174), is being recognised as an important 
consideration for older adults and their carers (182). A significant contribution of 
this thesis is in highlighting that patient factors, not just medical conditions and 
formulation factors, influence the need to modify medications for older patients. 
Therefore, “medicine acceptability”, is the best approach for assessing formulation 
suitability for older adults as it considers the variety of factors that can affect 
acceptability from a patient or carer perspective. It is vital that the acceptability of 
ODFs for older adults is considered early in the drug development process, when 
formulations and doses are being identified and selected for further development 
and commercialisation. However, this will necessitate the development of validated 
methods to assess medicine acceptability, as well as improving awareness that 
factors other than the formulation characteristics and patient’s medical conditions 
affect acceptability. Whilst significant improvements have been made in the area of 
medicine acceptability for paediatric patients, primarily due to regulatory 
requirements (185, 361), medicines for the geriatric cohort have lagged behind. A 
recent systematic review of methods used to assess the acceptability of oral 
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medicines identified seventeen studies that reported on the formulation 
characteristics that affect the acceptability of ODFs for older patients (362). The 
review authors reported a lack of standardisation of methods used to assess 
acceptability and called for a consensus agreement between academia, the 
pharmaceutical industry and regulators to harmonise methodology for assessing 
acceptability of pharmaceutical products (362). Therefore, this thesis adds weight 
to calls for the development of methods to assess medicine acceptability for older 
adults, but in addition, highlights the need for these methods to incorporate all of 
the potential contributing factors, including formulation characteristics, patient 
preferences, social influences etc., given the finding that many individuals without 
objective evidence of swallowing dysfunction and without any co-morbid medical 
conditions report difficulties with formulations. A recent attempt has been made by 
Vallet et al. (363) to take account of both user and product characteristics that 
influence acceptability, by developing a decision support tool to assist in the design 
of acceptable medication for older adults. This study used data from an 
observational study conducted in hospitals and nursing home settings to develop an 
acceptability reference framework using a multivariate data analysis approach. 
Efforts such as this should help the pharmaceutical industry and regulators to 
evaluate the acceptability of medicines for older adults, taking into account the 
various and complex user and formulation factors that influence acceptability. 
 
As stated previously, the issue of dose suitability for older adults has yet to be 
extensively addressed in the literature; however, evidence from this thesis 
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highlights that modifications for fractional dosing are commonplace, despite a lack 
of data on the accuracy of tablet splitting for individual formulations (Chapter 4 and 
6). This thesis has underlined the need for dose selection to be made relevant to 
the target patient population and for greater consideration of the neglected issue 
of modifications for fractional dosing. 
 
In Chapter 1, the regulatory perspective on medications for older adults was 
summarised. The increased focus by regulatory agencies on the issue of medication 
suitability for older adults has led to increased engagement, by both academics and 
the pharmaceutical industry, with older adults and carers in an attempt to identify 
their priorities related to medication (165, 359). The challenge now is to translate 
the learnings from this, and similar research, into improved medicines for older 
patients. This will undoubtedly be a challenging task for the pharmaceutical 
industry, given that, as highlighted by Page et al., a “one-size-fits-all approach” to 
geriatric medicine formulation will not be sufficient (364). However, the current 
approach, where extrapolations are made from adult populations and a one-size-
fits-all approach is applied throughout the entire adult population is obviously 
ignoring fundamental challenges encountered by the older populations. The 
findings of this thesis highlight the need for the pharmaceutical industry and 
regulators to engage with this area and consider the factors that affect medicine 
acceptability for older patients. This is likely to ultimately require the development 
of novel formulations or multiple formulation types, as well as the provision of 
information on the safety and efficacy of modified medications.  
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8.3.2 Medicines optimisation 
Whilst it is vital that the issues of medicine acceptability and the development of 
patient-centric formulations are addressed by the pharmaceutical industry and 
regulatory agencies, the marketing of new, more suitable formulations will take 
time. In the interim, the onus is on healthcare professionals and academics to 
consider what supports they can offer to help optimise medicines for older adults. 
This thesis has helped signpost some of the key areas for prioritisation of 
engagement.  
 
The research in this thesis has primarily focused on the aged care or long-term care 
setting. There have been numerous reports in the literature of interventions that 
sought to reduce inappropriate tablet crushing in nursing homes and geriatric units 
of hospitals (261, 304), as well as tablet splitting for fractional dosing in a 
community setting (259, 260). Various approaches were used including the 
dissemination of good practice recommendations and a list of medicines that 
cannot be crushed (261), use of warning symbols in combination with staff 
education (304) and computerised decision support systems (259, 260). These 
studies have demonstrated statistically significant reductions in inappropriate 
modifications (261, 304) and inappropriate tablet splitting (259, 260). However, 
none of these studies were performed in an Irish setting. Given that this research is 
the first to evaluate ODF modification practices in Ireland, the potential impact of 
similar interventions in an Irish setting should be assessed in light of the evidence 
gained in this thesis. These studies were designed based on the assumption that 
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inappropriate modifications are being undertaken, either at the prescribing, 
dispensing or administration level, despite appropriate alternatives existing (259-
261, 304). However, based on the results of the thesis, it is our contention that the 
modifications that are being undertaken in ACFs in Ireland cannot be attributed to 
aberrant practices by healthcare professionals, but rather arise due to limitations of 
marketed formulations and re-imbursement policies combined with a substantial 
variation in the medication needs and requirements of older adults. Therefore, the 
utility of similar interventions in the Irish setting is questionable. A factor that may 
contribute to the optimisation of modification practices in the Irish nursing home 
sector, within the constraints of available licensed formulations, is regulation. The 
nursing home sector in Ireland is heavily regulated, with HIQA responsible for 
monitoring, inspecting and registering nursing homes (365). A strict policy on 
medicine administration, which incorporates guidance on medicine modification, 
exists and nursing homes must demonstrate adherence to this policy to the 
satisfaction of the regulators (151). One intervention that may be warranted in an 
Irish setting would centre on improving knowledge, given that in Chapter 5, nurses 
reported concerns and uncertainty about modifications. Previous literature has 
described an intervention to improve healthcare professional knowledge about 
ODF modifications (262) and a similar intervention in an Irish setting may help to 
improve nurses’ confidence and knowledge around ODF modifications. 
 
Another striking finding, evident throughout this thesis, was the lack of sufficient 
engagement on the issue of formulation suitability by healthcare professionals, 
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patients and carers. This issue is not unique to an Irish setting, having been 
documented extensively in other studies investigating ODF modifications, 
particularly in the community setting (84, 86, 87). The need for increased 
engagement and various strategies that could be utilised to facilitate this have been 
discussed at length throughout the thesis. In Chapter 5, it was found that advocacy 
by nurses, in acute and long-term care settings, facilitates the optimisation of 
formulation choice for individual older adults. When combined with the findings of 
Chapter 7, it appears that the priority area for engagement and intervention, in the 
Irish context, is the community setting. The National Positive Ageing Strategy (341), 
which is being implemented under the Healthy Ireland framework (366), seeks to 
improve the delivery of services and supports for older people so that the 
challenges associated with population ageing are addressed. The Department of 
Health has identified that a key goal of this strategy is to support people as they age 
to maintain, improve or manage their physical and mental health and well-being 
(341). A central component to the maintenance, improvement and management of 
health is ensuring that patients receive safe, effective medication. The findings 
generated in this thesis highlight that the issue of ODF suitability represents one 
area where further supports are required to help patients and carers maintain, 
improve and manage their medicine. A key first step will be to increase awareness 
amongst healthcare professionals of the challenges faced by community-dwelling 
older adults and their carers around formulation suitability which should help to 
improve information provision and dosage form selection for these individuals. 
Whilst the dissemination of this research represents one method of improving 
awareness, more targeted interventions are likely to be required including: 
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undergraduate education of healthcare students; provision of continuing 
professional development resources for qualified healthcare professionals and; 
public information campaigns. Educational campaigns such as this should 
encourage a more proactive, rather than reactive, approach to assessing 
formulation suitability for older adults. Similar campaigns have been run in the area 
of antibiotic awareness which involved healthcare professional education, as well as 
media campaigns to increase knowledge amongst the public about the appropriate 
use of antibiotics (367). Similar interventions may be useful in the area of ODF 
suitability.  
 
8.4 Strengths and limitations 
The individual primary research studies (Chapters 4-7) were designed based on the 
findings of two comprehensive systematic reviews of the literature. Systematic 
reviews are viewed as the gold-standard in evidence synthesis and both reviews 
adhered to best practice recommendations for the conduct and reporting of 
systematic reviews (213, 216, 248). The findings of these reviews defined the 
current evidence on ODF modifications and allowed the identification of key gaps in 
the literature. Subsequently, the research studies undertaken were designed to 
address the aims and objectives of the thesis overall, whilst ensuring that these key 
deficits in the literature were addressed. 
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A key strength of this thesis is the use of a mixed methods approach. In Chapter 1, a 
brief overview of the strengths and weaknesses of quantitative and qualitative 
research methods, and the advantages of using a mixed methods approach, was 
provided. The rationale for using a mixed methods approach to investigate this 
topic was justified. The findings of the individual quantitative and qualitative 
components of this thesis are complementary and in many instances, the findings 
from one study helped explain observations from previous studies and led to the 
generation of research questions for subsequent studies. It is clear that the use of 
mixed methods has facilitated the generation of deeper insights than could have 
been elucidated by either method alone.  
 
This thesis is the first to formally investigate ODF modifications for older adults in 
an Irish setting. Particularly novel, from an international perspective, was the 
investigation of ODF modifications to facilitate fractional dosing as well as to 
facilitate intake. Both of these topics represent ways in which ODFs, as currently 
formulated, are not meeting the needs of older adults, however, these topics have 
not been examined in tandem previously. This thesis sought to investigate ODF 
suitability for older adults by investigating ODF modifications to meet older adults’ 
needs, which represents a novel approach to assessing formulation suitability. 
 
In addition, a major contribution of the thesis was the qualitative investigation of 
the views of community-dwelling older adults and carers. Research on ODF 
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modifications for older adults has primarily focused on the long-term care setting. 
The voice of the community-dwelling cohort has been neglected in the literature up 
until now and this thesis highlights the imperative for engagement with this cohort.   
 
The quality of the research conducted as part of this doctoral thesis is evidenced in 
the number of peer-reviewed academic publications and conference presentations 
achieved. This highlights that this research is: of value; of scientific merit; of interest 
to academic and healthcare colleagues and; of sufficient quality and rigour. 
Therefore, dissemination of the important findings of this research is already 
underway. In addition, the publication strategy targeted a number of different 
journals with a diverse audience including healthcare professionals and academics 
(236, 240, 289, 326), industry and regulatory representatives (240), as well as open-
access publication to encourage broader dissemination (326). Endeavours will be 
made to further broadcast the findings of this research to patients, healthcare 
professionals working in clinical practice, as well as regulatory and industry bodies 
in order to maximise the impact of this research.  
 
The issue of medication acceptability for the older cohort is gaining increasing 
traction and recognition amongst healthcare professionals, academics and 
importantly, regulatory bodies. This research provides crucial and comprehensive 
data which can serve as the basis for further research. These findings should 
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provide a stimulus for further engagement in the area of medication suitability for 
the geriatric cohort. 
 
Whilst there are numerous strengths associated with this research, a number of 
limitations must also be acknowledged. Firstly, this study was conducted in the Cork 
region of Ireland. Therefore, the study is limited to one geographical area, which 
could be seen to limit the generalisability and transferability of study findings. The 
healthcare structure in Cork is comparable to that throughout the Republic of 
Ireland and therefore, the study findings would be relevant throughout Ireland. In 
addition, many of the issues identified would also be of relevance in other 
jurisdictions given that problems experienced by the geriatric cohort in Ireland are 
likely to be reflective of issues encountered in many other jurisdictions. Literature 
reports from other countries have described similar issues with formulations and 
many of the same formulations are marketed throughout the EU, particularly given 
the increased utilisation of the centralised procedure for licensing of medicines. 
 
The individual chapters provide greater detail on the potential sources of bias 
associated with each research study. In addition, methods to minimise the impact 
of these biases are described. For the quantitative studies, issues related to data 
collection were encountered. As detailed in Chapter 4, there were limits to the 
depth of information that could be obtained using retrospective data collection. In 
Chapter 6, the limitations associated with retrospective data collection were 
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addressed by undertaking a direct observation of medication administration. This 
provided more detailed information on the methods of modification and 
administration of modified medicines and also provided the researcher with a first-
hand insight into the challenges associated with drug administration in a nursing 
home setting. Although it was anticipated that more nursing homes would be 
included in this study, issues around engagement, time-frame and the requirement 
for consent, limited the number of nursing homes that could be included in the 
study. However, the findings proved extremely useful and concurred with many of 
the findings from the retrospective audit, as well as the findings from the interviews 
with nurses, thereby adding to the confirmability of study findings. 
 
8.5 Recommendations for future work 
This thesis has provided novel insights into ODF modifications in an Irish setting and 
the factors that influence this practice. As such, it represents an ideal starting point 
for further research that aims to optimise formulation suitability for older patients. 
Future research should investigate the following areas: 
i) Exploration of the views of doctors and pharmacists around ODF 
modifications for older adults. This should take the form of qualitative 
investigations supplemented by a larger, quantitative study to elucidate 
the views of healthcare professionals nationwide. 
ii) Investigation of the availability and use of guidelines and information 
sources on ODF modifications, particularly amongst pharmacists.  
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iii) Engagement with representatives of the pharmaceutical industry and 
regulatory bodies to elucidate their perspectives on medication 
suitability for older adults. Again, both qualitative and quantitative 
approaches are likely to be necessary. 
iv) There is a need for greater investigation of the factors that affect 
formulation suitability or medication acceptability from the perspective 
of older patients and/ or their carers. This should include assessment of 
ideal formulation characteristics, preferred formulation types, 
palatability, ease of modification and ease of use. 
v)  Healthcare professionals should be educated about the need to engage 
with patients and carers about formulation preferences. In addition, 
education of healthcare professionals, patients and carers about 
modifications, particularly inappropriate modifications, is also necessary.  
vi) Further research in the community-setting is warranted. This should take 
the form of a large scale quantitative study to elucidate the prevalence 
of ODF modification and also patient characteristics and formulation 
types that are associated with increased likelihood of modification. This 
would facilitate the targeting of interventions to support those most 
affected.  
vii) Further validation and testing of a screening tool to identify patients 
and/or carers who are modifying ODFs to facilitate administration is 
required. The utility of the screening tool from the perspective of 
healthcare professionals should also be investigated.  
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8.6 Conclusions 
The overall aim of this thesis was to investigate ODF modifications for older adults 
and to gain an understanding of the factors influencing this practice in an Irish 
setting. The research presented provides detailed insights into ODF modification 
and administration practices for older adults in ACFs in Ireland. It was 
demonstrated that between one-third and one-half of patients in ACFs required 
medicines to be modified to meet their needs, highlighting the prevalent nature of 
ODF modifications. Particularly novel were the findings relating to the prevalence of 
modifications for fractional dosing given that previous research has focused on the 
suitability of ODFs from a swallowing perspective, with dosing suitability a 
neglected consideration. The lack of evidence-based information to support 
clinician decision-making was striking, given that two out of every five modifications 
were neither licensed nor recommended in BPGs.  
Through qualitative investigation, the knowledge, attitudes and beliefs of nurses, 
community-dwelling older patients and carers about ODF modifications were 
elucidated and again highlighted that modifications are a routine practice. The 
research highlights that nurses advocate on behalf of their patients and work 
closely with members of the MDT to ensure that the needs of the individual are 
met and medicine administration practices are optimised. In contrast, research 
found that in the community-setting, patients and carers tend to be very accepting 
of the medications prescribed and dispensed to them, resulting in lack of 
engagement around the issue of formulation suitability. However, it was found that 
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carers helped to bridge this lack of engagement by advocating on behalf of patients, 
particularly those with advanced needs.  
Taking into consideration all of the findings, this thesis demonstrates that ODFs are 
not meeting the needs of the older cohort and that the dosing requirements and 
swallowing capabilities of older adults are a neglected consideration in the design 
and authorisation of ODFs. This thesis substantially contributes to the literature, 
through the provision of comprehensive, novel data on the reality of ODF use for 
older adults. The value of this research is that it adds weight to calls for increased 
engagement with the issue of ODF suitability for older adults, by providing evidence 
from a “real-world setting” that ODFs are not fit for purpose and are routinely 
required to be modified.  
Significantly, the insights gained from this thesis provide direction for further 
research, with two key research streams required: greater engagement with 
patients, particularly in the community, to support them on the issue of 
formulation suitability and; the development of patient-acceptable ODFs and 
increased availability of evidence about the suitability and appropriateness of 
modification and administration practices.  
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Appendix 1: Search strategy for quantitative systematic review 
Database searched: PubMed 
Date searched: 11/11/14 
Search 
number 
Search terms 
#1 Search ((((((((((((((pharmaceutical preparations) OR tablets) OR 
capsules) OR dosage forms) OR administration, oral) OR pharmaceutical 
solutions) OR tablet*) OR capsule*) OR dosage form*) OR medicine*) 
OR medication*) OR pill*) OR solution*) OR suspension*) OR syrup* 
#2 Search (((((dysphagia) OR deglutition disorders) OR swallow* difficult*) 
OR swallow* disorder*) OR swallowing) OR deglutition 
#3 Search (((((((((crush*) OR grind*) OR cut) OR split) OR manipul*) OR 
modif*) OR dissolv*) OR dispers*) OR thicken*) OR mix 
#4 Search ((#1) AND #2) AND #3 
 
Search strategy for other databases: As for PubMed using index terms and 
truncation where appropriate. 
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Appendix 2: PRISMA checklist for quantitative systematic review 
Section/ topic # Checklist item Reported on page 
number 
Title    
Title 1 Identify the report as a systematic 
review, meta-analysis, or both. 
50 
Abstract    
Structured 
Summary 
2 Provide a structured summary 
including, as applicable: 
background; objectives; data 
sources; study eligibility criteria, 
participants, and interventions; 
study appraisal and synthesis 
methods; results; limitations; 
conclusions and implications of key 
findings; systematic review 
registration number. 
51, 52 
Introduction    
Rationale 3 Describe the rationale for the 
review in the context of what is 
already known. 
53 – 55  
Objectives 4 Provide an explicit statement of 
questions being addressed with 
reference to participants, 
interventions, comparisons, 
outcomes, and study design 
(PICOS). 
55 
Methods    
Protocol and 
registration 
5 Indicate if a review protocol exists, 
if and where it can be accessed 
(e.g., Web address), and, if 
available, provide registration 
information including registration 
number. 
N/A 
Eligibility criteria 6 Specify study characteristics (e.g., 
PICOS, length of follow-up) and 
report characteristics (e.g., years 
considered, language, publication 
status) used as criteria for eligibility, 
giving rationale. 
57 – 59  
Information 
sources 
7 Describe all information sources 
(e.g., databases with dates of 
coverage, contact with study 
authors to identify additional 
studies) in the search and date last 
searched. 
56 
312 
 
Section/ topic # Checklist item Reported on page 
number 
Search 8 Present full electronic search 
strategy for at least one database, 
including any limits used, such that 
it could be repeated. 
Appendix 1 
 
 
 
Study selection 9 State the process for selecting 
studies (i.e., screening, eligibility). 
56, 57 
Data collection 
process 
10 Describe method of data extraction 
from reports (e.g., piloted forms, 
independently, in duplicate) and 
any processes for obtaining and 
confirming data from investigators. 
60 
Data items 11 List and define all variables for 
which data were sought (e.g., 
PICOS, funding sources) and any 
assumptions / simplifications made. 
58 – 60 
Risk of bias in 
individual studies 
12 Describe methods used for 
assessing risk of bias of individual 
studies (including specification of 
whether this was done at the study 
or outcome level), and how this 
information is to be used in any 
data synthesis. 
60 
Summary 
measures 
13 State the principal summary 
measures (e.g., risk ratio, difference 
in means). 
N/A 
Synthesis of 
results 
14 Describe the methods of handling 
data and combining results of 
studies, if done, including measures 
of consistency (e.g., I2) for each 
meta-analysis. 
61 
Risk of bias across 
studies 
15 Specify any assessment of risk of 
bias that may affect the cumulative 
evidence (e.g., publication bias, 
selective reporting within studies). 
60 
Additional 
analyses 
16 Describe methods of additional 
analyses (e.g., sensitivity or 
subgroup analyses, meta-
regression), if done, indicating 
which were pre-specified.  
N/A 
Results    
Study selection 17 Give numbers of studies screened, 
assessed for eligibility, and included 
in the review, with reasons for 
exclusions at each stage, ideally 
with a flow diagram. 
61, 62 
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Section/ topic # Checklist item Reported on page 
number 
Study 
characteristics 
18 For each study, present 
characteristics for which data were 
extracted (e.g., study size, PICOS, 
follow-up period) and provide the 
citations. 
63 – 66 
 
 
 
 
Risk of bias within 
studies 
19 Present data on risk of bias of each 
study and, if available, any outcome 
level assessment (see item 12). 
67, 68 
 
 
 
Results of 
individual studies 
20 For all outcomes considered 
(benefits or harms), present for 
each study: (a) simple summary 
data for each intervention group (b) 
effect estimates and confidence 
intervals, ideally with a forest plot. 
69 – 72  
Synthesis of 
results 
21 Present results of each meta-
analysis done, including confidence 
intervals and measures of 
consistency. 
N/A 
Risk of bias across 
studies 
22 Present results of any assessment 
of risk of bias across studies. 
67, 68 
Additional 
analysis 
23 Give results of additional analyses, 
if done (e.g., sensitivity or subgroup 
analyses, meta-regression). 
69 – 72  
Discussion    
Summary of 
evidence 
24 Summarize the main findings 
including the strength of evidence 
for each main outcome; consider 
their relevance to key groups (e.g., 
healthcare providers, users, and 
policy makers). 
73 – 78 
Limitations 25 Discuss limitations at study and 
outcome level (e.g., risk of bias), 
and at review-level (e.g., 
incomplete retrieval of identified 
research, reporting bias). 
79 
Conclusions 26 Provide a general interpretation of 
the results in the context of other 
evidence, and implications for 
future research. 
79, 80 
Funding     
Funding 27 Describe sources and role of 
funding for the systematic review 
and other support (e.g., supply of 
data). 
80 and Thesis 
Acknowledgements 
314 
 
Appendix 3: Search strategy for qualitative systematic review 
Database searched: PubMed 
Date searched: 23/9/2015 
Search 
number 
Search terms 
#1 Patients [MeSH] OR Physicians [MeSH] OR Nurses [MeSH] OR 
Pharmacists [MeSH] OR Caregivers [MeSH] OR patient OR doctor OR 
nurse OR pharmacist OR speech and language therapist OR speech 
therapist OR carer OR caregiver 
#2 “Pharmaceutical Preparations” [MeSH] OR “Tablets” [MeSH] OR 
“Capsules” [MeSH] OR “Dosage Forms” [MeSH] OR “Administration, Oral” 
[MeSH] OR tablet* OR capsule*OR medicine OR medication OR 
“medicine management” OR “medication management” OR “medicine 
administration” OR “medication administration” 
#3 “Deglutition” [MeSH] OR “Deglutition Disorders” [MeSH] OR dysphagia 
OR swallow OR “swallowing difficulty” OR “fractional dosing” OR 
manipulation OR modification OR modify OR manipulate OR crush OR 
grind OR cut OR split OR mix 
#4 #2 AND #3 
#5 Knowledge  OR attitude OR belief OR view OR perception OR experience 
#6 “Qualitative Research” [MeSH]OR “Focus Groups” [MeSH] OR “Grounded 
Theory” [MeSH] OR qualitative OR interview OR “focus group” OR 
narrative OR “grounded theory” OR theme 
#7 #1 AND #4 AND #5 AND #6 
 
Search strategy for other databases: As for PubMed using index terms, free text 
terms and truncation as appropriate. 
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Appendix 4: ENTREQ statement for qualitative systematic review 
Item Description Reported on 
page 
number 
1. Aim To synthesise the available qualitative literature on 
the knowledge, attitudes and beliefs of patients, 
healthcare professionals and carers about oral dosage 
form (ODF) modification.  
 
86 
2. Synthesis 
methodology 
Thematic synthesis (Thomas and Harden (2008)). 90 
3. Approach to 
searching 
Comprehensive, systematic, pre-planned strategy to 
identify all available studies. 
 
86, 87 
4. Inclusion 
criteria 
Inclusion Criteria: 
Studies using qualitative data collection and analysis 
methods. 
Population: Adult patients (≥18 years) who require 
ODFs to be modified to meet their needs or healthcare 
professionals or carers providing care to such patients. 
Topic: Oral dosage form modification. 
Language: Full-text available in English (no language 
restriction on initial search). 
No date restrictions on search. 
 
Exclusion Criteria: 
Quantitative studies, systematic reviews, meta-
analyses, meta-syntheses, editorials, commentaries, 
letters and conference abstracts. 
 
88, 89 
5. Data sources Electronic databases: PubMed, Medline (EBSCO), 
EMBASE, CINAHL, PsycINFO, Web of Science, ProQuest 
Databases, Scopus, Turning Research Into Practice 
(TRIP), Cochrane Central Register of Controlled Trials 
(CENTRAL), Cochrane Database of Systematic Reviews 
(CDSR). 
 
Grey literature: OpenGrey database, internet 
searching, personal knowledge. 
 
Citation tracking of included studies.  
 
Reference lists of included studies were searched.  
 
Initial search: September 2015. 
Updated search: June 2016. 
86, 87 
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Item Description Reported on 
page 
number 
6. Electronic 
search strategy 
A combination of index and free text terms related to 
the following were used: 
(i) Patients or carers or healthcare 
professionals 
AND 
(ii) Medicine modification 
AND 
(iii) Knowledge 
AND 
(iv) Qualitative research 
The search strategy is provided in Appendix 3.  
The search strategy used was approved by a qualified 
medical librarian. 
86, 87, 
Appendix 3 
7. Study screening 
methods 
Titles were screened by the primary author (AMG) to 
remove any clearly irrelevant results. 
Abstracts were screened by 2 reviewers independently 
(AMG screened all abstracts, AMC and LJS screened 
half each). 
Full texts were assessed for inclusion by two 
independent reviewers (AMG reviewed all full texts, 
AMC and LJS reviewed half of the full-texts each). 
In the case of discrepancies between the two authors 
at any stage, the third reviewer independently 
examined the study and following discussion, 
consensus was reached by all three reviewers. 
87 
8. Study 
characteristics 
Details of the study characteristics are provided in 
Table 3.1. 
93 - 97 
9. Study selection 
results 
The study selection process is outlined in Figure 3.1. 91, 92 
10. Rationale for 
appraisal 
The appraisal process was undertaken to assess the 
quality of the included studies. The rigour, credibility 
and relevance of the studies were assessed. Quality 
appraisal was not used to guide inclusion or exclusion 
of studies but rather to moderate the findings of the 
review based on the quality of the studies contributing 
to the final analytical themes. 
89 
11. Appraisal items The Critical Appraisal Skills Programme (CASP) tool for 
Qualitative Research was used to appraise the studies.  
89 
12. Appraisal 
process 
Quality appraisal was undertaken independently by 
two reviewers (AMG and LJS). In the case of any 
discrepancies, a third reviewer independently 
appraised the study quality and following discussion, 
consensus was reached by all three reviewers. Referral 
to the third reviewer was not necessary. 
89 
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Item Description Reported on 
page 
number 
13. Appraisal 
results 
Results of quality appraisal are presented in Table 3.2. 98, 99 
14. Data extraction Data from the studies was extracted by one reviewer 
(AMG) into a modified version of the data extraction 
form developed by the National Institute for Health 
and Care Excellence. A second reviewer (AMC) 
independently verified the extracted data. 
For the thematic synthesis: any section of the primary 
study labelled “Results” or “Findings” was considered 
to be eligible for analysis.  
89 
15. Software QSR International’s NVivo 10 Qualitative Data Analysis 
Software 
90 
16. Number of 
reviewers 
Four authors for the study.  90 
17. Coding Followed the stages of thematic analysis outlined by 
Thomas and Harden (2008): 
Stage 1: Free line-by-line coding of the findings of 
primary studies - independently performed by two 
reviewers (LJS and AMG); 
Stage 2: Organisation of the free codes into descriptive 
themes - undertaken by two reviewers during a group 
discussion (LJS and AMG), verified by third reviewer 
(AMC); 
Stage 3: Development of analytical themes – 
independently generated by two reviewers (AMG and 
LJS) and consolidated through group discussion. 
90 
18. Study 
comparison 
Thematic synthesis was used to synthesise the findings 
of the primary studies. This approach allowed the 
advantage of “staying ‘close’ to the results of the 
primary studies, synthesising them in a transparent 
way, and facilitating the explicit production of new 
concepts and hypotheses” (Thomas and Harden 2008). 
Table 3.1 shows the contribution of each study to the 
analytical themes. 
90, 94 - 97 
19. Derivation of 
themes 
Data labelled “Results” or “Findings” in eligible studies 
were analysed to generate initial free line-by-line 
codes. The free codes were organised into descriptive 
themes. Finally, analytical themes were generated 
based on the descriptive themes. 
90 
20. Quotations Quotations are provided throughout the results 
section of the review to substantiate the findings. 
100 - 111 
21. Synthesis 
output 
The analytical themes generated provide new 
interpretations that “go beyond” the results of the 
primary studies.  
100 – 111 
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Appendix 5: Ethical approval for retrospective audit study 
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Appendix 6: STROBE checklist for retrospective audit study 
 Item 
No. 
Recommendation Reported on page 
number 
Title and 
abstract 
1 a)Indicate the study’s design in the 
title or abstract 
118 
  b) Provide in the abstract an 
informative balanced account of what 
was done and what was found 
119, 120 
Introduction    
Background/ 
rationale 
2 Explain the scientific background and 
rationale for the investigation being 
reported 
121 – 123 
Objectives 3 State specific objectives 124 
Methods    
Study design 4 Present key elements of study design 
early in the paper 
124 
Setting 5 Describe the setting, locations, and 
relevant dates, including periods of 
recruitment, exposure, follow-up and 
data collection 
124 – 127 
Participants 6 Give the eligibility criteria and sources 
and methods of selection of 
participants 
125 
Variables 7 Clearly define all outcomes, 
exposures, predictors, potential 
confounders and effect modifiers 
125 – 127 
Data sources/ 
measurement 
8 For each variable of interest, give 
sources of data and details of 
methods of assessment. 
125 – 128 
Bias 9 Describe any efforts to address 
potential sources of bias 
128 
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 Item 
No. 
Recommendation Reported on page 
number 
Study size 10 Explain how the study size was arrived 
at 
This was an initial 
investigation. Data 
from this study will 
be used to inform a 
larger study. 
 
Quantitative 
variables 
11 Explain how quantitative variables 
were handled in the analyses. If 
applicable, describe which groupings 
were chosen and why 
 
127, 128 
Statistical 
methods 
12 a) Describe all statistical methods 127, 128 
  b) Describe any methods used to 
examine subgroups and interactions 
127, 128 
  c) Explain how missing data were 
addressed 
128 
  d) If applicable, describe analytical 
methods taking account of sampling 
strategy 
N/A 
  e) Describe any sensitivity analyses N/A 
Results    
Participants 13 a) Report numbers of individuals at 
each stage of study e.g. numbers 
potentially eligible etc. 
128 
  b) Give reasons for non-participation N/A 
  c) Consider use of a flow diagram N/A- reported in 
results section. 
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 Item 
No. 
Recommendation Reported on page 
number 
Descriptive 
data 
14 a) Give characteristics of study 
participants 
128, 129 
  b) Indicate number of participants 
with missing data for each variable of 
interest 
128 – 138  
Outcome data 15 Report numbers of outcome events or 
summary measures 
128 – 138 
Main results 16 a) Give unadjusted estimates and if 
applicable, confounder adjusted 
elements 
128 – 138 
  b) Report category boundaries when 
continuous variables were categorized 
 
  c) If relevant, consider translating 
estimates of relative risk into absolute 
risk for a meaningful time period 
 
Other analyses 17 Report other analyses done 128 – 138 
Discussion    
Key results 18 Summarise key results with reference 
to study objectives 
139 – 145 
Limitations 19 Discuss limitations of the study 145 
Interpretation 20 Give cautious overall interpretation of 
results 
139 – 145 
Generalisability 21 Discuss the generalisability of the 
study results 
145 
Other 
information 
  N/A 
Funding  22 Give the source of funding and role of 
the funders 
Thesis 
acknowledgements  
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Appendix 7: Ethical approval for qualitative interview studies 
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Appendix 8: COREQ checklist for qualitative nurse interview study 
Topic Item 
no. 
Description Reported 
on page 
Domain 1: Research team and reflexivity 
Personal characteristics 
Interviewer 1 AMG (the primary author). 147 
Credentials 2 BPharm, MPharm, MPSI, PhD student. Cover page 
Occupation 3 Pharmacist, PhD student. 158 
Gender 4 Female. 158 
Experience and 
training 
5 Training in qualitative research methods 
and qualitative interviewing techniques 
completed in 2015. 
155, 158 
Relationship with participants 
Relationship 
established 
6 No 155 
Participant 
knowledge of 
interviewer 
7 Participants were aware that the interviews 
were being completed as part of the 
interviewer’s PhD studies. Participants 
were informed that the study was being 
undertaken to investigate the knowledge, 
attitudes and beliefs of nurses regarding 
the modification of oral medicines for older 
patients. The overall goal of the study was 
presented to participants as being to 
investigate the suitability of oral medicines 
for older adults. 
156 – 158, 
180 
Interviewer 
characteristics 
8 This study forms part of AMG’s PhD studies 
which aims to investigate if oral medicines 
are meeting the needs of older adults. The 
interviewer is a pharmacist which could 
potentially introduce bias into the study. In 
addition, all co-authors are pharmacists. 
Discussed potential bias introduced by this 
and chose to use a very inductive approach 
to try to overcome this possible bias and 
ensure that primacy is given to the 
interview participants experiences and not 
allow researchers assumptions and biases 
to predominate. 
 
156 – 158 
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Topic Item 
no. 
Description Reported 
on page 
Domain 2: Study design 
Theoretical framework 
Methodological 
orientation and 
theory 
9 Thematic analysis as per Braun and Clarke.  157 
Participant selection 
Sampling 10 Care settings were purposively selected. 
Participants were conveniently sampled at 
the purposively selected sites. 
153, 154 
Method of 
approach 
11 E-mail or telephone contact with medical 
director or nurse in charge at each site. 
Nurses were then conveniently sampled 
from these locations. 
154 
Sample size 12 Guided by Francis method. Initial analysis 
sample of 15 and stopping criterion of 3 
specified (18 nurses from 16 study sites) 
156 
Non-
participation 
13 All sites approached agreed to participate. N/A 
Setting 
Setting of data 
collection 
14 In a private area at the participant’s 
workplace. 
155, 156 
Presence of non-
participants 
15 Only the interview participant and 
interviewer were present. 
156 
Description of 
sample 
16 Detail provided in Section 5.5.1 and Table 
5.2. 
159, 160 
Data collection 
Interview guide 17 Topic guide developed by authors based on 
a review of the literature, observations 
from a prevalence study and authors’ 
practical knowledge of the research area. 
The topic guide was piloted with an 
experienced geriatric nurse who provided 
feedback on the content and language of 
the guide. In addition, the topic guide 
underwent iterative revision throughout 
the study to ensure that any emergent 
themes were captured in subsequent 
interviews. 
155 
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Topic Item 
no. 
Description Reported 
on page 
Repeat 
interviews 
18 No, repeat interviews were not conducted. 156 
Audio/ visual 
recording 
19 Interviews were audio-recorded. 156 
Field notes 20 Relevant notes made by interviewer. 156 
Duration 21 Mean interview duration (SD): 16 minutes 
29 seconds (6 minutes 21 seconds) 
Range: 7 minutes 19 seconds to 31 minutes 
41 seconds. 
159 
Data saturation 22 Guided by Francis method: initial analysis 
sample of 15 and stopping criteria of 3. 
Sampling continued until data saturation. 
156 
Transcripts 
returned 
23 No, transcripts were not returned to 
participants. 
156 
Domain 3: analysis and findings 
Data analysis 
Number of data 
coders 
24 Outlined in the text. 
AMG coded all transcripts, MK 
independently coded 3 transcripts, all co-
authors read 6 transcripts and confirmed 
that themes were reflective of interview 
content. 
157, 158 
Description of 
the coding tree 
25 N/A N/A 
Derivation of 
themes 
26 Themes were derived using thematic 
analysis, as described by Braun and Clarke. 
An inductive approach to coding was used. 
157, 158 
Software 27 QSR International’s NVivo 10 Qualitative 
Data Analysis Software. 
157 
Participant 
checking 
28 This was not conducted. 157 
Reporting 
Quotations 
presented 
29 Supporting quotations are present 
throughout the results sections. 
161 – 174 
Data and findings 
consistent 
30 Yes. All co-authors confirmed that the 
findings were consistent with the interview 
transcripts and illustrative quotes are 
presented to substantiate findings. 
161 – 174 
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Topic Item 
no. 
Description Reported 
on page 
Clarity of major 
themes 
31 Major themes are clearly discussed, with 
relevant supporting quotes, in the results 
section. Any variations in knowledge, 
attitudes and beliefs are also presented. 
161 – 171 
Clarity of minor 
themes 
32 Two minor themes emerged and are clearly 
discussed in the results section. 
171 – 174 
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Appendix 9:  Ethical approval for direct observation of medication 
administration study 
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Appendix 10: STROBE checklist for direct observation of medication 
administration study 
 Item 
No. 
Recommendation Reported on page 
number 
Title and 
abstract 
1 a)Indicate the study’s design in the 
title or abstract 
183 
  b) Provide in the abstract an 
informative balanced account of what 
was done and what was found 
184 – 186  
Introduction    
Background/ 
rationale 
2 Explain the scientific background and 
rationale for the investigation being 
reported 
187, 188 
Objectives 3 State specific objectives 188, 189 
Methods    
Study design 4 Present key elements of study design 
early in the paper 
190 
Setting 5 Describe the setting, locations, and 
relevant dates, including periods of 
recruitment, exposure, follow-up and 
data collection 
190 – 193 
Participants 6 Give the eligibility criteria and sources 
and methods of selection of 
participants 
190 – 192 
Variables 7 Clearly define all outcomes, 
exposures, predictors, potential 
confounders and effect modifiers 
192, 193 
Data sources/ 
measurement 
8 For each variable of interest, give 
sources of data and details of 
methods of assessment. 
192, 193 
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 Item 
No. 
Recommendation Reported on page 
number 
Bias 9 Describe any efforts to address 
potential sources of bias 
192 – 194  
Study size 10 Explain how the study size was arrived 
at 
194, 195 
Quantitative 
variables 
11 Explain how quantitative variables 
were handled in the analyses. If 
applicable, describe which groupings 
were chosen and why 
194 
Statistical 
methods 
12 a) Describe all statistical methods 194 
  b) Describe any methods used to 
examine subgroups and interactions 
194 
  c) Explain how missing data were 
addressed 
193, 194 
  d) If applicable, describe analytical 
methods taking account of sampling 
strategy 
N/A 
  e) Describe any sensitivity analyses N/A 
Results    
Participants 13 a) Report numbers of individuals at 
each stage of study e.g. numbers 
potentially eligible etc. 
195, 196 
  b) Give reasons for non-participation 195, 196 
  c) Consider use of a flow diagram 196 
Descriptive 
data 
14 a) Give characteristics of study 
participants 
196 – 199 
  b) Indicate number of participants 
with missing data for each variable of 
interest 
197, 198 
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 Item 
No. 
Recommendation Reported on page 
number 
Outcome data 15 Report numbers of outcome events or 
summary measures 
199 – 208  
Main results 16 a) Give unadjusted estimates and if 
applicable, confounder adjusted 
elements 
199 – 208 
  b) Report category boundaries when 
continuous variables were categorized 
 
  c) If relevant, consider translating 
estimates of relative risk into absolute 
risk for a meaningful time period 
 
Other analyses 17 Report other analyses done 199 – 208 
Discussion    
Key results 18 Summarise key results with reference 
to study objectives 
208 – 217 
Limitations 19 Discuss limitations of the study 218 – 221 
Interpretation 20 Give cautious overall interpretation of 
results 
221 
Generalisability 21 Discuss the generalisability of the 
study results 
218 
Other 
information 
  N/A 
Funding  22 Give the source of funding and role of 
the funders 
Thesis 
acknowledgements  
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Appendix 11: COREQ checklist for qualitative patient and carer 
interview study 
Topic Item 
no. 
Description Reported 
on page 
Domain 1: Research team and reflexivity 
Personal characteristics 
Interviewer 1 AMG (the primary author). 223 
Credentials 2 BPharm, MPharm, MPSI, PhD student. Cover page 
Occupation 3 Pharmacist, PhD student. 238 
Gender 4 Female. 238 
Experience and 
training 
5 Training in qualitative research methods 
and qualitative interviewing techniques 
completed in 2015. 
234, 238 
Relationship with participants 
Relationship 
established 
6 No 234 
Participant 
knowledge of 
interviewer 
7 Participants were aware that the 
interviewer was a pharmacist and 
researcher working in the School of 
Pharmacy at the local University. 
Participants were informed that the 
research team were interested in 
understanding the views and experiences 
of patients and carers about medicines 
administration and modification. 
234, 235 
Interviewer 
characteristics 
8 This study forms part of AMG’s PhD studies 
which aims to investigate if oral medicines 
are meeting the needs of older adults. The 
interviewer is a pharmacist which could 
potentially introduce bias into the study. In 
addition, all co-authors are pharmacists. 
Discussed potential bias introduced by this 
and chose to use a very inductive approach 
to try to overcome this possible bias and 
ensure that primacy is given to the 
interview participants experiences and not 
allow researchers assumptions and biases 
to predominate. 
 
238 
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Topic Item 
no. 
Description Reported 
on page 
Domain 2: Study design 
Theoretical framework 
Methodological 
orientation and 
theory 
9 Thematic analysis as per Braun and Clarke.  235 – 237 
Participant selection 
Sampling 10 Participants were recruited through 
community pharmacies. The community 
pharmacies were purposively sampled to 
include pharmacies located in 
socioeconomically “advantaged” and “less 
advantaged” areas, in both rural and urban 
settings. Individual participants were 
recruited using a combination of: 
convenience sampling at the participating 
pharmacies; purposive identification by 
pharmacists and; snowball sampling. 
 
231 – 233  
Method of 
approach 
11 A member of the research team contacted 
pharmacists at the identified pharmacies 
and provided them with an information 
sheet about the study. Following 
agreement to participate, a member of the 
research team approached potential 
participants in the participating pharmacies 
(convenience sampling). 
 A member of the research team or the 
pharmacist approached purposively 
identified participants. Participants were 
also asked to suggest any other potential 
participants. 
 
231 – 233 
Sample size 12 Guided by Francis method. Initial analysis 
sample of 10 and stopping criterion of 3 for 
both the patient and carer cohorts.13 
patients and 13 carers participated. 
 
237 
Non-
participation 
13 All sites approached agreed to participate. 239 – 241  
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Topic Item 
no. 
Description Reported 
on page 
Setting 
Setting of data 
collection 
14 In the private consultation room at 
participating pharmacies, in the 
interviewee’s home or the interviewer’s 
home, depending on the participant’s 
preference. 
235 
Presence of non-
participants 
15 Three of the patients requested the 
presence of a family member during the 
interviews, however only the patient 
contributed to the interview. 
240 
Description of 
sample 
16 Detail provided in Section 7.5.2. 239, 240 
Data collection 
Interview guide 17 Two topic guides were developed; one for 
interviews with patients and one for 
interviews with carers. Topic guides were 
devised based on the findings of the 
qualitative systematic review, taking the 
aims of the study into consideration. 
General content was the same, but 
language was tailored to address the varied 
roles and perspectives of each cohort. 
Topic guides underwent iterative 
refinement during the study. 
233, 234 
Repeat 
interviews 
18 No, repeat interviews were not conducted. 235 
Audio/ visual 
recording 
19 Interviews were audio-recorded. 235 
Field notes 20 Field notes were written by the interviewer 
after the interview. 
235 
Duration 21 Total cohort: median interview duration 11 
minutes 17 seconds (IQR 8 minutes 3 
seconds to 16 minutes 23 seconds). 
240 
Data saturation 22 Guided by Francis method. Initial analysis 
sample of 10 and stopping criterion of 3 for 
both the patient and carer cohorts.13 
patients and 13 carers participated. 
Recruitment continued until data 
saturation was achieved. 
 
237 
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Topic Item 
no. 
Description Reported 
on page 
Transcripts 
returned 
23 No, transcripts were not returned to 
participants. 
235 
Domain 3: analysis and findings 
Data analysis 
Number of data 
coders 
24 Outlined in the Section 7.4.5 and in Table 
7.3. 
 
235 – 236  
Description of 
the coding tree 
25 N/A N/A 
Derivation of 
themes 
26 Themes were derived using thematic 
analysis, as described by Braun and Clarke. 
An inductive approach to coding was used. 
235, 236 
Software 27 QSR International’s NVivo 11 Qualitative 
Data Analysis Software. 
235 
Participant 
checking 
28 This was not conducted. N/A 
Reporting 
Quotations 
presented 
29 Supporting quotations are present 
throughout the results sections. 
242 – 255  
Data and findings 
consistent 
30 Yes. All co-authors confirmed that the 
findings were consistent with the interview 
transcripts and illustrative quotes are 
presented to substantiate findings. 
237, 242 – 
255  
Clarity of major 
themes 
31 Themes are clearly discussed, with relevant 
supporting quotes, in the results section. 
Any variations in knowledge, attitudes and 
beliefs are also presented. 
242 – 255  
Clarity of minor 
themes 
32 No minor themes presented. N/A 
 
 
 
 
